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Summary
Zoonotic visceral leishmaniasis (ZVL) is a fatal disease caused by the sandfly-borne
intracellular protozoan parasite Leishmania infantum, and vaccine development in the
reservoir host (the domestic dog) is a current research priority. The aims of this study were
(1) to conduct safety and immunogenicity trials of two candidate vaccines in dogs, and (2)
to compare and demonstrate the utility of immunological and molecular tools for
measurement of vaccine efficacy in naturally exposed dogs.
DNA/ modified vaccinia virus Ankara (MVA) prime/boost canine vaccines expressing the
Leishmania proteins TRYP and LACK were safe, and elicited a type-1 cytokine response,
in vivo delayed-type hypersensitivity and IgG2 class responses, consistent with superior
protective immunogenicity of TRYP over LACK. However, inconsistent associations were
found between progressive disease in infected dogs and IgG class levels, prompting
caution in use of the latter as a proxy for protective immunogenicity. Specific serological
responses in vaccinated dogs did not cross-react with an unrelated diagnostic antigen
rK39, and responses to crude parasite antigen (CLA) were minimal, enabling serological
detection of infection incidence in vaccinated dogs. Particularly in early stage infection,
CLA ELISA was more sensitive than rK39 ELISA and an rK39-based rapid diagnostic
test, though rK39 serology was sensitive for diagnosis of symptomatic clinical cases.
A commercially available PCR kit incorporating a rapid oligochromatographic detection
step was tested for the first time in dogs, and proved highly sensitive for detection of ZVL
infection in bone marrow, comparable to existing nested PCR methods. Molecular
methods were investigated as proxy measures to replace labour-intensive xenodiagnosis
for detection of the infectiousness of dogs to biting sand flies. Conventional and real-time
PCR of tissues from naturally infected dogs were sensitive tests to identify infectiousness,
but showed low to moderate specificity. Recommendations are made to improve the
application of molecular methods as proxy measures of infectiousness and hence vaccine
efficacy.
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1Chapter 1: Introduction
1.1 Background
Leishmaniasis is a disease caused by vector borne protozoa of the genus Leishmania
(Kinetoplastida: Trypanosomatidae), which are obligate intracellular parasites of
macrophages and dendritic cells. The disease is endemic in 88 countries worldwide,
and the annual incidence is estimated as 2 million cases. Three quarters of these are
patients with the disfiguring skin disease cutaneous leishmaniasis (CL), while the
remaining 500,000 are cases of systemic visceral leishmaniasis (VL) that is fatal
unless treated (Desjeux, 2004). The annual mortality attributable to leishmaniasis is
approximately 60,000 (WHO, 2006), and the overall disease burden is calculated by
WHO as 2.4 million disability adjusted life years (DALYs). Incidence of VL is rising
with urban migration of people from rural areas (WHO, 2002), and increasing overlap
of the distribution of VL and human immunodeficiency virus (HIV) has led to the
emergence of Leishmania/HIV co-infection which has so far been reported from 34
countries (WHO, 2002; Desjeux, 2004; Alvar et al., 2008).
There are around 20 well-recognised species of Leishmania which are known to cause
CL or VL in humans (Desjeux, 2004). VL results from infection with members of the
L. donovani complex: L. donovani, L. infantum and L. chagasi, and as a visceralizing
infection VL is responsible for more severe clinical disease than CL. VL is subdivided
into anthroponotic and zoonotic forms. Zoonotic Visceral Leishmaniasis (ZVL) caused
by L. infantum (=L. chagasi) (Mauricio et al., 2000) causes disease in humans in South
America, the Mediterranean, and parts of Asia. Infection of humans occurs when
Leishmania spp. are injected into the dermis as the metacyclic promastigote life stage
following the bite of an infected female phlebotomine sandfly (Diptera: Psychodidae:
Phlebotominae). ZVL is maintained in the environment by a reservoir host, principally
the domestic dog – anthroponotic transmission of ZVL is thought not to occur, though
infection may be acquired by drug users sharing needles (Cruz et al., 2002). The
expansion in recent years of sandfly vector populations and hence ZVL into non-
endemic areas represents a threat to human health in both Old and New worlds
(Enserink, 2000; Maroli et al., 2008; Naucke et al., 2008; Otranto et al., 2009a), and
the easing of European travel restrictions for UK domestic pets means that there is
now a potential reservoir of infected dogs in Britain, should climatic change permit the
2establishment of the vector (Shaw et al., 2009). Novel methods for treatment, control
and prevention of leishmaniasis are thus a current research priority. Existing drug
therapy for human VL is expensive: the WHO-recommended first line treatment
(pentavalent antimonial) currently costs US$150 per patient for a 30-day course of
sodium stibogluconate injections, US$120 for meglumine antimoniate, and US$30 for
generic sodium stibogluconate. Unresponsive cases require more toxic second-line
drugs, such as amphotericin B or pentamidine, and although amphotericin B is
available in a less toxic liposomal formulation (AmBisome®), the cost is
approximately US$1,500 per patient. The first oral drug for VL (miltefosine), which
was licensed for use in India in 2002, currently costs US$120 per patient (WorldBank,
2006). Resistance to chemotherapeutic agents is on the increase (Perez-Victoria et al.,
2001; Sundar et al., 2001), and at present there are no vaccines available for routine
use in humans.
Control of the phlebotomine vector using traditional methods of interior residual
insecticidal spraying has been successful in reduction of disease transmission
(Boelaert et al., 2000; Kishore et al., 2006), however this control method may promote
insecticide resistance among the vector species, requires suitable infrastructure and
trained personnel, and is expensive and poorly sustainable (Maroli and Khoury, 2006).
Research is under way in the Indian subcontinent into the efficacy of insecticide
treated bed nets (ITN) for reduction of sandfly densities, and hence transmission of VL
(Joshi et al., 2009).
Reduction of disease by culling dogs has been traditionally targeted as a means of
disease control in man in Latin America. However, detailed studies in Brazil
(Quinnell et al., 1997; Quinnell et al., 2001b; Courtenay et al., 2002b; Reithinger et
al., 2002; Quinnell et al., 2003a) have demonstrated that culling of infected dogs is not
an efficient means of disease control in areas of high transmission, and may serve to
exacerbate the situation by replacing infected immune animals with susceptibles
(Courtenay et al., 2002b). Interruption of transmission using insecticidal dog collars
has been successful (Mazloumi Gavgani et al., 2002; Reithinger et al., 2004) although
the high price of collars and recurrent costs due to high loss rates (Foglia Manzillo et
al., 2006) make such measures impractical for community disease control.
Chemotherapeutic drugs against canine ZVL (most frequently consisting of
combination therapy with meglumine antimoniate (for 4-8 weeks) and allopurinol (for
6-12 months) can induce temporary remission of clinical symptoms (Noli and Auxilia,
32005), but are generally ineffective in achieving parasitological cure or abrogating
infectiousness to sand flies (Alvar et al., 1994; Solano-Gallego et al., 2009).
In recent years, research efforts aimed at controlling leishmaniasis have turned
towards vaccine development, following the observation that in humans spontaneous
or drug-induced recovery from VL is accompanied by solid immunity against re-
infection (Melby, 1991; Roberts, 2005). A successful human vaccine would solely
prevent infection of susceptible individuals, whereas a dog vaccine would not only
interrupt transmission from the reservoir host, but would also address a major
veterinary health problem. In dogs, although data is lacking on immune responses
following re-infection under natural conditions, experimental re-challenge of
previously infected animals has shown that previous exposure confers a degree of
resistance (Santos-Gomes et al., 2003). Even if only partially effective, a canine
vaccine which reduced clinical disease or tissue parasite load in infected animals could
reduce disease transmission to humans, since infectiousness of dogs to sandflies
appears to correlate with both parasite load, and the intensity of clinical signs (da
Costa-Val et al., 2007; Michalsky et al., 2007; Vercosa et al., 2008). A vaccination
strategy targeting the reservoir host would be of particular benefit to prevent disease in
humans who lack a functioning immune system (for example HIV patients) and are
therefore unable to mount a response to a human vaccine, were one to become
available. Development of canine vaccines for ZVL has been identified as a research
priority by WHO/TDR (Dumonteil et al., 2001), and mathematical models have
highlighted canine vaccination as potentially the most practical and effective means of
disease control in humans (Dye, 1996; Courtenay et al., 2002b). To date, only one
canine vaccine has been licensed for prevention of ZVL in Brazil (under the trade
name Leishmune®) (Borja-Cabrera et al., 2002; Dantas-Torres, 2006), and other
vaccine candidates are urgently being sought. In order to measure vaccine efficacy, a
variety of approaches have been employed in the growing number of canine vaccine
trials in published research. However, unlike the situation in human vaccine research,
in which well validated protocols exist for the conduct of Phase III trials of novel
vaccines, there is no standardized method for quantification of vaccine efficacy in
canine vaccine trials against leishmaniasis.
The overall aims of the present project were thus to carry out safety and
immunogenicity trials of two novel vaccines against zoonotic visceral leishmaniasis in
the domestic dog, and to validate diagnostic protocols suitable for detection of both
4infection and infectiousness of naturally exposed dogs, enabling the measurement of
vaccine efficacy in future large scale Phase III community-based trials of these
vaccines.
1.2 Immunology of Leishmania infection in mice, humans and dogs
The development of a vaccine against ZVL in dogs depends on a detailed
understanding of the canine immune response to Leishmania infection. Although
differences exist between the murine, human and canine response to Leishmania
infection, protective immunity in all species depends upon a functioning cellular
immune response (Kemp et al., 1993; Pinelli et al., 1994; Reiner and Locksley, 1995;
Kharazmi et al., 1999). Impaired cellular immune responses are correlated with
progression of disease, while in immune individuals strong T-cell lymphoproliferation
is seen in peripheral blood mononuclear cells after exposure to Leishmania antigens
(Cabral et al., 1992; Pinelli et al., 1994; Pinelli et al., 1999). The CD4+ subpopulation
of T-cells is important in the development of immunity, as demonstrated by the fact
that human patients with low CD4+ cell counts due to co-existing HIV infection suffer
from a particularly severe form of ZVL (Russo et al., 2003). In the most commonly
used experimental model for leishmaniasis, L. major infection in mice, the
immunological correlates of protective immunity appear relatively straightforward.
The most important determinant of murine immunity to L. major appears to be the
balance between two subpopulations of CD4+ cells, designated Th1 and Th2. A bias
towards the differentiation of Th1 cells in response to infection is associated with
protection from clinical disease, while expression of a Th2-dominated response results
in susceptibility (Reiner and Locksley, 1992; Mosmann and Sad, 1996). Studies in
human CL support the critical role of the ratio Th1/Th2 response as a determinant of
immunity or infection (Gaafar et al., 1995; Kemp, 1997; Kemp et al., 1998).
In the course of natural infection, Leishmania at the site of inoculation by the sandfly
vector survive uptake by neutrophils, by trafficking to non-lytic ER-like
compartments, and their carrier neutrophil is then engulfed by their target cell
(macrophages) in which parasite replication occurs (Gueirard et al., 2008). In immune
individuals, Th1 cells play a pivotal role in a series of events that lead to the
destruction of intracellular Leishmania parasites by activation of parasitized
macrophages. The main mechanism of parasite killing involves fusion of the
phagosome (the intracellular vacuole within the macrophage which contains the
5engulfed parasite) with lysosomes to form a phagolysosome. This is followed by nitric
oxide (NO) production driven by inducible nitric oxide synthase (iNOS), via an L-
arginine dependent intracellular pathway. Other proposed mechanisms include
destruction of infected macrophages by cytotoxic (CD8+) T lymphocytes (Muller et
al., 1991; Belkaid et al., 2002b) and FasL mediated macrophage apoptosis (Huang et
al., 1998). However, in all species so far studied, interferon gamma (IFN-) produced
mainly by Th1-type CD4+ T cells seems to be essential for the activation of
macrophages in order to kill the parasite. When an armed effector Th1 cell contacts an
infected macrophage, it produces IFN- in association with cell surface expression of
CD40 ligand, which together are responsible for the stimulation of highly microbicidal
activated macrophages. The importance of IFN- is shown by the failure of IFN-
knockout mice to clear Leishmania infection (Wang et al., 1994; Swihart et al., 1995).
A second important Th1 cytokine, tumor necrosis factor alpha (TNF-α) is believed to
synergize with IFN- in mediating parasite killing: in mice it has been demonstrated
that disease development after experimental infection with L. major was significantly
reduced by intra-lesional injection of recombinant IFN- and TNF-α together, but not
by either cytokine alone. Furthermore, it has been demonstrated that mouse peritoneal
macrophages incubated with TNF-α were effective in killing L. major parasites in
vitro (Liew et al., 1990b), and that experimentally infected mice treated with anti-
TNF-α antibody had higher L donovani parasite burdens than control mice (Liew et
al., 1990a). C57BL/6 mice, which are resistant to leishmaniasis, become extremely
susceptible to fatal L. major infection after deletion of the TNF gene by homologous
recombination, and show reduced formation of dendritic cells (DC’s) at the site of
infection. An improvement of survival time was observed after cutaneous
administration of TNF at the time of infection (Ritter et al., 2008). In marked contrast
to the cytokine profile described above which correlates with resistance to infection, in
BALB/c mice that are susceptible to L. major infection, the development of Th2 CD4+
T-cells which secrete IL-4, IL-13 and IL-5 (Janeway et al., 2001), and possibly IL-10
(Roberts, 2005), has been found to antagonize the Th1 response and allow persistence
of infection. Secretion of IL-10 by a third population of CD4+ cells, termed CD4+
CD25+ T regulatory cells (Treg), was also found to be pivotal in persistence of L.
major infection in mice (Belkaid et al., 2002a), and in the failure of an experimental
Leishmania vaccine (Stober et al., 2005).
6In dogs, clinical outcomes of ZVL infection comprise a whole spectrum of responses
from asymptomatic, through oligosymptomatic (with one or more mild signs), to fully
symptomatic disease. Clinical signs are related to granulomatous inflammatory tissue
reactions, associated with the presence of parasitized macrophages, and may include
generalized muscular atrophy, enlargement of lymph nodes and spleen, exfoliative/
ulcerative dermatitis, excessive nail growth, eye disease and pyrexia (Baneth et al.,
2008). Severe symptomatic disease frequently progresses to death of the animal due to
glomerulonephritis and subsequent renal failure. Symptomatic infection is associated
with the absence of delayed type hypersensitivity (DTH) in response to intra-dermal
inoculation of Leishmania antigen (Pinelli et al., 1994; Cardoso et al., 1998; Solano-
Gallego et al., 2000), and decreased CD4+ and CD8+ T cell numbers in peripheral
blood (Pinelli et al., 1994; Martinez et al., 1995; de Luna et al., 1999; Reis et al.,
2006a). Other features associated with clinical disease are absence of IFN- production
by peripheral blood mononuclear cells (PBMC) in vitro (Pinelli et al., 1994; Pinelli et
al., 1995; Santos-Gomes et al., 2002; Brandonisio et al., 2004) and a high titre of non-
protective anti-Leishmania IgG antibody (Abranches et al., 1991; Pinelli et al., 1994;
Martinez et al., 1995; Pinelli et al., 1995), which is partly responsible for immune-
complex mediated glomerulonephritis referred to above. Resistance to disease is
associated with activation of Th1 CD4+ cells producing IFN-, IL-2, and TNF-α
(Pinelli et al., 1994; Pinelli et al., 1995). In dogs, the significance of Th2 CD4+ cells
in antagonising the protective Th1 response is currently under investigation. Recent
research summarized below has suggested that the failure to generate a Th1 response,
rather than the predominance of a Th2 response per se, allows progression of ZVL
infection in the dog. In contrast to humans and murine infection, the role of IL-10
secreted by CD25+ CD4+ regulatory Treg cells in canine infection outcome is unclear
following contradictory evidence (Santos-Gomes et al., 2002; Brandonisio et al.,
2004; Chamizo et al., 2005; Pinheiro et al., 2005; Rafati et al., 2005). Previously
published work exists showing little correlation between Th2-type cytokine response
and progressive disease, for example, in bone marrow aspirates from infected
Brazilian dogs, it was shown that IL-4, IL-13 and IL-10 mRNA levels were not
elevated relative to uninfected controls, although infected dogs with detectable IL-4
mRNA had more severe clinical symptoms compared to those in which IL-4 was
absent, which implies some exacerbatory effect of this Th2 cytokine (Quinnell et al.,
72001b). In vitro antigen-driven memory cell responses were not measured. Manna et
al. found that, although IL-10 mRNA was expressed in naturally infected Italian dogs
that progressed to symptomatic infection, IL-10 was also expressed in dogs that
remained free of clinical signs of disease, suggesting that IL-10 expression could not
be used as a correlate of active disease caused by L. infantum (Manna et al., 2006).
Similarly, in a Brazilian study, high IL-10 levels detected in liver and spleen of
symptomatic dogs were not significantly different from levels in asymptomatic
animals (Correa et al., 2007). Conversely, in another study of Brazilian dogs, the
expression of IL-10 mRNA was high in symptomatic animals in association with high
parasite burden, whilst (consistent with the hypothesised role of Th-1 responses in
protection against disease) lymph node IFN-γ and TNF-α were high in asymptomatic 
dogs in association with low parasite burden (Alves et al., 2009). Other studies report
a mixed Th1/Th2 response in association with symptomatic disease in dogs, with no
particular polarization of the cytokine response. For example, in naturally infected
Brazilian dogs, levels of both IL-10 and IFN- mRNA expression in spleen cells were
positively associated with splenic parasite burdens and severity of clinical signs in
(Lage et al., 2007). In a study of experimental infection in laboratory beagles, mixed
Th1 and Th2 responses were found after antigen stimulation of canine PBMC, with
expression of mRNA for IFN-, IL-2 and IL-10. Though IL-2 and IFN- predominated
in asymptomatic animals in that study, development of symptoms could not be related
to IL-10 expression (Santos-Gomes et al., 2002). Mixed Th1 and Th2 responses were
also detected by measurement of mRNA in spleens of both experimentally and
naturally infected dogs, with an increase in expression of IFN-γ mRNA implicating a 
Th1-type immune response. However IL-4 levels also increased one month after
experimental infection while the expression levels of IL-10 and TGF-β, did not change
during the 7 month follow-up period (Strauss-Ayali et al., 2007).
Interpretation of data from canine vaccine trials is further complicated by controversy
surrounding other proxy measures of canine cellular immune response against
Leishmania. In experimental murine models of leishmaniasis, for example, the profile
of IgG class titres against crude Leishmania antigen (CLA) has been well validated as
a proxy measure of T-cell activation. In particular, a high ratio of specific IgG2a:IgG1
has been associated with a Th1-type pro-inflammatory cytokine response (production
of IFN-γ by CD4+ helper T lymphocytes), which in turn promotes resistance to 
8disease caused by Leishmania major infection. Conversely, a comparatively low
IgG2a:IgG1 ratio results from preferential activation of a non-protective Th2 response
involving production of IL-4 and progression to clinical disease (Snapper and Paul,
1987; Heinzel et al., 1989; Coffman et al., 1993; Germann et al., 1995).
As stated above, humoral immunity is not thought to contribute to resistance against
leishmaniasis, since IgG antibody titres produced in response to infection with
Leishmania are non-protective (Pinelli et al., 1994), although recent claims for the
existence of a functional role for anti-parasite IgG in contributing to protective
immunity (Bourdoiseau et al., 2009) require further investigation. However,
measurement of IgG class expression as a proxy for Th1/Th2 bias, as in the murine
model, is highly attractive as an additional measure of vaccine immunogenicity in
dogs, due to technical simplicity of the procedure and low cost in comparison with
cytokine assays. Unfortunately, the interpretation of IgG class profiles in relation to
clinical outcomes in dogs is currently unclear: some studies show an association
between asymptomatic and symptomatic infection, and elevated IgG2 and IgG1 levels,
respectively (Deplazes et al., 1995; Nieto et al., 1999; Iniesta et al., 2005; Carrillo et
al., 2007; Ramos et al., 2008), whilst others show the opposite associations (Cordeiro-
da-Silva et al., 2003; Reis et al., 2006b; Cardoso et al., 2007; Iniesta et al., 2007). The
lack of consistent associations from analysis of IgG1:IgG2 levels in infected animals
may result from lack of specificity of commercially available polyclonal conjugates
used in the majority of canine studies (Day, 2007), a potential problem which has been
largely ignored in published research to date.
In summary, it is clear that in all species studied, the main effector mechanism in
resistance to leishmaniasis is macrophage activation by IFN- and TNF-α to kill
intracellular parasites via the L-arginine dependent nitric oxide pathway, and in
addition CD8+ cytotoxic T lymphocytes may be involved in direct lysis of infected
macrophages (Pinelli et al., 1995; Ramiro et al., 2003; Rafati et al., 2005). However,
in dogs the importance of the Th1/Th2/Treg paradigm in developing/suppressing this
end pathway is still open to debate, and in particular the current controversy regarding
immunological correlates of protection in the dog (for example, specific IL-10
response and IgG class expression) requires further clarification.
Previous research has shown the importance of genetic factors in disease susceptibility
in mice and humans (Blackwell, 1996; Karplus et al., 2002; Jeronimo et al., 2007).
9Differential breed susceptibility to canine VL has also been observed in the Ibizan
hound (Solano-Gallego et al., 2000) which is more resistant to disease than other
breeds, and this has prompted interest in other genetic factors influencing canine
resistance and susceptibility to Leishmania, such as polymorphism at gene loci DLA-
DRB1 (Quinnell et al., 2003b), and NRAMP1 (Altet et al., 2002). This underlines the
need for a greater understanding of canine immunology and response to Leishmania
infection in genetically diverse populations of dogs, and suggests that the pure bred
beagle dogs most commonly used in experimental canine leishmaniasis studies may
not be broadly representative of immune responses in natural populations of dogs in
endemic areas.
1.3 Experimental vaccines against zoonotic visceral leishmaniasis
An effective vaccine against an infectious pathogen should confer long lasting
protection against disease resulting from exposure to the live organism, and should be
safe, biologically stable, cost-effective and easy to administer.
A variety of vaccination strategies against Leishmania have been attempted, in the
mouse model as well as in human and canine trials. An important feature of the
leishmaniases, which has been exploited in vaccine research, is that protection against
one species of Leishmania has the potential to induce cross-protection to all species
(Coler and Reed, 2005). For example, vaccination of Indian langur monkeys with L.
major confers protection against experimental challenge with L. donovani (Misra et
al., 2001).
However, despite the use of many different vaccine candidates, delivered by different
inoculation routes and protocols, no human vaccine yet exists for routine use, and only
one prophylactic vaccine has been licensed (in Brazil) for administration to dogs.
Leishmania vaccines fall into three main categories:
1) Live whole parasite vaccines
2) First generation vaccines: whole killed parasites or fractions of parasite
preparations.
3) Second generation vaccines: defined vaccines such as recombinant protein antigens,
naked and virally vectored DNA vaccines, and genetically engineered attenuated or
gene knockout parasites.
Routes for inoculation include subcutaneous, intradermal and intra-peritoneal
administration (the latter more commonly used in experimental mice). Vaccines are
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normally inoculated by injection using a needle and syringe, though needle-free
methods have been developed, such as propulsion of small particles of vaccine-coated
inert metal through intact epidermis (Liu, 2007). In addition to the vaccine itself, other
pro-inflammatory chemical components known as adjuvants may be co-administered
to augment the cellular immune response, and recent research has highlighted the
potential of sandfly salivary proteins in this role to promote a protective vaccine
response (Collin et al., 2009).
1.3.1 Live whole parasite vaccines and first generation vaccines
Early attempts at vaccine formulation were based on whole live, attenuated or killed
parasites. The earliest of these methods, known as “leishmanization”, was practised in
the former Soviet Union from the 1930’s onwards for immunization of humans against
cutaneous leishmaniasis, and was also used in Israel in the 1970’s and in the Islamic
Republic of Iran in the 1980’s (Nadim et al., 1983). The process involves deliberate
intradermal inoculation of cultured viable L. major promastigotes, in a preferred part
of the body where the resulting ulcerative lesion will cause least inconvenience for the
patient, usually the deltoid area of the arm. A solid immunity to natural infection is
usually developed, which lasts for the lifetime of the patient. This process is still used
in some former soviet countries such as Uzbekistan (Modabber, 2000). However,
difficulties with standardization of the dose and quality control, as well as safety
concerns regarding human (or canine) inoculation with live unattenuated parasites are
obstacles to widespread adoption of this method. Inoculation of live Leishmania is also
inadvisable in areas where HIV infection is significantly prevalent in the human
population.
Vaccination strategies have been developed using crude preparations of killed
Leishmania parasites for prevention of both CL and VL (Genaro et al., 1996). Trials to
investigate the safety, immunogenicity and efficacy of these vaccines in humans have
been conducted in South America and the Middle East, using preparations of killed
whole promastigotes with or without bacillus Calmette-Guerin (BCG) adjuvant. In
general these trials have been disappointing, demonstrating only partial protection in
some subgroups of vaccinated patients. In Brazil a multi-strain combination of 5
autoclaved Leishmania strains was developed (Mayrink et al., 1979) which was
partially protective against CL. A simplified version of this vaccine containing only
one strain (L. amazonensis) was tested in Columbia (Velez et al., 2000) and Equador
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(Armijos et al., 2004), with mixed results, and has been registered in Brazil, for
adjunctive use in humans alongside chemotherapy but not for prophylactic use
(Khamesipour et al., 2006). Other first generation experimental vaccines for humans
include a combination of autoclaved L. major (ALM) promastigotes and BCG which
has been tested in Iran and Sudan. In the Sudanese trial, ALM + BCG induced
significantly higher rates of Leishmanin skin test (LST) conversion in those vaccinated
(30%, vs. 7% by BCG alone), and there was a 43% lower incidence of visceral
leishmaniasis in skin test responders as compared to non-responders. However, there
was no significant difference overall in disease incidence between vaccinees and
controls (Khalil et al., 2000). In Iran, similar results were obtained with this vaccine
formulation (Sharifi et al., 1998; Momeni et al., 1999). Adsorption of ALM onto alum
(aluminium hydroxide) adjuvant has shown more promise as a vaccine candidate. In
Sudan, this vaccine induced a high rate of LST conversion in those vaccinated, which
was maintained for at least 90 days post vaccination (Kamil et al., 2003).
In dogs, experimental trials of crude Leishmania vaccines have also been undertaken,
with mixed results (see table in Appendix 1 for details of all published canine vaccine
trials against Leishmania to date). In Iran, vaccination of dogs with autoclaved L.
infantum or L. major plus BCG adjuvant was protective against experimental infection
with L. infantum promastigotes delivered intraperitoneally. Field trials of this vaccine
were not promising (Mohebali et al., 1998), so to enhance immunogenicity the vaccine
was adsorbed onto alum, as described above. A single dose of alum/ALM/BCG given
to naturally exposed dogs in a double blind field trial showed 69% efficacy for
prevention of seroconversion (Mohebali et al., 2004a). Cell-mediated immunity and
parasite persistence were not investigated.
As a refinement of crude vaccines, vaccination of dogs with Leishmania fractions,
derived from cultured parasites by procedures such as Mendonca-Previato aqueous
extraction (Mendonca-Previato et al., 1983) have also been investigated. One of the
first canine vaccines, a partly purified preparation of lyophilized L. infantum (LiF2),
was administered to animals in a holoendemic area together with muramyl dipeptide
adjuvant. Paradoxically, the incidence in vaccinated animals was significantly higher
than controls in the first year post vaccination (Dunan et al., 1989) (though these
differences disappeared in the second year), despite the fact that in previous tests, this
vaccine was protective against CL in experimental murine models (Frommel et al.,
1988; Monjour et al., 1988). The authors of those studies speculated that failure to
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protect dogs against natural exposure may reflect differences between experimental
and natural hosts. Other research has suggested that some immunization regimes based
on killed parasites may result in disease exacerbation (Titus et al., 1984; Liew et al.,
1985). Conversely, L. infantum antigens (LiESAp) excreted/secreted in culture
(consisting mainly of a 54kDa protein) were shown to be 100% protective against
development of clinical disease and detectable infection in bone marrow culture from
experimentally infected dogs after 14 months (Lemesre et al., 2005). Subsequently, in
field trials of several hundred dogs that were naturally exposed to infection for 24
months (two transmission seasons), the infection rate of bone marrow detected by PCR
was significantly lower in the vaccinated animals, and vaccine efficacy was calculated
as 92% (Lemesre et al., 2007). However, the low overall number of infections (12/175
in the placebo group in comparison with 1/165 in the vaccine group) suggest that this
vaccine should in future be trialled in an area of higher incidence. The LiESAp vaccine
is currently undergoing trials as a second generation defined peptidic formulation with
QA21 adjuvant, dubbed “Cani Leish” (Papierok and Lemesre, 2009).
The most promising of the purified fraction vaccines is the fucose mannose ligand
(FML) vaccine based on a glyoproteic complex purified from L. donovani
promastigotes, which was shown to be safe, immunogenic and protective against
experimental challenge in rodent models (Palatnik-de-Sousa et al., 1994; Santos et al.,
1999; Paraguai de Souza et al., 2001). In dogs, the FML vaccine with saponin
adjuvant elicited enhanced levels of IFN-γ, NO and anti-Leishmania chagasi IgG2
(Araujo et al., 2009), and in Phase III field trials in Brazil demonstrated 95%
protection against the development of clinical disease with an efficacy of 80% after 41
months follow-up (Borja-Cabrera et al., 2002). The vaccine was shown to block
transmission by eliminating canine Leishmania parasite loads (hence availability to
sandflies), as determined by PCR carried out on peripheral blood and lymph node
aspirates (Nogueira et al., 2005). The FML vaccine, formulated with saponin adjuvant
(Riedel de Hahn saponin mixture) was subsequently licensed in Brazil as Leishmune
(Fort Dodge, Brazil) being the first licensed canine anti-Leishmania vaccine
worldwide. In these studies (Santos et al., 2002) as in other vaccine studies which
employed saponin adjuvants (Schetters et al., 1994), short-term side effects
attributable to saponin were documented (localised pain at the site of inoculation;
listlessness and anorexia for a few days; development of a swelling at the injection site
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in approximately 15% of dogs) (Parra et al., 2007; Santos et al., 2007). These side
effects may be of concern regarding potential loss of compliance among dog owners
and vets, and difficulties in licensing of the Leishmune vaccine in developed endemic
countries including Europe.
1.3.2 Second generation vaccines
1.3.2.1 Recombinant antigens and peptides
Peptides are the most commonly selected defined vaccine candidates, since they
engage T-cells and elicit the full spectrum of adaptive immune responses. Defined
recombinant Leishmania antigens are an attractive target for development as vaccines
because, in comparison with crude killed or purified parasite preparations, they are
easily standardized to conform to Good Manufacturing guidelines, and not dependent
on maintaining cultures of live parasites. The development of recombinant peptides as
vaccines has been aided by genetic studies of Leishmania (Herrera-Najera et al.,
2009), in particular the sequencing of the complete genome of L. major (Ivens and
Blackwell, 1996) and the recent addition of the complete genomes for L. infantum and
L. braziliensis (Peacock et al., 2007). Recombinant peptides are generated by cloning
of Leishmania genes into bacterial plasmids, and subsequent expression of their
corresponding proteins in bacterial cultures. Cloning DNA which encodes more than
one protein into an expression vector permits the expression of recombinant
polyproteins. The concept of multi-antigen vaccines has been suggested as a means of
overcoming MHC-restricted antigen recognition which arises due to genetic
differences between individuals. This method has been used to create multivalent
recombinant protein vaccines presenting a broader range of protective epitopes, which
are less likely to suffer from MHC related unresponsiveness in a genetically
heterogeneous population, or between vaccinated individuals from different ethnic
backgrounds. In general, despite some success in trials summarized below, subunit
vaccines based on proteins or peptides have shown variable to poor protection against
challenge. Reasons for this may include failure of E. coli produced proteins to achieve
their native conformation with respect to folding, appropriate glycosylation and other
post translational modifications (Handman, 2001).
Experimental testing of recombinant proteins in vivo has been conducted mainly in
preclinical trials in the murine model of infection, although some work has been
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conducted with primates and in dogs. So far, Leishmania antigens which have been
trialled as protein/peptide vaccines include glycoprotein 63 (gp63) (Jardim et al.,
1990), Leishmania homologue of the mammalian receptor for activated protein C
kinase (p36/LACK) (Mougneau et al., 1995), membrane glycoprotein 46 (gp46)
(Champsi and McMahon-Pratt, 1988), recombinant hydrophilic acylated surface
protein B1 (rHASPB1) (Stager et al., 2000), L. major promastigote surface antigen
(PSA-2) (Handman et al., 1995), kinetoplastid membrane protein (KMP-11) (Tolson et
al., 1994; Trujillo et al., 1999), the L. chagasi antigen LCR1 (Wilson et al., 1995),
and histone (H1) antigen (Masina et al., 2003). Recombinant proteins based on
antigens which are mainly expressed in the amastigote form of the parasite include
type I cysteine proteases a and b (CPa/CPb) (Rafati et al., 2002; Zadeh-Vakili et al.,
2004), and L. donovani amastigote-specific antigen (A2) (Ghosh et al., 2001).
Recombinant protein Q, formed from genetic fusion of five L. infantum ribosomal and
histone proteins, is protective against challenge in dogs when administered
intraperitoneally together with BCG adjuvant (Molano et al., 2003), and resulted in
both reduced parasite load and clinical signs of disease when administered alone
(Carcelen et al., 2009). However, protein Q was not protective against challenge when
administered with several different adjuvants in another canine trial (Poot et al., 2009).
Leishmania recombinant proteins derived from 3 immunodominant antigens, L. major
stress-inducible protein 1 (LmSTI1) Leishmania elongation initiation factor (LeIF),
and thiol-specific-antioxidant, presented in a variety of combinations, have conferred
good protection against L. major in murine (Campos-Neto et al., 2001) and nonhuman
primate models (G. Grimaldi & S. Reed, unpublished observation). A tri-fusion
vaccine has been developed (Skeiky et al., 2002) in which the three antigens listed
above were incorporated into one recombinant polyprotein known variously as Leish
111-f or polyprotein MML, which conferred protection to BALB/c mice against L.
major. This vaccine is currently undergoing immunogenicity and safety trials in
humans (Reed et al., 2003). In dogs, although this vaccine elicited high IgG2:IgG1
antibody ratios thought to indicate a predominantly Th1-type immune response, it
failed to protect against natural Leishmania infection or disease progression (Gradoni
et al., 2005). In other canine trials of recombinant protein vaccines, it was found that
immunization with L. infantum rHASPB1 or L. donovani H1 proteins adjuvanted with
MontanideTM ISA 720 were partially protective against development of clinical
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symptoms in dogs experimentally inoculated with a high dose of L. infantum (Moreno
et al., 2007).
1.3.2.2 DNA vaccines
A common drawback of recombinant protein vaccines is failure to induce long lasting
memory T-cell responses (Gurunathan et al., 1998). This problem has led to the
development of alternative approaches to delivery of vaccine antigens. The discovery
in the 1990’s that plasmid DNA injected intramuscularly could transfect muscle cells
and lead to the expression of encoded protein antigens by myocytes, led to the
realization that in this way recombinant nucleic acids could be used to deliver vaccine
antigens, a process termed DNA or genetic vaccination (Wolff et al., 1990). This
vaccination approach has been trialled with success in species such as mice, hamsters,
dogs and humans. Circular plasmids encoding the gene for a Leishmania antigen are
introduced into the host by injection where they are taken up by host cells in muscle
and other tissues. Under the control of a host promoter, intracellular expression and
polyadenylation of the antigen are followed by expression of the molecule on the cell’s
surface, where it is exposed to the immune system. Peptide products of DNA vaccines
interact with both MHC class I (Doe et al., 1996) and II (Encke et al., 1999) receptor
mediated pathways, and therefore induce both CD4+ and cytotoxic CD8+ T cells. The
prolonged antigen production which results from DNA vaccination is also
advantageous for the development of immunological memory (Mendez et al., 2001) in
which CD8+ T-cells play an important role.
DNA vaccines are generally less costly to produce than peptide or protein vaccines,
can be produced on a large scale with high purity, and maintain stability under a wide
variety of environmental conditions (Gurunathan et al., 2000). Extensive testing of
DNA plasmid vaccines showed that plasmid DNA remained at the site of injection
where it was slowly cleared by the host, and that genomic integration was highly
unlikely (Sheets et al., 2006b). Treatment related toxicities were limited to the
inoculation site and no adverse systemic effects of vaccination were recorded at doses
of up to 8mg DNA plasmid per inoculation (Sheets et al., 2006a). In human trials
(Wang et al., 1998) DNA vaccines were safe, evoked specific immunity, and produced
no side effects even in immunocompromised individuals (MacGregor et al., 1998).
DNA vaccination has been shown to be effective against a variety of pathogens in
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rodents and nonhuman primates, including murine Trypanasoma cruzi and Leishmania
infection (Gurunathan et al., 1997; Sepulveda et al., 2000; Rosati et al., 2009).
Some DNA vaccine candidates against leishmaniasis were initially investigated for
their potential as recombinant protein antigens in studies discussed in the previous
section. Plasmid DNA expressing Gp63 was the first DNA vaccine against
Leishmania, which conferred partial protection in mice to challenge with L. major (Xu
and Liew, 1994). Other DNA vaccines previously tested as recombinant antigens
include KMP-11 (Bhaumik et al., 2009) (Basu et al., 2005), and L. donovani-specific
A2 proteins (Ghosh et al., 2001). Cysteine proteinases, previously used singly as
recombinant protein antigens, also show potential for development as DNA vaccine
candidates in mice as a cocktail of CPa and CPb plasmids (Rafati et al., 2001). In
dogs, a study in Iran examined the effect of a vaccination regime involving a cocktail
of CPa and CPb DNA followed by recombinant CPa and CPb protein antigens prior to
experimental infection with L. infantum promastigotes (Rafati et al., 2005).
Vaccinated dogs remained free of infection in bone marrow and showed elevated
lymphoproliferative responses to rCPa and rCPb protein antigens.
A highly promising DNA vaccine which was initially investigated as a recombinant
protein antigen vaccine against murine L. major infection is a homologue of eukaryote
thiol-specific-antioxidant (TSA) (Levick et al., 1998; Campos-Neto et al., 2002), a
22.1 kDa protein identified by screening an expression library with murine immune
sera (Webb et al., 1998). This molecule has been cloned, sequenced and characterized
as tryparedoxin peroxidase (TRYP) during expressed sequence tag (EST) analysis of
L. major cDNA libraries in the search for vaccine candidates (Levick et al., 1996;
Levick et al., 1998), and a possible functional role has been identified for TRYP in
resistance to antimonial drugs against Leishmania (Wyllie et al., 2008). Vaccination of
mice with a cocktail of plasmid DNA’s encoding TSA (TRYP), LACK and LMSTI1
was protective against low dose intradermal challenge infection at 2 weeks and at 12
weeks post vaccination (Mendez et al., 2001).
It is known that the method of delivery of DNA has an important influence on the
resultant immune response (Pertmer et al., 1996; Feltquate, 1998). Naked plasmid
DNA may be used, however heterologous so-called “prime/boost” strategies which
involve priming with DNA and boosting either with protein expressing the same
antigen, or the same DNA plasmid incorporated in an alternative delivery system such
as bacteria or a recombinant viral vector, may be more effective in stimulating long-
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lived immune responses. DNA/ recombinant vaccinia virus (rVV) heterologous
prime/boost vaccine protocols are now known to be superior to homologous challenge
with DNA, since they stimulate more robust so-called ‘synergistic’ cellular immune
responses (Gilbert et al., 2006). For example, it has been shown in mice that two
immunizations with naked DNA plasmids expressing TRYP elicit a similar protective
effect to prime/boost vaccination with DNA plasmids, followed by rVV expressing
TRYP, when infectious challenge was done in the effector phase of the immune
response (2 weeks post vaccination). However, the superior longevity of the memory
response induced by prime/boost DNA/rVV TRYP was confirmed by in vitro
restimulation of draining lymph node cells at 16 weeks post vaccination: the IFN-
responses and Th1 cytokine bias in mice vaccinated with the DNA/rVV prime-boost
protocol were similar at 16 weeks to those observed at 2 weeks post vaccination, and
significantly this memory response was not seen in mice vaccinated twice with DNA
TRYP alone (Stober et al., 2007). To date, the DNA/rVV prime/boost TRYP vaccine
described here has not been tested in dogs.
The p36/LACK antigen (Leishmania homologue for receptors for activated C kinase)
(Mougneau et al., 1995) has also been studied as a target for DNA vaccination
strategies against Leishmania. This highly conserved 36kDa protein is involved in
stimulation of an early expansion of IL-4 secreting cells (Julia and Glaichenhaus,
1999). In mice, vaccination with LACK DNA has been shown to be protective against
challenge with L. major (Mougneau et al., 1995; Gurunathan et al., 1997). However,
DNA-LACK vaccines were not protective against other Leishmania spp. such as L.
donovani and L. mexicana (Aguilar-Torrentera and Carlier, 2001; Melby et al., 2001).
Vaccination with DNA-LACK showed equivalent protective efficacy to LACK
recombinant protein antigen plus IL-12, in challenge experiments conducted in mice
with L. major (Gurunathan et al., 1997). However, vaccination with LACK DNA
together with DNA encoding Th1-type cytokines IL-12 or IL-18, followed by a
booster of LACK DNA expressed in rVV, led to greater cellular immune responses in
mice than were observed with the same protocol in the absence of cytokine DNA
(Tapia et al., 2003). In other work, prime/boost immunization carried out in BALB/c
mice with LACK protein followed by a booster with rVV co-expressing p36/LACK
and IL12 induced 52% reduction in lesion size and a reduction in parasite load
(Gonzalo et al., 2001).
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A critical factor influencing the efficacy of recombinant vaccinia virus vectors for
delivery of vaccine antigens is the strain of vaccinia virus selected. A prime/boost
vaccination with LACK DNA followed by the highly attenuated MVA expressing
LACK (MVA-LACK) elicited higher levels of IFN-γ and TNF-α secreting CD8+ T 
cells, and conferred greater protection against CL in mice, than the same protocol with
a replication competent Western Reserve strain rVV (Perez-Jimenez et al., 2006). In
contrast to Western Reserve strain rVV, MVA is a non-replicating vector with six
major genomic deletions in comparison with wild type vaccinia virus Ankara
(approximately 15% of the genome), and for this reason the probability of reversion to
virulence is extremely low. MVA is the current rVV strain of choice for clinical
investigations having been used in immunosuppressed macaques (Stittelaar et al.,
2001) and in over 120,000 human patients (Mayr and Danner, 1978) without
documented adverse side effects, even in immunocompromised humans (Meyer et al.,
2005). The DNA/MVA system has also been used for delivery of malaria vaccine in
humans without adverse side effects (Moorthy et al., 2003), and in dogs, a rabies
vaccine which employed the MVA vector has also been tested without signs of ill
effects (Weyer et al., 2007). The DNA/MVA approach is also currently being applied
in human vaccine development against HIV (Amara et al., 2002), tuberculosis
(McShane et al., 2001) and tumours (Palmowski et al., 2002).
In mice, a direct comparison of the protective efficacy of TRYP and LACK vaccines
delivered by DNA/DNA and DNA/MVA prime/boost protocols has been carried out,
which showed superior protective efficacy of DNA/MVA TRYP over LACK (Stober
et al., 2005). A higher ratio of antigen specific IgG1:IgG2a, and higher ex vivo IL-4
mRNA levels, in LACK compared to TRYP vaccinated mice suggested a bias towards
a Th2 response in the former. However, both antigens induced high IFN- and low IL-
4 following restimulation of draining lymph node cells with antigen in vitro. An
important predictor of the outcome of experimental infection was CD4+ T cell-derived
IL-10. In vaccinated mice, the ratio of post-vaccination, pre-challenge IFN-IL-10 in
draining lymph node cells was a clear indicator of vaccine success (Stober et al.,
2005), in that high IL-10 expression prior to infection predicted failure of the LACK
protocol, whereas low IL-10 predicted protection using TRYP. Challenge infection
caused further polarization to high IL-10/low IFN- with LACK and low IL-10/high
IFN- with TRYP. In vitro depletion experiments and ex vivo quantitative reverse
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transcriptase PCR demonstrated that antigen-driven CD4+CD25+Foxp3+ Treg1-like
cells were the primary source of IL-10 in LACK-vaccinated mice. Anti-IL-10
treatment in vivo demonstrated that IL-10 was functional in determining vaccine
failure, rendering LACK protective in the presence of high IFN-γ and low IL-4 / IL-5 
responses.
In dogs, however, Ramiro et al. (Ramiro et al., 2003) demonstrated good protective
efficacy of vaccines incorporating LACK. In that study, DNA/DNA vaccination using
the LACK antigen was effective in reducing organ parasite loads in dogs challenged
with L. infantum, and a heterologous prime/boost strategy using DNA followed by
recombinant rVV (wild-type Western Reserve strain) expressing LACK was even
more efficient at reducing clinical symptoms/score. The heterologous prime/boost
vaccination strategy gave 60% protection against infection in vaccinees tested over 17
months post experimental challenge with a high intravenous dose (1x108) of L.
infantum promastigotes, and 4/5 vaccinated dogs remained free of clinical disease
compared to 0/5 controls. In subsequent canine trials, comparing both DNA/Western
reserve rVV, and DNA/MVA heterologous prime/boost vaccines expressing LACK it
was demonstrated that fewer dogs showed clinical disease symptoms in the
DNA/MVA than DNA/Western reserve groups. Splenocytes from DNA/MVA dogs
showed a higher degree of antigen specific CD4+ and CD8+ T cell proliferation than
Western Reserve strain vaccinated dogs (Ramos et al., 2008). A further refinement of
the LACK vaccine has been expression of DNA in the antibiotic resistance gene free
pORT-LACK plasmid, to allay concerns regarding the spread of bacterial resistance in
the environment (Ramos et al., 2009). To date, there are no studies in dogs comparing
immunogenicity or efficacy of DNA/rVV LACK and TRYP vaccines.
1.3.2.3 Attenuated / genetically engineered live Leishmania vaccines
An alternative method for delivery of recombinant antigens is by cloning into a
suitable bacterial vector which is then inoculated (live) into the host. In the murine
model, gp63 delivered orally by an experimental vaccine strain of Salmonella
typhimurium has been shown to induce a significant degree of resistance against L.
major infection (Yang et al., 1990) Also in mice, the expression of the L. chagasi
antigen LCR1 by live intracellular bacteria (BCG strain of Mycobacterium bovis)
enhances the IFN- response to LCR1 and confers partial protection against challenge
with L. chagasi (Streit et al., 1996; Streit et al., 2000). A live vector such as BCG
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provides the advantage of prolonged exposure to the target antigen, increasing the
longevity of the immune response.
Genetic manipulation of Leishmania parasites to attenuate virulence or increase their
susceptibility to chemotherapy provides another avenue for live vaccine development.
A modified L. major with knock-out of the dihydrofolate reductase-thymidilate
synthetase (DHFR/TS) gene has been trialled in mice (Cruz et al., 1991). This
construct was able to survive for up to 2 months in vivo without causing pathology,
and intravenous or subcutaneous inoculation conferred short term protection against
challenge with L. major (Titus et al., 1995) and partial protection against L.
amazonensis (Veras et al., 1999). However, although this mutant parasite generated a
Th1-type response in human PBMC in vitro, further trials in primates were
disappointing.
Introduction of genes (so-called “suicidal cassettes”) into the Leishmania genome
which confer drug sensitivity to chemotherapeutics that are harmless to the human or
animal host, permits the establishment of a short-term infection that confers immunity
to the host before termination of the parasite with appropriate drug therapy. Infection
of BALB/c mice with a double drug sensitive strain of L. major induced progressively
growing lesions which resolved on treatment with either drug. No recurrence was
observed after 4 months (Davoudi et al., 2005) and high levels of IFN-γ correlated 
with protection against experimental challenge were observed.
A major obstacle to commercialization of any such vaccine that incorporates a live
attenuated organism is the potential for reversion to virulence, which together with
negative public perceptions of genetically modified organisms may be reasons why
genetically manipulated bacterial and live attenuated Leishmania vaccines have not
progressed beyond the experimental stages described above. Vaccines containing the
highly attenuated recombinant MVA are likely to be the only current exception to this,
given the extensive clinical trials of this vaccine vehicle which have been undertaken,
and the historical precedents described above.
1.4 Development of novel vaccines against zoonotic visceral leishmaniasis
The ability of DNA vaccines to induce long-lived CD4+ and CD8+ responses without
the absolute requirement for adjuvants, together with their high stability and lower cost
in comparison with recombinant antigens, makes this one of the most appropriate
avenues for the development of new canine vaccines against ZVL. Existing research
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summarized above suggests that prime/boost DNA/MVA LACK shows significant
potential for investigation as a vaccine candidate against canine Leishmania, and that
DNA/MVA TRYP is also highly promising, but as yet untested in dogs.
1.4.1 Safety and immunogenicity
In order to carry out trials of novel canine Leishmania vaccines as an initial step
towards commercialization and widespread use in both developing and developed
world endemic settings, it is necessary to demonstrate safety and immunogenicity of
the vaccine in the target species, as described in European Union legislative
frameworks (European Medicines Agency (1994; 1995)). Safety of vaccine
formulations at varying dose rates must be verified by monitoring physiological
parameters pre- and post-vaccination, to characterize the nature of any undesirable
local or systemic side effects, with defined clinical end points. This is important since
even relatively minor side effects may reduce the compliance of dog owners and
veterinary surgeons in uptake of a vaccine, reducing its commercial potential.
Assessment of immunogenicity requires measurement of pre-determined
immunological correlates of protective immunity. In the case of canine leishmaniasis,
research summarized above shows a fairly consistent association between protection
against progressive disease and specific Type-1 cytokine response, particularly IFN-γ. 
In vivo delayed type hypersensitivity, measured by intradermal reaction to crude or
defined parasite antigens, is also well validated as a correlate of protective cellular
immunity. In addition to these measures, other Th1- and Th2-type cytokines and
serological proxy measures of Th1/Th2 bias, as described, contribute to the evidence
base required to validate vaccine immunogenicity, despite some controversy over the
significance of Th2/Treg cytokine profiles and IgG subtype expression in dogs. It is
necessary initially to assess immunogenicity in dogs that are unexposed to infection,
since memory responses to vaccine alone cannot be assessed satisfactorily in animals
which have been boosted by challenge infection with the parasite.
1.4.2 Efficacy
Measuring the efficacy of vaccines against canine leishmaniasis is complicated by a
number of factors: some of these are inherent to the mechanism of transmission of this
vector-borne disease, while other issues concern the limitations of available diagnostic
methods for confirming infection in dogs. Traditionally, efficacy trials require
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experimental inoculation of the disease agent into vaccinated and control unvaccinated
(or placebo inoculated) animals, with assessment of efficacy based on the progression
of disease symptoms or evolution of parasite burdens in target tissues. In the case of
leishmaniasis, this method has questionable application to the measurement of vaccine
efficacy. There is increasing evidence to show that experimental intravenous injection
of high numbers (106-108 cultured promastigotes), as has been done in a majority of
vaccine trials to date (see Appendix I) is poorly representative of the intradermal
inoculation of lower numbers of the parasite by the sandfly vector (typically 100-1000
metacyclic promastigotes, in the presence of a large assortment of immunomodulatory
and vasoactive salivary compounds and parasite derived glycoconjugates) (Rogers et
al., 2004; Rogers et al., 2006; Peters et al., 2009). In theory, challenging vaccinated
dogs with infected sand flies could be done under laboratory conditions. In practice,
however, there are significant technical obstacles to maintaining and infecting large
insectary populations of the vector, and scaling-up this procedure to enable challenge
of sufficient numbers of dogs to enable observation of significant differences between
vaccine and control group incidence rates. Ultimately, large scale community-based
vaccine trials in dogs exposed to natural field infection will be required to validate
efficacy in target populations of domestic dogs. Assessment of vaccine efficacy in field
trials will be dependent on measurement of infection incidence in vaccinated vs control
animals, however there is no widely accepted ‘gold’ standard method for the diagnosis
of canine leishmaniasis. Clinical signs of disease are non-specific (Blavier et al.,
2001), and a significant proportion of infected dogs are asymptomatic (Baneth et al.,
2008), thus diagnosis must be confirmed with laboratory techniques. Many serological
methods are available, including indirect immunofluorescence (IFAT), direct
agglutination test (DAT), latex agglutination, immunochromatography, as well as a
number of ELISA procedures, each with their own advantages and disadvantages
(Iniesta et al., 2002; Alvar et al., 2004). Parasitiological techniques include direct
examination of stained tissues, impression smears by microscopy, and laboratory
culture of parasites (Manson-Bahr, 1987; Spreng, 1993). Culture is insensitive and
time consuming, and different strains of Leishmania vary in their capacity to grow in
vitro (Iniesta et al., 2002). PCR detection of Leishmania has improved the sensitivity
of parasitological diagnosis of ZVL in dogs, however there is a lack of standardization
of target DNA sequences and tissue sample types in the published research to date,
which complicates objective comparisons between vaccine trials. Furthermore,
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molecular techniques are technically more complex and considerably more expensive
than most serological methods, and these factors become important in the design of
vaccine trials involving longitudinal follow-up of large numbers of dogs in the field.
Thus, before embarking on vaccine efficacy field trials there is a need to validate
laboratory protocols which are sensitive and specific for the detection of canine
Leishmania infection, able to detect infection in its early stages to provide precise
estimates of vaccine efficacy, and which are cost-effective for use in potentially
resource-poor field environments. Finally, when measuring vaccine efficacy in the
canine reservoir of ZVL, an important additional factor of relevance to public health is
the infectiousness of infected dogs to sand flies, which are the vectors for transmission
of disease to humans. Even if only partially effective in preventing infection and/or
disease in the dog, a vaccine which reduced the infectiousness of dogs to the sand fly
vector has the potential to impact on transmission. To date, information on
experimental methods to measure canine infectiousness without the use of laboratory
bred sand flies in xenodiagnosis experiments is scanty, and further research is needed
in this area.
1.5 Overall aims
The overall aims of this study were thus:
(1) to carry out safety and immunogenicity trials of novel vaccines against canine ZVL
(prime/boost DNA/MVA TRYP and LACK) in domestic dogs, and
(2) to validate experimental protocols for detection of Leishmania infantum infection
and infectiousness in naturally exposed dogs, as diagnostic tools to enable the
measurement of vaccine efficacy in future large scale community-based trials of
experimental vaccines against canine leishmaniasis.
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Chapter 2: Materials & Methods
2.1 General methods
2.1.1 Cytokine assays
Measurement of IFN-γ, TNF-α, and IL-10 cytokine levels expressed by antigen 
stimulated lymphocytes was carried out in whole blood assays (WBA) (Shifrine et al.,
1978). Blood collected from study dogs by jugular or cephalic venepuncture into
heparin anticoagulant was diluted 1:10 in RPMI (Sigma) supplemented with 100IU/ml
penicillin, 100g/ml streptomycin and 2mM L-glutamine (Sigma), and incubated in
96-well flat bottomed polystyrene tissue culture plates (BD Biosciences). Triplicate
wells (200l per well) were incubated for each antigen or mitogen (TRYP, LACK,
CLA and Concanavalin A - all at 10g/ml), including negative control (unstimulated)
wells, for a period of 5 days at 37°C in 5% CO2 in air. Supernatants from each of the
three replicate wells were pooled and stored at -80oC until required, avoiding freeze-
thawing. Measurement of cytokines expressed in culture supernatants was carried out
by quantitative ELISA using commercially available reagents (R&D systems). Duoset
kits were used to detect IFN-γ and TNF-α, while matched pair monoclonal 
capture/polyclonal detection antibodies were employed for IL-10 measurement,
according to the manufacturer’s recommendations. Quantification of cytokine levels
was measured from optical absorbance of the coloured ELISA reaction product, with
reference to a standard dilution curve constructed from a known quantity of the
supplied recombinant protein standards. Background levels in unstimulated control
wells were deducted from antigen-stimulated values to quantify antigen-specific
cytokine production (with negative values recorded as zero).
2.1.2 Intradermal tests
Cellular immune responses in vivo were measured in vaccinated dogs by intradermal
skin testing (Pinelli et al., 1994) using 0.1µg TRYP and LACK recombinant antigen in
0.1ml sterile pyrogen-free PBS (or 0.1ml PBS alone, as a control) injected
intradermally at the right inner thigh, a distance of 5cm apart. The size of the indurated
area was measured at 72h after injection. Two measurements were taken at 90 degrees
to each other using vernier calipers, and the mean of the two numbers was recorded. A
positive reaction was considered as >5mm.
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2.1.3 ELISA
Total antigen-specific IgG, and IgG1/IgG2 subtypes, were measured in canine sera by
ELISA. 96-well polystyrene microtitre plates (Maxisorp; Nunc) were coated overnight
at 4oC with 50µl 0.05M carbonate/bicarbonate coating buffer, pH 9.6 (Sigma-Aldrich)
containing the appropriate amount of antigen (0.5µg TRYP, 0.25µg LACK, 50ng
rK39, or 1.0µg crude Leishmania antigen (CLA), which were obtained as described
below) per well. Wells were washed 3 times with PBS/0.05% Tween 20 (repeated
between each step detailed below). Blocking was performed with 2% dried milk
powder in carbonate/bicarbonate buffer for 2 hours at 37oC, and 50µl of the
appropriate dilution of dog serum in PBS/0.05% Tween20/2% dried milk powder was
added to each well. All samples were run in duplicate. For detection of total IgG, 50ul
of rabbit anti-dog IgG conjugated to horseradish peroxidase (HRP) (Sigma-Aldrich)
was used at 1:1000 dilution for 1 hour incubation at 37oC, while for antibody
subtyping, goat anti-IgG1-HRP conjugate at 1:500 dilution, or sheep anti-IgG2-HRP
conjugate at 1:10,000 dilution (Bethyl Laboratories) were added. Conjugate and
antigen concentrations stated above were selected based on the results of preliminary
experiments using checkerboard titrations. 100µl substrate solution
(Tetramethylbenzidine (TMB); Sigma-Aldrich) was then added, the reaction was
stopped after 20 minutes incubation at room temperature in darkness using 50µl 0.5 M
H2SO4, and the optical density of reaction product was read using an automated ELISA
plate reader (Multiskan EX, Thermo Fisher) set at 450nm. Positive and negative
controls were included on each plate. The sample-to-positive ratio (s/p) (Tijssen,
1985) for each sample was calculated as the mean raw absorbance at 450nm of
duplicate test samples relative to a strongly seropositive reference positive control
(from a polysymptomatic Brazilian dog with parasitologically confirmed Leishmania
infection) which was included on every ELISA plate. The method for determination of
the cut-off s/p value to define test samples as positive or negative is described in detail
in individual chapters. In assays requiring dichotomous output (positive/negative),
serum samples were tested at 1:100 dilution, in duplicate. Alternatively, in
experiments which required quantification of antigen-specific antibody titre (arbitrary
units), titration curves were plotted from doubling dilutions of each serum sample, in
duplicate. Negative controls were obtained from sera of 30 UK resident dogs with no
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history of foreign travel, presented at veterinary clinics in the UK for unrelated
reasons.
2.1.4 rK39 serological dipstick tests
rK39 immunochromatographic dipstick tests (Kalazar Detect Canine Rapid Test: Lot
No. HA1047 and HD1037) were obtained from Inbios International Inc. WA, USA,
and used to test 20 µl serum samples according to the manufacturer’s instructions. The
test involves detection of specific antibodies in serum which migrate by capillary
action from the pad on the end of the strip, carried by the supplied test buffer.
Antibodies bind to immobilized rK39 recombinant Leishmania antigen on the stick,
where a visible colour change (colourless to red) indicates positive binding. A positive
test result was recorded after 10 minutes when a red line appeared in the test area
(however faint), in addition to a red line in the migration control area to indicate
correct running of the test buffer.
2.1.5 Leishmania immunofluorescent antibody test (IFAT)
Sera were tested by the indirect immunofluorescence test with promastigotes of L.
infantum zymodeme MON-1, using anti-dog IgG conjugated to fluorescein
isothiocyanate (FITC) (Sigma-Aldrich), using standard techniques described
elsewhere (Gradoni and Gramiccia, 2004). A series of two-fold serum dilutions were
performed, with a conservative cut-off point of 1/40. Positive samples were titrated to
the end point, with the IFAT titre stated as the last dilution which gave positive
fluorescence. Positive and negative controls were included in each batch of 10
samples, and the negative cut-off titre was validated from the results of IFAT tests
carried out on 30 UK non-endemic dogs, all of which gave negative results at 1/40.
2.1.6 Clinical biochemistry and haematology
Blood was collected from vaccinated dogs by jugular or cephalic venepuncture in 2 ml
EDTA anti-coagulated and plain serum gel tubes. Samples were sent by same day
courier at +4°C to a commercial laboratory (Microanalysi, Athens), and processed for
routine biochemical tests (urea, creatinine, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), creatine phosphokinase (CPK) and total bilirubin) using a
standard Aeroset dry chemistry analyzer (Abbott-Toshiba, USA) and red/white blood
cell counts using a PCE-210 automatic blood cell counter (Erma Inc., Japan).
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2.1.7 DNA extraction
In the present study, DNA was extracted from canine skin biopsies using a commercial
kit (DNeasy, Qiagen) according to the manufacturer’s recommendations. DNA
extraction was also performed on 100µl aliquots of bone marrow, which were digested
in 100µl PK buffer (50mM KCl, 10mM Tris pH8.0, 0.05% Tween-20, 100µg/ml
Proteinase K). After overnight incubation at 56oC, a phenol-chloroform protocol was
used to extract DNA as follows: in a phase lock gel tube (VWR international, UK),
100µl of phenol: chloroform: isoamyl alcohol (25:24:1) was added and mixed,
followed by centrifugation at 13,000rpm for 5 minutes to separate the aqueous phase.
In a new phase lock tube, 100µl of chloroform: isoamyl alcohol (24:1) was added and
mixed, and the sample was centrifuged as before. 500µl of 30% polyethylene glycol
(PEG 6000)/1.6M NaCl solution was then added to the aqueous phase, before standing
for 1 hour at room temperature. Samples were centrifuged as before, and the DNA
pellet was washed with 70% ethanol and air dried before elution in 100µl molecular
biology grade H20. Total DNA quantity was measured by optical absorbance at 260nm
using a Nanodrop 1000 spectrophotometer (Thermo Scientific, UK) and purity was
estimated from the ratio of optical absorbance at 260:280 nm (Abs260/280). Extracted
DNA was stored at -20oC until required.
2.1.8 Conventional polymerase chain reaction (PCR) procedures
2.1.8.1 Nested ITS-1 PCR
DNA extracts were subjected to nested PCR targeting the internal transcribed spacer-1
region (ITS-1) of the ribosomal RNA (rRNA) gene (Parvizi et al., 2005). Using a
conventional thermal cycler (iCycler, BioRad), first round reactions were carried out
to amplify the complete ITS1 region, with primers IR1 and IR2 (Cupolillo et al., 1995)
(see Appendix I for primer sequences). 2µl DNA extract was added in a 20µl reaction
mix, with primers at 1µM, 2.5mM MgCl2, 0.2mM dNTPs, and 1.25U Truestart Taq
(Fermentas). Second round PCRs were performed in separate tubes, using 1µl of a
1:10 dilution of first round PCR product in molecular biology grade H20. In the second
round, primers ITS1F and ITS2R4 were used to amplify ITS1 (together with the 5.8S
rRNA gene) (Parvizi et al., 2005; Parvizi and Ready, 2008). Second round primers
were used at 1µM, with 1.5mM MgCl2, and all other reaction conditions as described
above. Cycling conditions for both amplification rounds were: 1 cycle of 95oC for 1
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min, followed by 37 cycles of 95oC for 30 sec; 58oC for 30 sec; 72oC for 90 sec,
followed by 1 cycle of 72oC for 10 min. PCR products were electrophoresed on 1.5%
agarose gel as described below to look for a second round reaction product of 480bp.
The positive control was DNA taken from a highly symptomatic Brazil dog with
confirmed L. infantum infection by in vitro/in vivo parasitological culture, as
determined from the results of a previous study (Quinnell et al., 1997). Negative DNA
controls from non-endemic (UK) dogs were included in each run, in addition to
contamination controls for PCR solutions and sham extractions.
2.1.8.2 Nested kDNA PCR
A nested Leishmania genus-specific PCR (Noyes et al., 1998) was used to amplify a
variable region of kinetoplast minicircle DNA (kDNA). First round reactions were
carried out with external primers CSB2XF and CSB1XR. 2µl DNA extract was added
to make a total 20µl reaction mix, with primers at 1µM, 2.0mM MgCl2, 0.2mM
dNTPs, and 1U Truestart Taq (Fermentas). Second round PCR was performed in a
separate tube using 1µl of a 1:10 dilution of first round PCR product in molecular
biology grade H20 with primers 13Z and LiR and all reaction conditions as described
above. Cycling conditions for both rounds were: 1 cycle of 95oC for 1 min, followed
by 40 cycles of 95oC for 30 sec; 55oC for 30 sec; 72oC for 90 sec, followed by 1 cycle
of 72oC for 10 min. Electrophoresis was carried out as described below to enable
visualization of PCR products. The described kDNA nested PCR is not species-
specific, however species can be identified from reaction product sizes of approx.
750bp (L. tropica), 680bp (L. infantum), or 560bp (L. major). Positive and negative
controls were as described above.
2.1.8.3 Leishmania OligoC-TesT kit
OligoC-TesT kits were provided by the manufacturer (Coris Bioconcept, Gembloux,
Belgium) and were used according to product recommendations, for genus-specific
detection of Leishmania DNA (Deborggraeve et al., 2008). The test targets the
Leishmania 18S rRNA gene to carry out PCR amplification of a 115-bp product,
alongside which an internal PCR control template is co-amplified with the same
primers, allowing detection of PCR inhibition. 5µl DNA extract was amplified in a
total 50µl reaction volume with 1U Taq polymerase (Truestart Taq, Fermentas, UK)
using a conventional thermal cycler (iCycler, BioRad, UK). Thermal cycling
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conditions were: 1 cycle of 95oC for 15 minutes, followed by 40 cycles of 94oC for 30
sec; 60oC for 60 sec; 72oC for 60 sec, followed by 1 cycle of 72oC for 5 min; 94oC for
30sec.
Detection of specific PCR product was carried out within 30 minutes of completion of
the PCR, using the supplied double-sided dipsticks which replace detection by gel
electrophoresis. Briefly, 40µl PCR product was mixed with 40µl of the supplied
migration buffer in individual assay tubes. Leishmania and internal control PCR
amplicons hybridize with gold-labelled detection probes and specific biotinylated
capture probes in the lower part of the strip, and migrate upwards to capture areas,
where they accumulate on Neutralite avidin lines and become visible to the naked eye
as a red line. Following the manufacturer’s recommendations, a positive result was
recorded after 10 min incubation at 55oC when both the Leishmania test line and the
internal control line were visible, together with migration control lines which indicate
correct running of the test strip buffer. A positive result was also recorded when only
the Leishmania test line and migration control lines were visible. Negative results
were recorded when only the internal control line and migration control lines were
visible. PCR inhibition was recorded when migration control lines were visible but
neither Leishmania test nor internal control lines were visible. Positive and negative
controls, and sham DNA extractions, were also tested. Positive results were obtained
with control DNA extracted from cultured parasites of L. infantum
MHOM/FR/78/LEM75, L. tropica MHOM/SU/74/K27, L. major MHOM/SU/73/5-
ASKH, and L. donovani MHOM/IN/80/DD8. Negative control DNA from UK dogs
and sham extractions were OligoC-TesT negative. The lower limit of detection
claimed for the OligoC-TesT kit is 10fg Leishmania DNA (Deborggraeve et al.,
2008).
2.1.9 Agarose gel electrophoresis of PCR products
DNA amplified in conventional PCR was visualized through the use of 1.5% agarose
gels (Fermentas) made with 1× TAE, to which ethidium bromide was added during the
casting process to a final concentration of 0.025µg/ml. 10µl samples of PCR product
with 2µl 6× loading buffer (Fermentas) were pipetted into each gel lane. Gels were run
submerged in 1×TAE for 1 hour at 120V. A 100bp molecular size marker ladder
(Generuler 100bp Plus; Fermentas) was run alongside samples to allow determination
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of PCR product sizes. DNA was visualized, and bands were photographed, by
fluorescence on a UV transilluminator.
2.1.10 Real-time quantitative PCR (qPCR)
Primers and a fluorophore-labelled probe were used in a previously validated protocol
specific for a conserved region of L. infantum kDNA, which produces a 120-bp
amplicon (Francino et al., 2006). Primers LEISH-1 and LEISH-2 and Leishprobe (a
FAM-labelled TaqMan MGB probe: Applied Biosystems, UK) were added at 900nM
and 250nM respectively, in a 25µl total reaction volume with 2× TaqMan Universal
PCR Master Mix containing UNG Amperase (Applied Biosystems, UK) to avoid
carry-over contamination, and 5µl sample DNA at 1:10 dilution (bone marrow
samples) or 1:100 dilution (skin biopsies). Optimal dilution rates for sample DNA
were determined by preliminary optimization experiments. All DNA samples were
amplified in duplicate. The thermal cycling profile was 50oC for 2 min, 95oC for
10min, followed by 40 cycles of 95oC for 15s and 60oC for 60s, carried out on an
Applied Biosystems 7500 Fast Real-Time PCR system. Quantification of Leishmania
DNA was performed using an absolute method, by comparison of Ct values with those
from a standard curve constructed from 10-fold dilutions of L. infantum DNA
extracted from cultured parasites, from 1×106 to 0.1 parasite equivalents/ml (strain
MHOM/MA/67/ITMAP-263), which were run in triplicate on every plate. Pre-
developed TaqMan Assay reagents (Applied Biosystems, UK) were used to amplify
the 18S rRNA gene as an internal reference of canine genomic DNA, to normalize
Leishmania parasite load to canine gene copy number using the 2-ΔΔCt method (Livak
and Schmittgen, 2001), and to detect PCR inhibition. The positive control was DNA
from a bone marrow sample taken from a polysymptomatic Brazil dog with
parasitologically confirmed ZVL. Negative controls were DNA extracted from blood
samples of 10 UK dogs with no history of foreign travel.
2.1.11 Entomological monitoring
Entomological monitoring to detect the presence of sandflies in the area surrounding
kennels used for vaccine trials in Crete was carried out using standard techniques
(Alexander, 2000). Light trapping was done on 2 consecutive nights at monthly
intervals throughout the trial, using a battery operated CDC mini-light trap hung
adjacent to kennels at a height of 0.5m above ground level. Sticky paper trapping
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using 5 sheets of castor oil coated A4 paper attached to the front of the kennels and 5
sheets hung on a line from nearby vegetation was carried out continuously, with
inspection of sheets daily, and changing of sheets weekly. Insects caught by means of
light or sticky trapping were identified using standard entomological dichotomous
keys.
2.1.12 Statistical analysis
Comparison of mean cytokine levels in quantitative ELISAs, and antibody titres, were
performed using non-parametric Wilcoxon rank sum tests. Differences between
vaccine group biochemical and haematological parameters were tested for using one-
way ANOVA, with Scheffe multiple comparison tests where appropriate. Qualitative
agreement between paired (dichotomous) test results in individual dogs was assessed
using Cohen’s kappa (k) coefficient (Cohen, 1968) where agreement has been
characterized as excellent (k=1.00–0.81), good (k=0.80–0.61), moderate (k=0.60–
0.41), weak (k=0.40-0.21), or negligible (k=0.20–0.00) following others (Landis and
Koch, 1977). When comparing the sensitivity of different diagnostic tests to detect
ZVL infection, differences in proportions of positive samples were compared pairwise
by calculation of McNemar’s Chi-square (χ
2). In comparisons of ELISA and PCR tests
(with dichotomous results), Pearson’s χ
2 and Fisher’s Exact tests were used as
appropriate to compare the proportions positive between different groups. Receiver
operating characteristic (ROC) curve analysis of the sensitivity and specificity of
diagnostic tests is reported as the area under-the curve (AUC) statistic ranging from 0
to 1. Using this AUC value, diagnostic test performance was classified as excellent
(0.90-1), good (0.80-0.89), fair (0.70-0.79), poor (0.60-0.69), or worthless (0.50-0.59)
(Tape, 2004). In longitudinal analyses, binning of longitudinal time points was used
where indicated to equalize group sizes. When examining large longitudinal data sets
to measure trends and correlations between measured parameters, it is likely that
multiple non-independent observations were made in the same dog at different time
points. This feature of panel data is known as autocorrelation. Associations were thus
confirmed using generalized linear modelling (GLM) and generalized estimating
equation regression models (XTGEE) as appropriate, using robust standard errors,
accounting for autocorrelation by clustering on dog ID, and controlling for
confounding variables such as time from patent infection and clinical score. Statistical
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significance was set at P≤0.05; all analysis was carried out using STATA v9.0
(StataCorp, 2005).
2.1.13 Ethics
Samples from Greek dogs were collected in the field with the written informed
consent of dog owners (see Appendix III for example consent forms). Trials were
undertaken to confirm safety in the target population of genetically diverse outbred
dogs following EMeA scientific guidelines for veterinary medicinal products (EMeA,
1994; 1995), EEC directive 86/609/EEC (EEC, 1986) and with approval from local
government and the University of Warwick Biological Ethics Committee. Dogs were
cared for by fully trained animal house staff under veterinary supervision. Kennels
were approved by Hellenic Government Veterinary Officers and compliance with
relevant legal requirements under Greek laws (160/1991) relating to animal welfare
certified by the Hellenic Republic Ministry of Rural Development & Food: General
Veterinary Authority K.A.F.E. Department ‘A’ (see Appendix IV). Written informed
consent was gained from dog owners prior to commencement of all trials. Animals
remained the legal property of owners, and were returned after completion of the
study. In the absence of a Cretan ethical committee for animal procedures, protocols
conformed to the spirit of UK Home Office requirements for United Kingdom
research establishments, and with ethical approval from the University of Warwick
Biological Ethics Committee. Institutional approval for the use and modification of
kennels for the vaccine trials was granted by the University of Crete Scientific Board
(see Appendix IV).
Ethical issues pertaining to all Brazilian dog sampling have been described before
(Quinnell et al., 1997; Courtenay et al., 2002b). UK dog sera were collected from two
UK veterinary practices, with consent of owners, using surplus from samples taken for
veterinary clinical diagnostic purposes.
33
2.2 General laboratory reagents
Buffer solutions and reagents used in this study include:
 PBS/Tween 20: 138mM sodium chloride, 2.7mM potassium chloride (pH7.4),
0.05% (v/v) Tween 20.
 1 × TAE buffer: 40 mM Tris acetate, 1 mM EDTA (pH8.3).
 PK buffer: 50mM potassium chloride, 10mM Tris, (pH8.0), 100µg/ml proteinase
K, 0.05% (v/v) Tween 20.
 PEG buffer: 30% (w/v) PEG (polyethylene glycol) 6000, 1.6M sodium chloride.
 TE buffer: 10 mM Tris-HCl, 1 mM EDTA (pH 8.0).
Commercially available reagents used in the study are summarized in Table 1.
Primers used for polymerase chain reaction (PCR) amplification of DNA are listed in
Appendix II.
Table 1: Commercially sourced reagents used in the study
Reagent Purpose Manufacturer
RPMI cell culture medium Cytokine assays Sigma-Aldrich
L-glutamine-penicillin-streptomycin
solution (200 mM L-glutamine, 10,000
u/ml penicillin, and 10 mg/ml
streptomycin)
Cytokine assays Sigma-Aldrich
Concanavalin A Cytokine assays Sigma-Aldrich
Chloroform: isoamyl alcohol (24:1) DNA extraction Sigma-Aldrich
Phenol:chloroform: isoamyl alcohol
(25:24:1), 10mM Tris, pH8.0, 1mM
ETDA
DNA extraction Sigma-Aldrich
DNeasy blood and tissue kit DNA extraction Qiagen
Proteinase K DNA extraction Sigma-Aldrich
TaqMan Universal PCR Master Mix
(with UNG amperase)
Real-time PCR Applied
Biosystems
TaqMan Ribosomal RNA control
reagents
Real-time PCR Applied
Biosystems
Truestart Taq polymerase PCR Fermentas
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Reagent Purpose Manufacturer
Loading dye solution (6x) Gel
electrophoresis
Fermentas
Low melting point agarose Gel
electrophoresis
Fermentas
Generuler 100bp Plus DNA ladder Gel
electrophoresis
Fermentas
Goat anti-dog IgG1 antibody HRP
conjugate
ELISA Bethyl
Laboratories
Sheep anti-dog IgG2 antibody HRP
conjugate
ELISA Bethyl
Laboratories
Rabbit anti-dog IgG antibody HRP
conjugate
ELISA Sigma-Aldrich
Rabbit anti-dog IgG antibody FITC
conjugate
IFAT Sigma-Aldrich
Tetramethylbenzidine (TMB) substrate ELISA Sigma-Aldrich
Carbonate/bicarbonate coating buffer ELISA Sigma-Aldrich
Canine IL-10 MAb (Clone 138111) Cytokine
ELISA
R&D Systems
Canine IL-10 Biotinylated Affinity
Purified Polyclonal Ab
Cytokine
ELISA
R&D Systems
Canine TNF-α DuoSet Cytokine
ELISA
R&D Systems
Canine IFN-γ ELISA Duoset  Cytokine 
ELISA
R&D Systems
Streptavidin-HRP substrate Cytokine
ELISA
R&D Systems
Leishmania OligoC-TesT kit PCR Coris
Bioconcept
(provided FOC)
Kalazar detect dipsticks Serology Inbios
(provided FOC)
35
2.3 General equipment
Agarose gels were prepared in a 15 x 15 cm gel cast, and subsequent electrophoresis
was performed in an MS Choice 15 horizontal gel tank (Geneflow, UK) with electric
current supplied by a Consort EV215 power pack (Jencons, UK). DNA bands stained
with ethidium bromide were visualized on an UV transilluminator and photographed
on a Geneflash system (Syngene Bio Imaging).
Centrifugation was performed with a Minispin Plus microfuge (Eppendorf) for 0.5-
1.5ml microfuge tubes, and in a 5810R bench-top centrifuge (Eppendorf) with a
swing-out rotor for centrifugation of 96-well PCR plates.
Optical absorbance in ELISA assays was measured using a Thermo Fisher Multiskan
EX linked to a desktop PC running Ascent plate reading software.
DNA quantity and purity was measured in 2µl sample aliquots by optical absorbance
at 260/280nm using a Nanodrop 1000 spectrophotometer (Thermo Scientific, UK).
Conventional endpoint PCR was carried out in a heated-lid thermal cycler (iCycler,
BioRad, UK). Real time PCR was performed in an Applied Biosystems 7500 Fast
PCR system, and output plots were analyzed using Applied Biosystems sequence
detection software version 1.4.
2.4 Materials & samples sourced from study collaborators
2.4.1 Source of Leishmania antigens, DNA and MVA vaccines
Recombinant proteins used for in vitro immunology assays, and to test intradermal
reactivity in vivo, were prepared by Novexin Ltd (Babraham, UK) under conditions
conforming to Good Laboratory Practice (GLP) using constructs originally prepared
by the Cambridge Institute for Medical Research (Stober et al., 2005) by cloning
TRYP or LACK into the expression vector pET-15b (Novagen) and transformation
into Escherichia coli BL21 (DE3) host cells. Recombinant protein was purified by
affinity column chromatography using 1ml HisTrap FF columns (GE Healthcare).
Immobilised target proteins were washed with buffer containing NV polymer to
dissociate and remove endotoxin contamination before being eluted with 10 mM Tris-
HCl (pH 8.5), 0.5 M NaCl and 250 mM imidazole, and desalted into low-LPS PBS
using PD10 desalting columns (GE Healthcare). Proteins were diluted in pyrogen-free
PBS for intradermal inoculation into dogs. Crude freeze-thawed Leishmania infantum
antigen (CLA) was prepared from stationary phase promastigotes of L. donovani LV9
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as described previously (Stober et al., 2005), by re-suspension in 10 mM Tris-HCl (pH
8.5), 0.5 M NaCl, 1 mM PMSF, and 50 µg/ml leupeptin, and freeze-thawing three
times over liquid nitrogen. Recombinant rK39 antigen, prepared as previously
described (Burns Jr et al., 1993) from L. chagasi (MHOM/BR/82/BA-2,C1), was
provided by Prof. K.P. Chang (Rosalind Franklin University of Medicine and Science,
Chicago).
DNA and recombinant MVA TRYP and LACK vaccines were manufactured by our
collaborators as described below, and in previous research (Stober et al., 2005).
To produce DNA vaccines, LACK (amino acids 143–312) and TRYP (full-length,
amino acids 1–199,) were amplified from cDNA clones lmk5 (accession number
W88311) and lmf30 (accession number T67356), respectively, obtained from a L.
major substrain LV39 (MRHO/SU/59/P) cDNA library. Both genes were inserted
downstream of the CMV promoter into the expression vector pcDNA3 (Invitrogen
Life Technologies). Empty pcDNA3 was used as vector control. Plasmid DNA for use
in vaccines was purified using EndoFree Plasmid Maxi kits (Qiagen) with pyrogen-
free material, and the final pellet was resuspended for injection in pyrogen-free PBS.
This work was carried out by the Cambridge Institute for Medical Research, and DNA
vaccines were supplied as frozen aliquots for use in the present study.
To manufacture recombinant MVA vaccines, the viral expression vector pMJ601 was
modified by replacing the early 7.5-kDa promoter and lacZ with the early/late 7.5-kDa
promoter and the selectable marker gene vaccinia virus K1L, respectively, to generate
pMJ601K1L. LACK and TRYP were cloned into the thymidine kinase locus of
pMJ601 vector downstream of the synthetic strong promoter. rMVA was obtained by
infecting permissive hamster Syrian kidney cells (BHK-21) with wild-type MVA and
simultaneously transfecting BHK-21 cells with LACK, TRYP, or vector plasmids
using the FuGENE 6 transfection reagent (Roche Diagnostics). After 48h, infected
cells were harvested, and rMVA was selected by plaque assay in nonpermissive rabbit
kidney epithelial cells (RK13). Coinsertion of the vaccinia virus K1L gene with the
Leishmania antigen confers rMVA the ability to grow in RK13 cells. This selection
procedure was repeated three times, and the insertion of LACK and TRYP into the
viral genome was confirmed by PCR. For vaccinations, semipurified stocks of rMVA
grown in RK13 cells were prepared by ultracentrifugation through a sucrose cushion,
resuspended in 10 mM Tris-HCl (pH 9.0). Expression of protein from MVA-infected
culture lysate was demonstrated by Western blotting using sera from DNA-vaccinated
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mice. The expected protein bands at 18kDa for LACK and at 22 kDa for TRYP were
observed. This work was carried out by the Centro de Biología Molecular Severo
Ochoa, and recombinant MVA vaccines were supplied for the present study as frozen
aliquots.
2.4.2 Source of positive control Leishmania DNA for PCR procedures
Positive control DNA from cultured Leishmania promastigotes, for use in
conventional PCR procedures, was provided by Dr. I. Mauricio at the London School
of Hygiene and Tropical Medicine. Species and strains obtained were: L. infantum
MHOM/TN/82/IPT1(LEM235) & MHOM/FR/78/LEM75, L. tropica
MHOM/SU/74/K27, L. major MHOM/SU/73/5-ASKH, and L. donovani
MHOM/IN/80/DD8. To quantify L. infantum parasite burdens using real-time qPCR, a
standard curve was constructed using serial dilutions of DNA extracted from known
numbers of cultured promastigotes, which were enumerated using a haemocytometer.
DNA extracted from L. infantum strain MHOM/MA/67/ITMAP-263 was obtained
from Dr. A. Tomas (Instituto de Biologia Molecular e Celular, Portugal) for this
purpose.
2.4.3 Clinical samples from naturally ZVL infected Brazilian dogs and foxes
We used samples taken from a previously described large-scale longitudinal field
study of dogs in the municipality of Salvaterra, Marajó Island, Pará state, Brazil. In
that study, blood, bone marrow, and ear biopsy samples were obtained from naturally
exposed outbred dogs at approximately 2 month intervals for up to 24 months post
initial natural exposure to infection in the field. These dogs were previously tested by
serology, bone marrow PCR and parasitological culture (in vitro and in vivo in
hamsters), and clinically examined, as described below and elsewhere (Quinnell et al.,
1997; Quinnell et al., 2001a; Courtenay et al., 2002b). A sympatric population of
free-living crab-eating foxes (Cerdocyon thous) were also trapped for testing as above
(Courtenay et al., 2002a).
In the previous research, bone marrow samples were aspirated from the iliac crest of
anaesthetized dogs or foxes whilst full-thickness skin biopsies were taken from the
pinna of each animal’s left ear using a 5mm biopsy punch, as described (Quinnell et
al., 2001a). Both sample types were collected into 200µl buffer (15 mM Tris, pH 8.3,
1 mM EDTA, 150 mM NaCl) containing 1% SDS, incubated at 65 °C for 2 h and
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stored at -20°C. 20ml venous blood was collected from each animal, and serum
samples were similarly stored at -20°C. These samples were kindly made available for
the current study from the archived material, by Dr. R. Quinnell at the Institute of
Integrative and Comparative Biology, University of Leeds.
2.4.4 Previous serology and parasitology on Brazilian dog and fox samples
In the previous Brazil study, DNA was extracted from bone marrow samples using a
phenol-chloroform extraction protocol as described (Quinnell et al., 2001a). PCR was
carried out using primers DBY and AJS31 (specific for L. donovani group parasites),
followed by gel electrophoresis and hybridization with the digoxygenin-labelled
oligonucleotide probe B4Rsa to amplify and detect an 805-bp fragment of minicircle
kDNA (Smyth et al., 1992; Scrimgeour et al., 1998), and with primers R221 and R332
to amplify a 604-bp fragment of the small ribosomal subunit RNA gene of all
Leishmania species, for detection using probe R331 (Van Eys et al., 1992). Positives
were defined as samples that were positive by both primer sets. Also in the previously
performed study, bone marrow samples were inoculated onto sterile Difco blood agar
slopes or into golden hamsters for in vitro / in vivo parasite culture and isolation using
standard techniques, as described (Quinnell et al., 1997).
Sera were previously tested for anti-Leishmania IgG in enzyme linked immunosorbent
assays (ELISAs), using crude parasite antigen (CLA), and defined as positive or
negative using a cut-off point calculated as previously described (Quinnell et al.,
1997). IgG antibody titre was obtained from doubling dilutions of test samples titrated
from 1/50 to 1/800 in duplicate where possible. Titres were expressed with reference
to a highly positive control serum which was titrated 2-fold from 1:100 to 1:3,276,800
on every plate, and assigned a number of arbitrary units equal to the reciprocal of the
highest dilution at which optical density (O.D.) of the reaction product exceeded the
mean +3S.D. of the background (no sample) wells.
2.4.5 Previous clinical examinations of Brazilian dogs and foxes
Dogs and foxes in the previously described study in were clinically examined and
scored using a semi-quantitative method by scoring on a scale 0 (absent) to 3 (intense)
six typical clinical signs of leishmaniasis (alopecia, dermatitis, chancres,
conjunctivitis, onychogryphosis, and lymphadenopathy), as described (Quinnell et al.,
2001a). A total clinical score of 0-2 was classed as asymptomatic, 3-6 as
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oligosymptomatic, and 7 as polysymptomatic, based on inspection of background
clinical presentations.
2.4.6 Previous xenodiagnosis carried out on Brazilian dogs and foxes
Xenodiagnosis experiments on dogs and mark-recaptured foxes in Brazil were carried
out previously, as described (Courtenay et al., 2002a; Courtenay et al., 2002b).
Briefly, dogs or anaesthetized foxes were placed into individual cages sheathed in
sandfly-proof netting. Unfed female Lutzomyia longipalpis laboratory-reared sandflies
(2–3 days after emergence) were introduced into the cage and were allowed to feed
overnight (dogs) or for 1-2 hours in darkness (foxes) under black hessian with access
to the whole body. Four to five days after the blood meal, fully-fed flies were dissected
and examined by microscopy for visible promastigote life stages in the thoracic
midgut, indicative of parasite development to the infectious stage. The number of
engorged infected/uninfected flies per cage was recorded, to calculate the proportion of
flies infected by each animal at each repeat time point.
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Chapter 3: Safety and immunogenicity of prime/boost
DNA/ modified vaccinia virus Ankara Leishmania vaccines
in dogs.
3.1 Introduction
Currently the sole commercially available Leishmania vaccine (Leishmune®), based
on a purified parasite preparation with saponin adjuvants, is licensed for use in dogs
only in Brazil (Dantas-Torres, 2006). Although trials showed high vaccine efficacy
(Borja-Cabrera et al., 2002), transient adjuvant-related side effects (Parra et al., 2007)
may reduce uptake and compliance among vets and dog owners. Development of
additional novel vaccine candidates is advisable, since the next generation
vaccines/vaccine antigens should be available to combat the evolution of parasite
strains which are capable of infecting vaccinated individuals. We should also continue
to improve on methods of delivery that will elicit lasting immunological memory in
the absence of side effects. Experimental DNA vaccines are the subject of increasing
numbers of human and veterinary clinical trials, since they elicit the T-cell memory
required for long term protection (Mendez et al., 2001), are extremely safe, easy to
standardize, and are highly stable for storage and distribution purposes in tropical
environments where cold chain may be unavailable (Dumonteil, 2007). As a
development of DNA vaccination, DNA/rVV prime boost protocols are a promising
avenue for development of a vaccine against canine ZVL, as discussed more fully in
Chapter 1.
Analysis of expressed sequence tags from cDNA libraries of Leishmania major
(Levick et al., 1996) led to the discovery and functional characterisation (Levick et al.,
1998) of tryparedoxin peroxidase (TRYP, also known as thiol specific antioxidant or
TSA (Webb et al., 1998)). DNA alone or DNA/MVA prime/boost vaccine delivery
highlighted TRYP as a highly effective inducer of protective immunity against
virulent challenge with Leishmania major in susceptible BALB/c mice (Stober et al.,
2005). These findings are consistent with studies using TRYP protein/adjuvant
combinations in mice and non-human primates (Campos-Neto et al., 2001).
Importantly, TRYP was shown to be far superior as a protective vaccine to the
previously described Leishmania homolog of the receptor for activated C kinase
(LACK) (Mougneau et al., 1995), the functional correlate for this being higher IL-10
from regulatory T cells elicited by LACK and a higher IFN-γ:IL-10 ratio associated 
41
with TRYP (indicative of a type-1 pro-inflammatory response driven by IFN-γ 
secreting Th1-type CD4+ cells) compared to LACK vaccination (Stober et al., 2005).
To date, no research has been published describing the immunological responses of
dogs to DNA/MVA TRYP as a potential vaccine against ZVL.
Following the previous successful safety, immunogenicity and efficacy studies of the
prime/boost DNA/MVA TRYP vaccine against L. major in mice (Stober et al., 2005;
Stober et al., 2007), this study aimed to demonstrate safety and immunogenicity of
DNA/MVA TRYP and LACK in a cohort of 22 uninfected, unexposed outbred dogs
followed-up for 4 months. The need for development of new vaccines in genetically
diverse outbred individuals is highlighted by research suggesting an important
genotypic component in immune responses (Altet et al., 2002; Quinnell et al., 2003b),
which may influence vaccine efficacy.
3.2 Methods
3.2.1 Study population and experimental set-up
A cohort of 22 young (median age 18 months, range 4-24 months) uninfected outbred
dogs from a ZVL endemic area (Crete, Greece) were enrolled for vaccination with
DNA/MVA TRYP, LACK or control, and followed-up for 4 months post prime/boost
vaccination between June and November 2007. Dogs were recruited with informed
consent from owners (see information sheet and owners declaration forms; Appendix
III) in villages of the Heraklion prefecture within 15km radius of the city of Heraklion,
on the criteria of being negative to all diagnostic tests: (1) Indirect immunofluorescent
antibody test (IFAT) (Gradoni and Gramiccia, 2004), (2) Crude Leishmania parasite
antigen (CLA) ELISA (Quinnell et al., 1997), and (3) ITS-1 PCR of buffy coat DNA
(Parvizi et al., 2005). The sample comprised 59% mixed breeds, the remainder
including local breeds (Cretan / Hellenic hounds) (n=4), Belgian Shepherd (n=2) and
pit bull terrier (n=1), at a male:female ratio of 1.2:1.
Dogs were housed in pairs, or individually (adjacent and within sight of each other), in
kennels located at the University Hospital of Crete, Heraklion, which were modified
for the purpose to conform with EC regulatory standards and UK Home Office Code
of Practice for housing of laboratory dogs (UK Home Office, 1989). Prior to
commencement of trials, all dogs received routine vaccination for distemper, canine
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parvovirus, canine adenovirus and leptospirosis (Hexadog, Merial), in addition to oral
antihelminthic treatment with praziquantel/ fenbendazole (Caniquantel Plus, New Vet
AE). To rule out exposure to Leishmania wild type during the transmission season
(May – October), dogs were fitted with deltamethrin-impregnated collars (Scalibor,
Intervet) and checked daily for collar loss, or treated instead with fortnightly doses of
topical 10% imidacloprid / 50% permethrin solution (Advantix, Bayer AG). Kennels
were monitored continuously for sandfly activity by routine light trapping and sticky
traps (Alexander, 2000), as described in Chapter 2. No sandflies were detected at the
kennels during the trial. After completion of trials, all dogs were returned to their
owners.
3.2.2 Vaccine administration
Dogs were randomized to receive intramuscular injections, from blinded operators, in
the craniolateral aspect of the right quadriceps femoris, with DNA TRYP or LACK
(100µg; n=4, or 1000µg; n=5), or control plasmid DNA (1000µg; n=4) on day 0,
followed 28 days later by 108 pfu MVA TRYP or LACK vaccine (or empty MVA
vehicle as control). This prime/boost regime is similar to that employed in previous
canine studies (Ramiro et al., 2003; Ramos et al., 2008), in which administration of
plasmid DNA (100µg) and recombinant vaccinia virus (107 – 108 pfu) were carried out
14 days apart. Safety and immunogenicity were measured as described below.
3.2.3 Safety
Dogs were kept under veterinary surveillance post “prime” and “boost” to detect the
occurrence of potential adverse reactions. Safety was assessed by daily clinical
examinations for 4 days post-vaccination (as detailed in European Medicines Agency
(EMeA) requirements (1994)), with defined clinical end-points (local pain on
palpation; inflammation; ulceration; alopecia; apathy; fever; diarrhoea; anorexia).
Body weight and condition score were recorded weekly. Pre- and post-vaccine
haematological and biochemical parameters were measured by collection of blood
samples at 2 days before and 2 days after each vaccination. Blood was collected by
jugular or cephalic venepuncture in 2ml EDTA anticoagulated and plain serum gel
tubes. Samples were sent by same day courier at +4oC to a commercial laboratory
(Microanalysi, Athens), and processed for routine biochemical tests (urea, creatinine,
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aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine
phosphokinase (CPK) and total bilirubin) as described in Chapter 2.
3.2.4 Immunogenicity
3.2.4.1 Cytokine assays
Immunogenicity was assessed by measurement of cytokine levels (IFN-γ, TNF-α, and 
IL-10) expressed by antigen stimulated lymphocytes in whole blood assays (WBA)
(Shifrine et al., 1978), measured pre-vaccination (day 0) and on days 26, 42, 70, 98
and 126 following first vaccination, as described in Chapter 2. Background levels in
unstimulated control wells were deducted from antigen-stimulated values to quantify
antigen-specific cytokine production (with negative values recorded as zero). The
mean values for background levels of IFN-γ, TNF-α and IL-10 were 65pg/ml (range 0-
313), 47pg/ml (range 0-527), and 162pg/ml (range 0-982). TRYP and LACK antigens
were not available to measure pre-vaccination (day 0) cytokine levels, therefore
cytokine measurements for these antigens commenced from day 26 onwards.
3.2.4.2 ELISA
Serological responses to vaccination (total specific IgG, IgG1 and IgG2 subtypes)
were measured by anti-TRYP and anti-LACK ELISA in all dogs at all 6 follow-up
time points (day 0-126), as described in Chapter 2. Positive and negative controls were
included on each plate. The sample-to-positive ratio (s/p) (Tijssen, 1985) for each
sample was calculated as the mean raw absorbance at 450nm of duplicate test samples
relative to a highly positive reference positive sample (from a parasitologically
confirmed polysymptomatic Brazilian dog (Quinnell et al., 1997)) which was included
on every ELISA plate. For subtyping experiments, to measure antigen-specific
antibody titre in arbitrary units, titration curves were plotted for each serum sample
using doubling dilutions from 1:100 to 1:3200 (IgG1) or alternate doubling dilutions
from 1:200 to 1:204,800 (IgG2). The cut-off point was calculated as the mean s/p ratio
of all dogs at time 0 (pre-vaccination). Using a maximum likelihood method
(Microsoft Excel software), a straight line was fitted to the linear portion of the s/p
ratio titration curve, and the reciprocal of the dilution rate at the point of intersection
with the cut-off value was calculated as an estimate of antibody titre.
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3.2.4.3 Intradermal tests
Cellular immune responses in vivo were measured at day 156 by intradermal skin
testing (Pinelli et al., 1994) using 0.1µg TRYP and LACK recombinant antigen
(prepared as described in Chapter 2) in 0.1ml sterile pyrogen-free PBS (or 0.1ml PBS
alone, as a control) injected intradermally at the right inner thigh, as described in
Chapter 2.
Summary of vaccine administration regime and sampling protocol
0 26 28 42 70 98 126 156
3.3 Results
3.3.1 Safety
3.3.1.1 Clinical examination
Examination post-vaccination detected no adverse clinical side effects except transient
pain on palpation of the injection site in one low dose LACK dog on the morning
following second vaccination. No swelling, alopecia or systemic signs were recorded
in any animal. Mean body weights of all vaccine groups increased slowly throughout
the trial (Figure 1), partly due to growth of young dogs in each group. One female
animal in the TRYP low dose group was vaccinated in the early stages of gestation,
before the pregnancy was apparent on clinical examination. Subsequently to discovery
of the pregnancy, this bitch was monitored closely throughout an uneventful gestation,
and delivered normal puppies. Data from this animal were excluded from all
subsequent analyses.
Prime
(DNA)
Boost
(MVA)
Intradermal test
Days
Blood samples for whole blood cytokine assays, and serology.
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Figure 1. Mean body weight (kg) of vaccine and control dogs.
Mean body weight (kg) at the indicated time points after 1st vaccination on Day 0 with
TRYP or LACK (low or high dose) DNA vaccine, or control placebo DNA. 2nd
vaccination with MVA TRYP, MVA LACK or placebo (as appropriate) was carried
out on Day 28.
3.3.1.2 Clinical biochemistry and haematology
Between group comparison of blood biochemical (AST, ALT, creatinine, urea, total
bilirubin and CPK) and haematological parameters (total red blood cell count) pre- and
post-prime and boost vaccinations showed no statistically significant differences
between TRYP, LACK and control groups (ANOVA; P0.11). Comparison between
group mean white blood cell counts at time 0 (before 1st vaccine) approached
significant difference (ANOVA; P=0.053), however no statistically significant
differences between individual vaccine groups were identified using the Scheffe
multiple comparison test, and no subsequent post-vaccine between-group differences
were found (P0.20) (Table 2).
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3.3.2 Immunogenicity
3.3.2.1 IFN-γ cytokine response 
Mean IFN-γ levels in response to WBA stimulation with TRYP antigen in TRYP high 
dose vaccinated dogs (1000µg DNA) were significantly higher than controls at all time
points from day 42 onwards. In the TRYP low dose (100µg DNA) group, after
removal of an outlier IFN-γ value of 3576 pg/ml at day 126, vaccinated dogs showed 
higher mean IFN-γ levels than controls at day 42 only (Figure 2). LACK-specific IFN-
γ responses in both high and low dose LACK vaccine groups were not significantly 
different from controls at any time point. As expected, TRYP vaccinated dogs showed
no IFN-γ response in LACK stimulated assays, and LACK vaccinated dogs were 
similarly unresponsive in TRYP stimulated assays. We did not detect any significant
difference in TRYP-specific IFN-γ levels between high and low dose TRYP groups at 
any time point (P0.27; Wilcoxon rank sum test). Similarly, no significant difference
was detected between high and low dose LACK dogs’ mean IFN-γ levels, in LACK-
stimulated WBA (P0.45; Wilcoxon rank sum test). The combined results of high and
low dose groups (Figure 3) showed that, overall, mean IFN-γ levels in response to 
TRYP WBA were significantly higher in TRYP vaccinated dogs than in controls at
3/4 time points post vaccination (P≤0.05: Wilcoxon rank sum test), whereas no
significant difference was seen between LACK vaccinated dogs and controls in LACK
WBA.
Mean IFN-γ responses to CLA antigen in all vaccine groups were consistently low 
(120pg/ml) or below background (data not shown), showing no significant
association with vaccine group.
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Vaccine
group
Erythrocytes Total white cells Lymphocytes
N Pre Post Pre Post Pre Post
TRYP
low dose
4 6.72
(5.84-
7.60)
6.58
(5.92-
7.23)
13.90
(7.88-
19.92)
13.05
(9.42-
16.67)
4.43
(2.63-
6.23)
4.50
(3.25-
5.75)
TRYP
high dose
5 6.03
(5.27-
6.80)
5.93
(4.93-
6.93)
12.00
(9.54-
14.46)
10.74
(8.27-
13.20)
3.84
(2.96-
4.72)
3.72
(2.87-
4.57)
LACK
low dose
4 6.24
(5.38-
7.10)
6.41
(5.99-
6.82)
10.90
(7.53-
14.27)
12.08
(5.57-
18.58)
3.53
(2.79-
4.26)
3.60
(0.77-
6.43)
LACK
high dose
5 6.56
(4.94-
8.17)
6.35
(5.26-
7.44)
12.98
(10.79-
15.16)
11.10
(8.62-
13.58)
3.98
(1.99-
5.96)
3.74
(2.82-
4.66)
Control 4 6.25
(3.84-
8.65)
6.10
(5.03-
7.16)
9.10
(5.60-
12.60)
9.68
(6.26-
13.10)
3.07
(0.08-
6.05)
2.83
(1.49-
4.16)
Vaccine
group
Erythrocytes Total white cells Lymphocytes
N Pre Post Pre Post Pre Post
TRYP
low dose
4 6.60
(5.57-
7.63)
6.59
(5.76-
7.42)
16.03
(10.92-
21.13)
14.60
(11.92-
17.27)
4.63
(4.10-
5.15)
4.10
(2.89-
5.31)
TRYP
high dose
5 6.69
(5.78-
7.60)
6.67
(5.74-
7.60)
13.88
(11.00-
16.76)
14.40
(11.20-
17.60)
4.44
(2.91-
5.97)
4.20
(3.10-
5.29)
LACK
low dose
4 6.45
(6.16-
6.73)
6.45
(6.01-
6.89)
11.48
(3.88-
19.07)
13.92
(8.47-
19.38)
3.40
(0.60-
6.20)
4.15
(3.13-
5.16)
LACK
high dose
5 6.56
(5.63-
7.49)
6.50
(5.72-
7.26)
12.50
(9.35-
15.65)
14.20
(12.48-
15.91)
4.18
(3.29-
5.07)
4.78
(2.88-
6.68)
Control 4 6.98
(5.86-
8.09)
6.89
(5.63-
8.14)
11.38
(8.34-
14.41)
11.99
(8.94-
15.00)
3.43
(2.49-
4.36)
3.70
(2.61-
4.78)
Table 2. Pre- and post-vaccination clinical haematological parameters.
Cell counts (×106 / ml blood; (95% C.I. in italics)) of erythrocytes, total white blood
cells and lymphocytes in venous blood samples taken from the cephalic or jugular vein
of vaccine trial dogs at 2 days pre- and 2 days post-vaccination. (A) DNA prime, (B)
MVA boost.
(A)
(B)
(B)
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Figure 2. Median IFN-γ in whole blood assays stimulated with TRYP.  
IFN-γ levels were measured in whole blood cytokine stimulation assays using TRYP 
antigen, at the indicated time points after 1st vaccination on Day 0 with TRYP or
LACK (low or high dose) DNA vaccine, or control placebo DNA. 2nd vaccination
with MVA TRYP, MVA LACK or placebo (as appropriate) was carried out on Day
28. Error bars indicate interquartile range. For each time point, the x-axis has been
stretched to allow clear visualization of error bars. *Denotes a significant difference
between vaccine group and control (Wilcoxon rank sum test; P ≤0.05). One outlier
point in TRYP low dose vaccine group at day 126 removed (IFN-γ = 3576 pg/ml); 
upper limit of interquartile ranges are truncated at 1000 pg/ml on the vertical scale, for
clarity.
0
100
200
300
400
500
600
700
800
900
1000
IF
N
-γ
 (
pg
/m
l)
Days from 1st vaccination
26 42 70 98 126
TRYP low dose
TRYP high dose
LACK low dose
LACK high dose
Control
*
*
*
*
*
49
Figure 3. Median IFN-γ in whole blood assays stimulated with TRYP and LACK.  
IFN-γ levels were measured in whole blood cytokine stimulation assays (WBA) by 
ELISA using TRYP and LACK antigen, at the indicated time points after 1st
vaccination. Error bars indicate interquartile range. Results from TRYP and LACK
low and high dose vaccine groups were not significantly different, and are
amalgamated here for clarity. Filled points on the graph represent IFN-γ response to 
TRYP antigen stimulation in whole blood assays, open points with show IFN-γ 
response to LACK stimulation. *Denotes a significant difference between vaccine
group and control (Wilcoxon rank sum test; P ≤0.05).
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3.3.2.2 IL-10 cytokine response
No significant differences were observed between high and low dose TRYP (P0.10)
or LACK (P0.09) vaccine group IL-10 responses, therefore results from the two dose
rates were combined for further analysis. Mean IL-10 levels in vaccinated dogs were
not significantly different from controls, showing no obvious trend over time apart
from a transient increase in mean IL-10 levels at Day 70 in both TRYP and LACK
vaccinated dogs (not significantly different from controls: P0.12; Wilcoxon rank sum
test), in response to both TRYP (Figure 4) and LACK antigens (similar results, data
not shown). Mean IL-10 responses to CLA antigen were consistently low (62pg/ml)
or below background, showing no significant association with vaccine group.
Figure 4. Median IL-10 in whole blood assays stimulated with TRYP.
IL-10 levels were measured in whole blood cytokine stimulation assays with TRYP
antigen, at the indicated time points after 1st vaccination. Error bars indicate
interquartile range. Results from TRYP and LACK low and high dose vaccine groups
are amalgamated for clarity. IL-10 responses to LACK were similar (data not shown).
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3.3.2.3 TNF-α cytokine response
None of the vaccinated groups showed significant differences in mean TNF-α level
compared with controls at any time point, though a significant upward trend in TNF-α
response to TRYP antigen over time was observed in dogs from all groups, including
controls, until the end of the study (linear regression: r2=0.32; P<0.001; n=21 dogs)
(Figure 5). In response to LACK antigen, a similar pattern and rising mean TNF-α
trend over time was observed (linear regression: r2=0.36; P<0.001; n=21 dogs; data
not shown graphically), moreover TRYP and LACK TNF-α responses within
individual samples correlated strongly (r20.89; P<0.001), irrespective of vaccine
group. The mean levels of TNF-α in ConA stimulated wells showed a less pronounced
but significant upward trend over time (linear regression: r2=0.40; P<0.001; n=21
dogs). Mean TNF-α responses to CLA antigen in all vaccine groups at all time points
were consistently low (100pg/ml) or below background, showing no significant
association with vaccine group (Figure 6).
Figure 5. Median TNF-α levels in whole blood assays stimulated with TRYP.
TNF- α levels were measured at the indicated time points after 1st vaccination. The
between-group differences in TNF-α levels were not significant. The trend of TNF-α
responses to LACK antigen were similar to those depicted (data not shown). Error bars
indicate interquartile range. The y-axis has been truncated at 5000 pg/ml for clarity.
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
TN
F-
al
ph
a
(p
g/
m
l)
Days from 1st vaccination
26 42 70 98 126
TRYP low dose
TRYP high dose
LACK low dose
LACK high dose
Control
52
Figure 6. Median TNF-α levels in response to stimulation with all antigens.
TNF- α levels were measured in whole blood cytokine stimulation assays with TRYP,
LACK, CLA and antigens, and the non-specific mitogen Concanavalin A, at the
indicated time points after 1st vaccination. Error bars indicate interquartile range.
Results from all dogs (n=21) are amalgamated.
3.3.2.4 Intradermal tests
A positive skin test response to TRYP antigen (>5mm) was observed in 4/5 TRYP
high dose dogs and 2/3 TRYP low dose dogs at day 156. The TRYP low dose dog
with a negative skin test result corresponded to an animal which had consistently low
IFN-γ cytokine assay responses to TRYP, whereas the skin test negative animal in the 
high dose TRYP group paradoxically showed high IFN-γ responses to TRYP 
throughout the trial. In LACK vaccinated dogs, there was a positive skin test response
to LACK antigen in 2/5 high dose dogs and 0/4 LACK low dose dogs.
3.3.2.5 ELISA IgG1/ IgG2 subtyping
High TRYP-specific total IgG sample-to-positive (s/p) ratios (as defined in section
3.2.4.2) were seen in dogs post TRYP vaccination, however LACK-specific total IgG
in LACK vaccinated dogs remained at baseline levels. Measurement of TRYP-specific
IgG1 and IgG2 subtypes demonstrated significantly higher levels of IgG2 in both high
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and low dose TRYP dogs compared to controls at all time points post vaccination (P
≤0.05; Wilcoxon rank sum test). No difference in IgG2 levels was detected between
high and low dose TRYP dogs, therefore data were combined (Figure 7). Data from
LACK vaccinated dogs are not shown due to absence of specific antibody response in
these dogs. IgG1 levels in TRYP vaccinated dogs were uniformly low, and not
significantly different from controls at any time point (Figure 7).
Figure 7. Median TRYP-specific IgG1 and IgG2 antibody class titres by vaccine
group.
TRYP-specific IgG responses were measured at the indicated time points by
ELISA using HRP conjugated polyclonal antibodies to detect IgG1 and IgG2
subtypes. Dogs were vaccinated with DNA TRYP or control placebo at Day 0.
MVA TRYP or placebo was administered at Day 28. N.B. Error bars indicate
interquartile range.
* denotes a significant difference between mean IgG levels in vaccinated and
control dogs (Wilcoxon rank sum test: P≤0.05).
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3.4 Discussion
The data presented in this chapter shows that uninfected, unexposed outbred endemic
dogs vaccinated with DNA/MVA TRYP prime/boost vaccine produced higher
antigen-specific levels of the signature type-1 cytokine IFN-γ in whole blood cytokine 
stimulation assays than placebo vaccinated dogs. LACK vaccinated dogs showed a
similar trend that was not statistically significant. A majority of TRYP and a minority
of LACK vaccinated dogs exhibited in vivo delayed-type hypersensitivity responses
to intradermal inoculation with the appropriate recombinant vaccine antigen at day
156, indicative of antigen-specific cellular memory recall responses. The elevated
antigen-specific IFN-γ level in TRYP vaccinated dogs compares with the reported 
high levels of IFN-γ associated with protection in murine models against L. major
(Stober et al., 2005; Stober et al., 2007) and L. donovani infection (Kaye et al., 1991;
Wilson et al., 2005; Ferreira et al., 2008), and in dogs against L. infantum infection
and disease (Pinelli et al., 1995; Lemesre et al., 2005; Rafati et al., 2005), and is thus
indicative of vaccine-induced protective type-1 immunity and memory phase
response.
TRYP vaccinated dogs were also characterized by an IgG2 class dominated response,
whereas IgG1 class levels remained low and were not significantly different to control
dogs at any time point. Taking IgG2/IgG1 ratio as a proxy measure of Th1/Th2
polarization of the immune response following previous research (Fujiwara et al.,
2005; Lemesre et al., 2005; Rafati et al., 2005; Lemesre et al., 2007), these results are
further evidence of a type-1 dominated response in the TRYP vaccine group, despite
some controversy over the association between canine IgG class ratio and protective
cellular immune response (Day, 2007), different to the clear patterns observed in mice
(Stober et al., 2005; Stober et al., 2007). In our hands, despite previous evidence of
seroconversion to LACK antigen after DNA/MVA LACK prime/boost vaccination in
murine trials (Stober et al., 2005), LACK-specific IgG1 and IgG2 did not increase
measurably from baseline levels. Strong responses to positive control sera excluded
the possibility of LACK ELISA failure. Undetectable specific IgG2 in LACK
vaccinated dogs contrasts with high levels in TRYP vaccinated animals, and may be
further evidence of superior vaccine immunogenicity of the latter. The absence of
significant IgG1 (Th2) responses in vaccinated dogs described here was as expected
due to the absence of challenge infection or restimulation with Leishmania antigens,
in contrast with previous canine trials of DNA/rVV prime/boost vaccines in which
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humoral responses were measured post-experimental challenge (Ramiro et al., 2003;
Ramos et al., 2008). For the same reason, we detected no antigen-specific increases in
IL-10 levels in either vaccine or control groups, making analysis of IFN-γ:IL-10 ratios 
uninformative until natural challenge experiments are conducted. In murine models
vaccinated with the same TRYP vaccine, a high ratio of pre-challenge IFN-IL-10 in
draining lymph node cells after in vivo crude parasite antigen restimulation was a
clear indicator of vaccine success, whereas a low ratio (due to elevated IL-10 levels)
predicted failure (Stober et al., 2005). In dogs, the existence of the Th1/Th2/Treg
paradigm in relation to L. infantum infection as observed for L. major in mice (Reiner
and Locksley, 1992; Reed and Scott, 1993; Mosmann and Sad, 1996) is not
completely resolved (as reviewed (Barbieri, 2006)), and there are conflicting results
regarding the role of IL-10, with some studies demonstrating IL-10 elevation in
symptomatic naturally or experimentally infected dogs, whereas other work failed to
show any association between IL-10 and clinical disease, as discussed in Chapter 1.
In dogs, additional type-1 cytokines associated with protective cellular mediated
responses include TNF-α, IL-2, IL-12, and IL-18 (Pinelli et al., 1994; Santos-Gomes
et al., 2002; Chamizo et al., 2005), with TNF-α the most frequently measured of these
in canine ZVL studies. Our results show that TNF-α produced in WBA in response to
both TRYP and LACK increased over time in all vaccine groups and controls
(Figures 5&6), and the lack of antigen specificity of this response was evident from
the approximately 1:1 relationship between TRYP- and LACK-stimulated TNF-α
within individual samples. Macrophages present in WBA may raise innate TNF-α
responses to contaminants such as bacterial lipopolysaccharide (LPS) (Kornbluth and
Edgington, 1986), however this would not explain the upward trend in mean WBA
TNF-α production in relation to the time from vaccination, nor the differing TNF-α
levels between dogs, nor the similar upward trend in response to ConA stimulation.
LPS contamination is also unlikely due to stringent manufacturing protocols under
which TRYP and LACK antigens were produced. An alternative explanation is that
non-specific priming of cellular immune responses occurred as a result of exposure to
DNA plasmids or MVA vaccine, regardless of the encoded antigen, with a similar
effect seen even in placebo dogs exposed to empty plasmids and MVA vehicle. This
may result from MVA-induced expansion of polyfunctional, TNF-α producing CD8+
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T-cells as previously seen in humans, though in that study, TNF-α production upon
re-exposure to antigen was virus specific (Precopio et al., 2007).
We did not detect specific cytokine responses to CLA in the present study, however
this does not preclude vaccine efficacy, as indicated elsewhere, for example in mice,
where protection afforded by sterol 24-c-methyltransferase vaccine against L.
infantum correlated with high levels of antigen-specific IFN-γ, but by comparison 
only very low levels IFN-γ were induced by CLA (Goto et al., 2007). Moreover, a
canine trial of HASPB1/H1 vaccine, in which lymphoproliferative responses to CLA
were absent post-vaccination, subsequently demonstrated partial protection against
high dose experimental challenge with L. infantum (Moreno et al., 2007).
In conclusion we have shown that vaccination of the important reservoir host of ZVL,
the domestic dog, with prime/boost DNA/MVA TRYP vaccine is free from adverse
side effects and shows appropriate immunogenicity consistent with protective
efficacy. The combination of in vitro and in vivo test results clearly demonstrates that
DNA/ MVA TRYP vaccine induces a type-1 dominated pro-inflammatory cellular
immune response which is necessary for protection against Leishmania challenge, and
that immune memory persists for at least four months post-vaccination in the absence
of restimulation or infection. Further research is required to replicate the trials
reported here in larger numbers of dogs, to identify and characterize cell surface
markers of cell populations mediating IFN-γ and TNF-α release, and to validate 
vaccine formulations such as freeze-dried MVA which would reduce reliance on cold
chain. In accordance with the 3R’s principles of animal research (Russell and Burch,
1959), this pilot study enables sample size calculations to be carried out, based on
detection of minimum expected differences in IFN-γ levels between vaccinated and 
control dogs of 446pg/ml (standardized difference = 1.39) (Whitley and Ball, 2002),
from the experimental data reported here. To achieve 90% power at the 0.05
significance level to detect this difference will require approx. 40 animals (assuming
unequal group sizes, ratio of vaccinated to control dogs = 5:1) (Whitley and Ball,
2002). Accounting for a pessimistic estimate of 15% loss to follow-up, it would be
necessary to enrol 48 dogs (or 2 cohorts of 24), i.e. 40 vaccinated dogs and 8 controls.
Subsequent to adequately replicated safety and immunogenicity trials in unexposed
dogs, community based field trials will next be required to test DNA/MVA TRYP
vaccine efficacy for prevention of ZVL infection and disease in naturally exposed
dogs in Leishmania endemic areas.
57
Chapter 4: Selection of appropriate serological tests to
measure the incidence of natural Leishmania infantum
infection during DNA/MVA prime/boost canine vaccine
trials.
4.1 Introduction
A growing number of canine experimental vaccines against L. infantum are under
development and being taken forward into field efficacy trials. To capture the
dynamics of vaccine efficacy over time, measurement of infection incidence (or force
of infection) by repeated longitudinal testing is required (Quinnell et al., 1997;
Courtenay et al., 2002b; Gradoni et al., 2005). Serological tests are technically
straightforward and may be more appropriate for large scale surveys than
parasitological methods which rely on time consuming, and often invasive sampling
methods, and are generally insensitive relative to serology. However, false positive
serological test results due to the presence of vaccine-induced antibodies would
invalidate incidence measures, depending on the magnitude and time course of the
vaccine-induced immunoglobulin response. This is a particular issue with vaccines
which incorporate crude or purified parasite derivatives, such as autoclaved L. major
(Lasri et al., 1999) or excreted/secreted L. infantum fractions (Lemesre et al., 2005).
Some investigators have used end-point seroconversion (e.g. at 16 months post
vaccination) as an indicator of natural infection for calculation of vaccine efficacy
(Mohebali et al., 2004a), on the unconfirmed assumption that vaccine-induced
antibody levels would decay rapidly. Dogs vaccinated with the fucose mannose ligand
(FML) vaccine (Leishmune®, Fort Dodge, USA), currently licensed for use only in
Brazil, may also test positive to serological tests for L. infantum (Borja-Cabrera et al.,
2002), rendering these tests ineffective for surveillance and intervention, though flow
cytometric procedures to distinguish antibody responses to Leishmune® from natural
infection have been described (Andrade et al., 2009).
Second generation vaccines which employ prime/boost DNA/rVV protocols
expressing Leishmania antigens have been successful in eliciting cellular immune
responses in murine and canine infection models, with concurrent high titres of
vaccine antigen-specific IgG (Ramiro et al., 2003; Stober et al., 2006; Stober et al.,
2007; Ramos et al., 2008; Carson et al., 2009). To date, no studies have characterized
differences in standard serological test results between DNA/rVV vaccinated
58
unexposed dogs and naturally infected dogs. Therefore, the first aim of the present
study was to test two widely used ELISAs, one based on crude Leishmania antigen
(CLA), the other based on the recombinant antigen rK39, to confirm that antigen
specific canine IgG responses to natural L. infantum infection differ from those
mounted after DNA/rVV vaccination. rK39 is a 39 amino acid repetitive
immunodominant B-cell epitope in a kinesin-related protein, conserved between L.
infantum and the L. donovani complex (Burns Jr et al., 1993). Recombinant rK39
ELISA has been used successfully as a diagnostic antigen for serodiagnosis in human
visceral leishmaniasis (VL) patients (Qu et al., 1994; Singh et al., 1995; Badaro et al.,
1996; Houghton, 1998; Zijlstra et al., 1998; Pedras et al., 2008) and in canine cases of
ZVL (Ozensoy et al., 1998; Rhalem et al., 1999; Zerpa et al., 2000; Scalone et al.,
2002; do Rosario et al., 2005; Mettler et al., 2005; Porrozzi et al., 2007; Taran et al.,
2007).
Longitudinal studies to measure vaccine efficacy require a diagnostic test with high
sensitivity to detect early stage infection, particularly since the period from infection
to clinical disease may vary from months (Quinnell et al., 1997) to more than a year
(Rioux et al., 1979), and asymptomatic dogs may comprise up to 50% of infected
animals in cross-sectional surveys (Lanotte et al., 1978; Fisa et al., 1999; Sideris et
al., 1999). However, longitudinal studies using serological tests to detect
asymptomatic recently infected dogs reveal that their comparative
sensitivity/specificity varies during the course of natural canine L. infantum infection
(Quinnell et al., 1997; Quinnell et al., 2001a; Solano-Gallego et al., 2001; Scalone et
al., 2002; Oliva et al., 2006; Otranto et al., 2009b). Furthermore, longitudinal follow-
up of experimentally challenged dogs (Rosypal et al., 2005; Talmi-Frank et al., 2006)
is unlikely to reflect immunological events in natural infection caused by the bite of
infected sandflies (Rogers et al., 2004; Poot et al., 2005; Peters et al., 2009).
Therefore the second aim of the present study was to quantify the sensitivities of CLA
and rK39 ELISAs as examples of two routine tests to detect early stage infection in
longitudinal analysis of a cohort of naturally infected dogs, for which the time course
of infection was parasitologically well characterized.
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4.2 Methods
4.2.1 Study animals and samples
Blood samples were obtained from three groups of dogs: (i) an unexposed group in
the UK, (ii) a DNA/rVV vaccinated, unexposed group in Crete, Greece, and (iii) a
naturally exposed group in Brazil. These groups are described in more detail below.
(i) 30 unexposed outbred UK dogs with no history of foreign travel that had attended
two UK veterinary clinics during June–December 2007 for unrelated clinical reasons.
(ii) 22 unexposed outbred Cretian dogs <24 months old (median 18 months, range 4-
24 months; 59% mixed breeds; male:female ratio=1.2:1) enrolled in trials of
experimental DNA/rVV Leishmania vaccines previously validated in mice (Stober et
al., 2006; Stober et al., 2007), reported in full in Chapter 3. Briefly, vaccination was
carried out on day 0 with plasmids encoding Leishmania antigens (DNA “prime”) and
on day 28 with 1x108 pfu modified vaccinia virus Ankara (MVA) (rVV “boost”).
Dogs were DNA/MVA vaccinated with either tryparedoxin peroxidase (TRYP; n=9),
Leishmania homolog of the receptor for activated C kinase (LACK; n=9), or control
placebo (n=4). Two different DNA dose rates were tested: low dose 100µg DNA
(n=4) and high dose 1000µg DNA (n=5). Dogs were blood sampled pre-vaccination
(time 0) and at 26, 42, 70, 98 and 126 days after first vaccination.
(iii) 81 outbred dogs from a previously described large-scale longitudinal field study
in Brazil (Quinnell et al., 1997), from which blood and bone marrow samples were
obtained at approximately 2 month intervals for up to 24 months post initial natural
exposure. These dogs were previously tested by CLA ELISA (L. infantum), bone
marrow PCR and parasitology (in vitro and in vivo bone marrow culture in hamsters),
and clinically examined, as described in Chapter 2 and elsewhere (Quinnell et al.,
1997; Quinnell et al., 2001a; Courtenay et al., 2002b), with subsequent storage of
serum at -20oC.
4.2.2 ELISA
In the present study, serum samples were tested using an ELISA based on the
recombinant antigen rK39, For comparison we also tested a CLA ELISA, which is
reported to be more sensitive (Mettler et al., 2005) and is widely used for serological
diagnosis. ELISA methods were as described in Chapter 2. ELISA cut-off points were
established by testing 30 unexposed non-endemic UK dogs (described in section
60
4.2.1). Conservative cut-off values were calculated from the UK dogs’ mean log10 s/p
ratio +3 S.D. and then back-transformed to obtain the raw s/p ratio cut-off value to
classify all dogs.
Serum samples from vaccinated dogs were additionally tested by the indirect
immunofluorescence test (IFAT) as described in Chapter 2. The negative cut-off titre
was validated from the results of IFAT tests carried out on 30 UK non-endemic dogs,
all of which gave negative results at 1/40.
For the Brazilian dogs, results were available from previous diagnostic tests as listed
in 4.2.1 (iii), above (Quinnell et al., 1997).
4.2.3 Serological responses in exposed, and vaccinated unexposed dogs
To compare CLA and rK39 ELISA sensitivity required populations of dogs that were
positive and negative for Leishmania infection. Using sera from Brazilian dogs
naturally exposed to Leishmania in the field, samples were defined as ‘true’ negatives
at all longitudinal sampling time points before first detection of infection (t0) by bone
marrow PCR, and/or in vitro/ in vivo culture, based on previous tests (Quinnell et al.,
1997). Samples were designated as ‘true’ positives at all sampling time points after
first detection of infection. For calculations of sensitivity, a single post-infection
sample was selected at random from each Brazilian dog, giving 63 ‘true’ positive
samples. Similarly, we selected a single pre-infection sample at random from each
dog to obtain 62 ‘true’ negatives. This method allowed estimation of CLA and rK39
ELISA sensitivity and specificity, removing potential statistical bias due to
autocorrelation (i.e. non-independent repeat samples from the same dog).
4.2.4 Serological test performance in the early stages of infection
Sensitivities of rK39 and CLA ELISAs in early stage infection were measured using
additional longitudinal sample series from dogs selected from the larger Brazilian
cohort study. A total of 128 samples were aligned relative to the longitudinally
assigned time of first detection of infection t0, as described above, to represent up to 4
consecutive time points: -2, t0, +2 and +4 months from t0.
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4.3 Results
4.3.1 Comparison of serological responses between vaccinated and infected dogs
Cut-off values for the rK39 and CLA ELISAs were first calculated from the
backtransformed mean log10 s/p ratio +3 S.D. of 30 UK unexposed dogs giving s/p
values of 0.259 and 0.422 respectively. Similarly, IFAT cut-off was established at the
first serial dilution (1/40), as none of the 30 UK dogs sampled showed positive results
at or above this dilution. All samples at all time points from TRYP and LACK
vaccinated unexposed dogs fell below the designated rK39 and CLA ELISA cut-off
values, and were therefore classed as negative, with no misclassification errors. There
were no significant differences between mean s/p ratios of low and high dose TRYP
or LACK vaccine groups at any time point (Wilcoxon rank sum test: P0.14), thus
aggregated results are shown (Figure 8). None of the vaccinated dogs had an
increased rK39-specific IgG titre post-vaccination, and responses were all lower than
the maximum response in UK negative controls. In contrast, two TRYP-vaccinated
dogs showed a transitory modest rise in anti-CLA response at 42 and 70 days post-
vaccination, but these responses had declined by day 98, and did not exceed the cut-
off at any follow-up time point. Weak positive IFAT titres of 1/40 – 1/80 were
detected in samples from 4 vaccinated dogs at day 28 and, 1 dog at days 42 and 70.
Measurement of ELISA sensitivity and specificity, using the same cut-off points to
classify the 62 ‘true’ negative and 63 ‘true’ positive dogs in Brazil (Figure 8), showed
significantly higher sensitivity of CLA (81%; 51/63) over rK39 ELISA (61.9%;
39/63: 2=5.60; P=0.018). Specificity was marginally lower for CLA than rK39
ELISA to correctly identify ‘true’ negatives (69.4% (43/62) vs 82.3% (51/62),
respectively; 2=2.81; P=0.093). The coefficient of agreement between ELISAs
indicated moderate agreement (kappa=0.53; S.E.=0.09; P<0.001).
4.3.2 ELISA sensitivity in longitudinal samples from naturally infected dogs
To test the relative sensitivities of the rK39 and CLA ELISAs with time from first
parasitological detection of infection t0, Brazil cohort dog samples (n=128) were
examined between t-2 to t+4 months (Table 3). This analysis showed that the
sensitivity of both ELISAs increased with time from t-2 months, and the cumulative
sensitivity of the rK39 ELISA by t+4 was not significantly different to the CLA
ELISA (Fisher’s Exact test; P=0.13). Analysis of the results for individual follow-up
62
time points showed that the sensitivity of rK39 ELISA was significantly lower
relative to CLA ELISA at t-2, t0 and t+2 months (2≥3.79; P≤0.05), whilst at t+4
months the rK39 ELISA sensitivity was not significantly different from that of the
CLA ELISA (Fisher’s Exact test; P=0.42). Agreement between rK39 and CLA
ELISAs was moderate (kappa=0.47; S.E.=0.08; P<0.001). Clinical scores in the
longitudinally sampled dogs increased over time, with the proportion of symptomatic
dogs (total clinical score >2) rising from 0.03 at t-2 to 0.38 at t+4 months. The
possibility that missing data introduced bias in our results was tested for and excluded
using logistic regression in a generalized linear model (GLM), which showed no
significant association between number of different parasitological tests (bone
marrow PCR, and/or in vitro/ in vivo culture) performed on a sample, and infection
status (z=1.45; P=0.15).
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Figure 8 . Comparison of IgG responses to rK39 (A) and crude Leishmania antigen
(CLA) (B) in vaccinated and naturally infected dogs.
Total IgG response was measured by (A) rK39 ELISA and (B) CLA ELISA. Sample-
to-positive (s/p) ratios of individual vaccine control and TRYP/LACK vaccinated
dogs (left), with s/p ratios of UK negative, and Brazil positive and negative dogs
(filled diamonds, right) as defined in text (error bars in the right hand panel show 95%
C.I. around mean s/p ratios of UK and Brazilian dogs). Brazil positive dogs were
defined as those with at least one previous positive sample by bone marrow PCR and
/or culture. Brazil negative dogs were defined as all those sampled before the time of
infection. Cut-off s/p values are rK39 = 0.259 and CLA = 0.422, representing the
back-transformed mean +3S.D. of the log10 s/p ratios of 30 UK negative dogs.
Vaccine trial dogs were vaccinated at day 0 (DNA TRYP/LACK) and day 28 (MVA
TRYP/LACK).
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Table 3. Proportion of Brazilian dogs positive in CLA and rK39 ELISAs, relative to
time of first detection of infection (t0).
Infection was defined by positivity to bone marrow PCR, and/or in vitro/in vivo
parasitological culture. Binomial 95% C.I. are shown in parentheses.
Test t-2 months t0 t+2 months t+4 months Cumulative
CLA 0.34
(0.19-0.52)
0.76
(0.59-0.88)
0.90
(0.74-0.98)
0.92
(0.75-0.99)
0.95
(0.82-0.99)
rK39 0.09
(0.02-0.23)
0.54
(0.37-0.71)
0.63
(0.44-0.80)
0.81
( 0.61-0.93)
0.84
(0.68-0.94 )
N 35 37 30 26 37
P-value 0.009** 0.05** 0.015** 0.42 0.13
N: Number of samples tested
** denotes a statistically significant difference between CLA ELISA and rK39 test
sensitivity at the indicated time point, at the stated level of probability (P-value),
using χ
2 or Fisher Exact tests as appropriate.
4.4 Discussion
Characterization of vaccine-induced antibody responses in the target species is an
essential component of vaccine development. Here, we compared IgG responses to
CLA and rK39 antigens in L. infantum naturally infected dogs, with those of
DNA/MVA TRYP and LACK vaccinated dogs. CLA is likely to contain significant
quantities of both TRYP and LACK (Mougneau et al., 1995; Levick et al., 1998),
while rK39 is derived from an unrelated gene in the parasite genome with no evidence
for cross-reactive epitopes at the level of amino acid sequence identity (Omnigene
BLAST analysis at www.geneDB.org). We therefore expected to observe CLA
ELISA seroconversion in vaccinated dogs and in naturally infected animals, and rK39
seroconversion only in the latter. Surprisingly, we found that both CLA and rK39
ELISA s/p ratios in vaccinated dogs were statistically similar to unexposed UK dogs,
and below the calculated cut-off values for seroconversion. A similar lack of specific
IgG for CLA, in response to vaccination with recombinant Leishmania proteins
HASPB1, Histone 1 and polyprotein MML has been reported previously (Moreno et
al., 2007). As described in Chapter 3, strong antigen-specific IgG responses to TRYP
(but not LACK) after vaccination of dogs in the present study demonstrated that weak
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or absent IgG responses were not due to vaccine failure, and whilst LACK-vaccinated
dogs did not mount significant IgG responses to LACK antigen, vaccine
immunogenicity was indicated by measurable cytokine responses to LACK.
Although all CLA ELISA s/p ratios in vaccinated dogs were below the cut-off value,
2 dogs showed a transitory CLA IgG response to vaccination. In contrast,
seroconversion above the cut-off value is consistently seen in natural infections, as
reported here and elsewhere (Quinnell et al., 1997; Solano-Gallego et al., 2005). This
important distinction would be apparent from the results of repeated testing of dogs in
longitudinal vaccine efficacy field trials. Low IFAT titres above the cut-off point
were observed in 6 post-TRYP-vaccination samples (n=4 dogs) suggesting that IFAT
would not be a suitable serological test to measure natural infection incidence in these
vaccinated dogs. The cut-off value of 1/40 used in the present study may be
conservative, as laboratories elsewhere specify cut-off values ranging from 1/20 to
1/200 (Abranches et al., 1983; Sideris et al., 1996; Acedo-Sanchez et al., 1998;
Mettler et al., 2005; da Silva et al., 2006; Oliva et al., 2006). The second aim of the
current study was to identify which serological test would give the most sensitive
measure of infection incidence. Whilst there is little doubt that sensitivity increases
with time from infection (Quinnell et al., 1997; Quinnell et al., 2001a; Courtenay et
al., 2002a; Courtenay et al., 2002b), precise incidence estimates will depend on the
test’s sensitivity to diagnose early stage infection. Our longitudinal comparisons of
relative test sensitivities show that the post-infection increase in rK39 ELISA
sensitivity lags behind that of CLA by up to 6 months. In contrast, a previous study of
6 experimentally infected beagles found that rK39 ELISA seroconversion preceded
CLA seroconversion (Talmi-Frank et al., 2006). This apparent difference could be
due to the use of i/v high dose challenge in the latter study, c.f. natural intradermal
inoculation by sand fly bite here. In cross-sectional analysis, CLA ELISA was the
more sensitive test (81% vs 61.9%), and rK39 ELISA was marginally more specific
(82.3% vs 69.4%). Absolute values of sensitivity and specificity for both ELISAs are
lower than published estimates (Reithinger et al., 2002; Scalone et al., 2002; Mettler
et al., 2005), though in longitudinal testing the sensitivities of both CLA and rK39
ELISAs after t+4 were relatively high (92% and 81%, respectively). ELISA
specificities calculated here will likely be underestimates since our ‘gold’ standard for
leishmaniasis diagnosis (bone marrow PCR and/or in vitro/in vivo culture) was itself
imperfect. The sensitivity of parasitological culture is low, whilst that of PCR is
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known to decline after the earliest stages of infection (Quinnell et al., 2001a). Hence,
samples that were ‘gold’ standard negative but tested rK39 or CLA ELISA
seropositive do not necessarily represent false positives. Further evidence of
discordance between PCR/culture and serological test results exists in other research
(Reithinger et al., 2002; Otranto et al., 2009b). On the other hand, it is always
necessary to rule out false positives due to serological cross-reactivity with antibodies
to other endemic canine parasitic infections. A CLA ELISA false positive rate of up
to 85% has been observed in studies testing serum from small numbers of dogs
infected with Trypanosoma cruzi (do Rosario et al., 2005; Ferreira et al., 2007),
consistent with data from human infections (Reed et al., 1987). Limited data exist
showing CLA ELISA false positives in dogs infected with Leishmania braziliensis
(5/9), Babesia canis (1/24), Ehrlichia canis (1/3), and Dirofilaria immitis (4/10)
(Mancianti et al., 1996; do Rosario et al., 2005; Ferreira et al., 2007). Since the
geographical distributions of many of these canine parasites overlap with that of ZVL
(Trotz-Williams and Trees, 2003; Solano-Gallego et al., 2006), significant cross-
reactivity may preclude the use of CLA ELISA to gain accurate estimates of infection
incidence in some areas. However, signal strength is likely to be lower with less
related pathogens, and many studies support high diagnostic value CLA ELISA in
diverse settings. It is recommended therefore that pre-intervention survey sampling in
vaccine trial field sites should be done to characterize the prevalence of potentially
cross-reacting canine pathogens in CLA ELISA. Conversely, rK39 ELISA appears to
show high specificity (Scalone et al., 2002; do Rosario et al., 2005) though cross-
reactions have been documented with L. braziliensis and Leptospira interrogans
(Porrozzi et al., 2007); due to the small numbers of animals tested in the latter study,
further large scale studies are required to investigate the specificity of rK39 ELISA.
In conclusion, our results confirm the important requirement for efficacy field trials:
seroconversion to either CLA or rK39 ELISA can be used to measure the incidence of
natural infection in DNA/MVA TRYP or LACK vaccinated dogs. CLA ELISA
provides maximum serological sensitivity in early stage infection, whereas rK39 as a
defined recombinant antigen with fewer potentially cross-reactive epitopes is likely to
reduce false positives. The imperfect agreement between CLA and rK39 ELISAs
suggests that when monitoring infection incidence, a combination of both rK39 and
CLA ELISAs should ideally be employed.
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Chapter 5: Comparison of monoclonal and polyclonal
antibodies for detection of canine IgG1 and IgG2, and
associations with infection outcome in Leishmania
infantum naturally infected dogs.
5.1 Introduction
In experimental murine models of leishmaniasis, the profile of IgG class titres against
crude Leishmania antigen (CLA) has been well validated as a proxy measure of T-cell
activation. In particular, a high ratio of specific IgG2a:IgG1 has been associated with
a Th1-type pro-inflammatory cytokine response (production of IFN-γ by CD4+ helper 
T lymphocytes), which in turn promotes resistance to disease caused by Leishmania
major infection. Conversely, a comparatively low IgG2a:IgG1 ratio results from
preferential activation of a non-protective Th2 response involving production of IL-4
and progression to clinical disease (Snapper and Paul, 1987; Heinzel et al., 1989;
Coffman et al., 1993; Germann et al., 1995). Measurement of IgG class expression as
a proxy for Th1 response is highly attractive as an additional measure of vaccine
immunogenicity in dogs, the reservoir host of zoonotic visceral leishmaniasis (ZVL).
However, the interpretation of IgG class profiles in relation to clinical outcomes in
dogs is currently unclear: some studies show greater elevations in IgG2 than IgG1
level in dogs with asymptomatic compared to symptomatic infection (Deplazes et al.,
1995; Nieto et al., 1999; Iniesta et al., 2005; Carrillo et al., 2007; Ramos et al., 2008),
whilst others show the opposite association (Cordeiro-da-Silva et al., 2003; Reis et
al., 2006b; Cardoso et al., 2007; Iniesta et al., 2007). One reason for these
inconsistent results may be a lack of specificity of the commercially available
polyclonal conjugate antibodies used in those studies (Day, 2007). For example, four
subfractions of IgG from normal canine serum were found to cross-react with both
IgG1 and IgG2 polyclonal antibodies (Mazza et al., 1993). It was suggested that
higher specificity for canine IgG classes might be achieved using a previously
described panel of monoclonal antibodies (Mazza et al., 1994a; Mazza et al., 1994b;
Day, 2007), hereafter referred to as ‘monoclonal’ antibodies. Only two studies to date
have employed these monoclonal antibodies to measure IgG subtypes in dogs with
ZVL and both have involved cohorts of naturally exposed outbred dogs in Brazil. In
the first of these investigations, the IgG2:IgG1 ratio was lower in clinically ill and
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PCR positive dogs, but signs of disease were associated with generalized elevation in
all four IgG classes, and great variation between individual dogs meant that relative
IgG class levels were not a useful marker of resistance or susceptibility (Quinnell et
al., 2003a). In the second investigation a similar broad elevation in all four classes
was found in seropositive, parasite positive and symptomatic dogs, but seropositive
and asymptomatic dogs had a serological response dominated by IgG1 to the
exclusion of IgG2. Moreover, this second study included a group of naïve dogs
vaccinated with the commercially available Leishmune® vaccine and these animals
had a striking serological response dominated by IgG2 (Oliveira et al., 2009).
The current study tests the association between IgG1 and IgG2 classes and
clinical/parasitological outcomes using commercially available polyclonal antibodies
(generated in goats and sheep, respectively) on archived samples from the study
described above (Quinnell et al., 2003a) which were previously tested using
monoclonal antibodies. This study is important to establish (1) whether IgG1 and
IgG2 classes measured by polyclonal antibodies are related to clinical/parasitological
outcomes in this population, and if so, (2) whether choice of antibodies will bias
associations with these outcomes. Analysis was performed to detect associations
between absolute levels and ratios of IgG1 and IgG2 classes, and a range of infection
outcome measures (clinical signs of leishmaniasis, bone marrow PCR, and
parasitological culture). This study represents the first direct comparison between
evaluation of canine IgG classes with the polyclonal and monoclonal antibodies.
5.2 Methods
5.2.1 Sample selection
Samples were generated during a longitudinal study comprising a cohort of naturally
exposed Brazilian dogs, as described in Chapter 2 and previously (Quinnell et al.,
1997). In that study, Leishmania-specific total IgG titres and IgG class levels were
quantified by ELISA, using the monoclonal antibody mAb B6 for IgG1 measurement,
and mAb E5 for IgG2, as described (Quinnell et al., 2003a). Clinical scores were
calculated as described in Chapter 2: dogs with total scores 0-2 were considered
asymptomatic, while total scores>2 were classed as symptomatic. Dogs were
categorized as infected at all time points after first detection of infection by in vitro/in
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vivo culture, and/or crude parasite antigen total IgG ELISA, and/or bone marrow
PCR, as described in Chapter 2 and previously (Quinnell et al., 1997).
In the current study, previously tested stored sera from infected dogs were selected
from this population for re-testing using commercially available polyclonal antibodies
(anti-IgG1 and anti-IgG2 HRP conjugates: Lot No. A40-120P-13 & A40-121P-14,
respectively; Bethyl Laboratories, Montgomery, Tx. USA). To avoid possible bias
due to autocorrelation (i.e. non independent repeat samples from the same dog) one
serum sample was selected at random from the larger longitudinal sample series from
each of 60 infected dogs, yielding samples at varying stages of infection with a
median 70.5 days (range: 0-535 days) from first detection of infection. The previously
determined serological, parasitological and clinical status of the dogs at the time of
collecting these cross-sectional samples for the current study are shown in Table 4.
Table 4. Serological, parasitological and clinical status of 60 longitudinally confirmed
infected dogs at the time of cross-sectional sampling.
5.2.2 IgG Class ELISAs
ELISA to measure CLA specific IgG1 and IgG2 titres with polyclonal anti-dog IgG1
and IgG2 (Bethyl Laboratories) was carried out as described in Chapter 2. Samples
were run in duplicate, at doubling dilutions as described below.
To calculate IgG class levels from assays with polyclonal antibodies, we used the
methodology previously employed on the same samples tested by monoclonal
antibodies (Quinnell et al., 2003a). A highly positive control serum was titrated 2-fold
from 1:100 to 1:3,276,800 on every plate, and assigned a number of arbitrary units
equal to the reciprocal of the highest dilution at which OD exceeded the mean +3S.D.
of the background (no sample) wells. A standard line was fitted using a log-logit
PCR CLA ELISA Culture Clinical signs
Positive 20 55 12 22
Negative 15 5 30 37
Not tested 25 0 18 1
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transformation (Peterman and Butler, 1989) to plot dilutions of the standard from
1:200 to 1:3,276,800. Test sample IgG1 and IgG2 levels were quantified from
titration curves plotted over doubling dilutions from 1:100 to 1:6400. The geometric
mean number of antibody units was estimated from the range of dilutions at which the
test sample titration curve was parallel to the standard. All subsequent analysis was
carried out on log-transformed data expressed in arbitrary units.
5.3 Results
The values of Pearson’s correlation coefficient, calculated for pairwise comparisons
of IgG class level measurements, are shown in Table 5. Anti-CLA IgG1 units
measured by polyclonal and monoclonal antibodies were positively correlated, though
the r2 value was not particularly high (Pearson’s correlation coefficient=0.75; r2
=0.56, P<0.001; (Figure 9A). IgG2 units measured by the two antibodies were also
significantly correlated, but with a lower r2 value (Pearson’s correlation
coefficient=0.54; r2 =0.29, P<0.001) (Figure 9B). In the study using monoclonal
antibodies, samples with titres above or below the linear range of the standard curve
were truncated and assigned the maximum or minimum values of the linear range -
this is seen clearly in Figure 9B, where the maximum upper value for monoclonal
antibodies IgG2 log10 titre is 3.20. To assess the extent to which this biased
correlations, analysis was repeated after removing samples truncated at the upper
maximum and lower minimum values for IgG1 and IgG2 titre. This procedure did not
substantially alter the results of analyses (IgG1: r2=0.52, Pearson’s correlation
coefficient=0.72; IgG2: r2=0.26, Pearson’s correlation coefficient=0.51; P<0.001 in
both analyses).
There was a generally high positive correlation between IgG1 and IgG2 units
(regardless of antibody type), and between each class and total IgG (Table 5),
reflecting a general elevation in anti-CLA IgG. The lowest correlation was seen
between IgG2 measured by monoclonal antibodies, and all other IgG levels
(Pearson’s correlation coefficient ≤0.54). As expected, the absolute values for class
levels obtained using monoclonal and polyclonal antibodies differed, since values
were expressed in arbitrary units relative to positive controls. There was no significant
correlation between IgG2:IgG1 ratios using monoclonal and polyclonal antibodies to
measure levels in each individual sample (r2<0.01, P=0.52; Pearson’s correlation
coefficient=-0.08).
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Table 5. Correlation between total CLA-specific IgG, and IgG class log10 units
measured using monoclonal and polyclonal antibodies.
Numerical values indicate Pearson’s correlation coefficient calculated from all possible
pairwise comparisons of monoclonal and polyclonal class log-transformed units, and
total IgG (log10 units) (P≤0.01 in all cases).
Poly: polyclonal antibodies; Mono: monoclonal antibodies.
Total
IgG
Poly
IgG1
Poly
IgG2
Mono
IgG1
Mono
IgG2
Total IgG 1.00
Poly IgG1 0.79 1.00
Poly IgG2 0.84 0.87 1.00
Mono IgG1 0.90 0.75 0.85 1.00
Mono IgG2 0.50 0.47 0.54 0.51 1.00
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Figure 9. Relationship between polyclonal and monoclonal IgG1 (A) and IgG2 (B)
class titres in naturally infected dogs.
IgG1 and IgG2 were measured using both monoclonal and commercial polyclonal
HRP conjugate antibodies. Both scales represent log10 arbitrary units as described in
the text.
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When dogs were stratified by clinical signs (i.e. asymptomatic or symptomatic), mean
IgG2:IgG1 ratios measured by either monoclonal or polyclonal antibodies did not
differ significantly between clinical groups (z≤1.11, P≥0.27; Table 6). This result
indicates an absence of IgG class polarization associated with the dichotomised
clinical outcome. However, mean log10 units of both IgG1 and IgG2, measured by
both antibodies, were 1.11-1.18 times higher in clinically symptomatic than in
asymptomatic dogs (Wilcoxon rank sum test: polyclonal antibodies IgG1, z=2.32,
P=0.02; IgG2, z=2.16, P=0.03: monoclonal antibodies: IgG1, z=2.27, P=0.02; IgG2,
z=3.00, P<0.01; Table 6). When dogs were stratified based on bone marrow PCR
positivity, mean log10 IgG1 and IgG2 levels measured by polyclonal antibodies were
each significantly higher (by a factor of 1.16-1.17) in PCR positive animals than in
PCR negative animals (z=2.50, P=0.01; z=2.27, P=0.02, respectively). Conversely,
using monoclonal antibodies, mean log10 IgG1, but not IgG2, was 1.28 times higher in
PCR positive dogs (z=2.52, P=0.01; z=0.25, P=0.80, respectively). Analysis for
associations between bone marrow culture positivity and log10 class level found that
only IgG1 measured by monoclonal antibodies was significantly elevated (by a factor
of 1.19) in culture-positive dogs compared with culture-negatives (z=2.00, P=0.05).
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Table 6. Associations between infection status and IgG1/IgG2 log10 units by polyclonal
and monoclonal antibodies.
Values represent n-fold difference in the mean log10 units of dogs that were positive for
clinical signs of leishmaniasis, or test positive by PCR or culture, relative to negatives.
IgG1 IgG2 IgG2:IgG1 ratio
NPoly Mono Poly Mono Poly Mono
Clin 1.11* 1.16* 1.11* 1.18** 0.99 1.04 59
PCR 1.16** 1.28** 1.17* 1.03 1.00 0.75 35
Culture 1.08 1.19* 1.10 1.00 1.00 0.77 42
Poly: polyclonal antibodies; Mono: monoclonal antibodies.
N: no. of dogs tested.
Clinical signs, PCR, Culture: Dogs showing clinical signs of leishmaniasis (total
score>2), or that were test-positive by PCR or in vitro/in vivo parasitological culture,
respectively.
* P≤ 0.05, **P≤ 0.01 : Statistical significance of the association between IgG
units/ratio and clinical status/diagnostic test result by Wilcoxon Rank Sum test.
Clinical signs
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5.4 Discussion
The results of this study suggest that reported differences in the immunological
specificity of monoclonal and polyclonal antibodies are sufficient to cause
inconsistent associations between IgG class levels and parasitological outcomes
(Table 6). Similarly, the lack of a correlation between IgG2:IgG1 ratios measured in
each sample using the different antibodies, suggests that results of studies using these
different reagents will not be directly comparable. This confirms the concerns
expressed by others (Day, 2007). The latter study also cautioned that it is unsafe to
assume cross-species functional similarity between human, dog and mouse IgG
subclasses, when criteria for numbering the canine IgG classes 1-4 were based solely
on similar relative serum concentrations and electrophoretic mobility to human IgG 1-
4 fractions. Whilst levels of anti-CLA IgG1 and IgG2 measured using each antiserum
were positively correlated, there were also strong positive correlations between IgG1,
IgG2 and total IgG levels. Thus correlation between monoclonal and polyclonal
reagents for the same class may not reflect similar specificity; rather, it may reflect a
general upregulation of antibody responses of all classes. Moreover, both antibodies
detected significantly higher IgG1 and IgG2 levels in clinically symptomatic dogs
compared with asymptomatic animals. This was consistent with results of the original
larger longitudinal study, in which elevation of all four IgG classes was detected by
monoclonal antibodies in dogs with clinical disease (Quinnell et al., 2003a) and
consistent with the more recent study of symptomatic dogs (Oliveira et al., 2009).
However the findings of the present study with respect to asymptomatic dogs conflict
with those of Oliveira et al. (2009). Asymptomatic animals in the present cohort had
a similar ratio of IgG1:IgG2 compared with symptomatic dogs, but in the population
examined by Oliveira et al. (2009) the serological response of asymptomatic dogs was
almost exclusively attributed to IgG1. Therefore, current findings using polyclonal
antibodies did not confirm polarization of IgG class expression according to clinical
status and therefore do not support the hypothesis that differential IgG1/IgG2 class
expression is a useful proxy measure of resistance or susceptibility in endemic
populations of dogs naturally infected with L. infantum. There were clearly
differences in the level of characterization of the asymptomatic populations examined
in these two studies. Those in the present investigation were very well investigated
using a range of diagnostic procedures, whilst the asymptomatic population in the
study of Oliveira et al. (2009) was a randomly sourced serosurvey group. Moreover,
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although both populations were from endemic areas in Brazil, these were not
geographically identical. In the present study, IgG class ratios were also not useful as
predictors of parasitological infection status or PCR positivity. The collective results
reported here suggest that class responses to leishmaniasis in dogs may be more
similar to those in humans than in mice: in human patients with clinically and
parasitologically confirmed visceral leishmaniasis, a general upregulation in all four
IgG class titres has been reported with no particular class polarization (Elassad et al.,
1994).
Due to the complexity of cytokine interactions during the course of natural infection,
a simplified canine model to investigate correlations between class expression and
cytokine responses is desirable. Such models already exist in the form of
immunogenicity trials of canine ZVL vaccines in unexposed dogs, where vaccine
effectiveness relies on preferentially stimulating a Th1 cellular immune response. In
the DNA/MVA prime/boost vaccination of naïve dogs carried out as described in
Chapter 3, peak production of the Th1-type cytokine IFN-γ in response to vaccination 
occurred concurrently with significant elevation of IgG2 (measured by commercially
available polyclonal antiserum), and in the absence of detectable IgG1 or the
Th2/Treg type cytokine IL-10. This observation is of note, as in the study of Oliveira
et al. (2009) vaccination of naïve dogs with the commercially produced Leishmune®
vaccine also led to a markedly skewed serological response dominated by IgG2, in
that case detected by monoclonal antibody. Given the relatively poor correlation
between IgG2 polyclonal and monoclonal antibodies observed in the present study,
this finding is of interest. Thus, in addition to more extensive comparison of
monoclonal and polyclonal IgG class specificity in larger groups of naturally exposed
dogs, it is recommended that canine trials of vaccines that elicit Th1 responses in the
absence of infection should be used as a test bed to examine the extent of IgG class
bias, in parallel with cytokine measurement and the use of both polyclonal and
monoclonal antibodies.
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Chapter 6: Evaluation of an immunochromatographic
rK39 dipstick test for detection of infection in longitudinal
follow-up of dogs with naturally acquired ZVL
6.1 Introduction
Diagnosis of ZVL infection in the reservoir host, the domestic dog, is usually carried
out using serological tests based on crude or recombinant parasite antigens. One of
the most widely tested recombinant antigens for serological detection of Leishmania-
specific IgG is rK39, as described more fully and used in ELISA format in Chapter 4.
The rK39 antigen has been incorporated into commercially available rapid diagnostic
tests (RDT’s), in the form of immunochromatographic dipsticks. In recent years,
increasing numbers of RDT’s have become available for field diagnosis of human and
animal diseases, such as malaria, Chagas disease and babesiosis. Published work
describes a number of currently commercially available rK39 dipsticks for use in
humans, and 3 dipstick tests specifically for veterinary use (DiaMed-Vet-IT Leish
(Diamed AG, Switzerland), Kalazar Detect Canine Rapid Test (Inbios, USA) and
visceral Leishmania dipstrip (Cypress Diagnostic Company, Belgium)). These tests
display a coloured band to indicate a positive result within minutes of addition of
serum, are ideal for resource-poor field environments, and do not require a high level
of operator technical skill making them potentially very useful for large-scale field
surveys or vaccine trials against canine leishmaniasis. The use of rK39 dipstick tests
for diagnosis of VL/ZVL has been described by previous research in both humans
(Sundar et al., 1998; Zijlstra et al., 2001; Schallig et al., 2002; Chappuis et al., 2003;
Veeken et al., 2003; Chappuis et al., 2005; Diro et al., 2007; Sundar et al., 2007;
Boelaert et al., 2008) and in dogs (Mancianti et al., 2002; Reithinger et al., 2002; da
Costa et al., 2003; Mohebali et al., 2004b; Otranto et al., 2004; Toz et al., 2004;
Mettler et al., 2005; Otranto et al., 2005; Lemos et al., 2008). Although these studies
have aimed to quantify rK39 dipstick sensitivity in naturally infected cases, tests have
been performed in cross-sectional samples, generally from groups of clinically
symptomatic or confirmed parasite-positive humans or dogs. Little information is
available to characterize test performance in longitudinal samples from infected dogs,
particularly to examine test sensitivity in the early stages of natural infection.
Experimental longitudinal work is limited to one study which describes rK39 ELISA
results during follow-up of just 4 artificially challenged dogs (Scalone et al., 2002).
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The association between clinical disease and rK39 dipstick test positivity, which has
been suggested by results from a number of canine studies which stratified dogs by
clinical status (Mettler et al., 2005; Lemos et al., 2008), also requires further
investigation using longitudinal data to control for duration of infection.
To address these research needs, in the present study we describe the results of
longitudinal follow-up of uninfected dogs exposed to natural infection in an endemic
area (Brazil), tested by rK39 dipstick, crude Leishmania parasite antigen (CLA)
ELISA, PCR, microscopic examination and in vitro / in vivo culture of bone marrow,
and clinically examined, at bi-monthly intervals. Data were analysed to compare the
sensitivity of rK39 dipsticks against CLA ELISA, and to look for associations
between rK39 dipstick test positivity, clinical status, and PCR positivity.
6.2 Methods
6.2.1 Selection of animals
Clinical samples of a cohort of 54 confirmed positive dogs were selected from
archived material from a larger Brazilian longitudinal population study described in
Chapter 2 and previously (Quinnell et al., 1997; Quinnell et al., 2001a; Quinnell et
al., 2001b; Courtenay et al., 2002b; Quinnell et al., 2003a), and aligned relative to the
longitudinally assigned time of patent infection t0 (defined as the first time point of
detection of Leishmania infection by bone marrow PCR and/or in vitro/in vivo
culture, as previously defined in Chapter 4), as indicated by the results of the original
cohort study. Dogs in that study were also clinically examined and scored as
described in Chapter 2: a total clinical score of 0-2 was classed as asymptomatic, 3-6
as oligosymptomatic, and 7 as polysymptomatic.We purposively selected the sample
series which had the longest periods of follow up, thereby obtaining samples from 39
dogs which had clinical symptoms of ZVL at 1 time point during the course of
follow-up, and from 15 dogs that remained asymptomatic at all time points, despite
parasitological evidence of infection.
A total of 323 samples were thus tested. PCR results were not available for all time
points. 53/54 dogs had PCR results on at least one follow-up time point (mean 3.7;
range 1-10). In total, PCR results were available from 196/323 samples.
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rK39 dipsticks were also tested in 30 unexposed, non-endemic UK dogs with no
history of foreign travel that had attended two UK veterinary clinics during June –
December 2007 for unrelated clinical reasons.
6.2.2 Serology
CLA ELISA was carried out as described in the previous study, to obtain total anti-
CLA IgG titres as described in Chapter 2. (Quinnell et al., 1997).
In the current study, rK39 dipstick tests (Kalazar Detect Canine Rapid Test: Lot No.
HA1047 and HD1037) were obtained from Inbios International Inc. WA, USA, and
used according to the manufacturer’s instructions as described in Chapter 2. rK39
ELISA results were also available for a proportion of samples (181/323) from the
work described in Chapter 4, above.
6.3 Results
6.3.1 Cross-sectional analysis
A total of 133/323 serum samples from 38/54 Brazilian dogs tested rK39 dipstick
positive, while 16/54 dogs remained rK39 negative throughout the course of
sampling. CLA ELISA gave positive results in 246/323 samples from 54/54 dogs. In
samples with confirmed infections by parasitological tests (i.e. samples taken on or
after t0), the cross-sectional sensitivity for detection of infection by CLA ELISA was
88% (185/210) whereas rK39 dipsticks were significantly less sensitive (56%;
117/210), as shown in Table 7 (χ
2=54.5; P≤0.001). The proportion of samples positive
by rK39 dipsticks was highly correlated with log10 anti-CLA IgG titre as shown in
Figure 10 (Logistic regression; χ2=252; p<0.001). Results were available from rK39
ELISA (see Chapter 4) for 181/323 of the samples which were tested with rK39
dipsticks. As shown in Figure 11, rK39 ELISA s/p ratios were high (≥0.770), in all
samples which tested positive by rK39 dipsticks (60/181), well above the cut-off
point calculated from negative UK control dogs (cut-off=0.259; see Chapter 4).
Excluding pre-t0 samples from the subset of samples tested by rK39 dipsticks and
rK39 ELISA, the sensitivity of rK39 dipsticks was 46.2% (55/119), lower than the
sensitivity of rK39 ELISA (66.3%: 79/119; χ
2=51.6; p≤0.001).
As shown in Table 7, analysis of crude cross-sectional data from 210 post-infection
serum samples showed a strong association between rK39 dipstick positivity and
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clinical disease: only 37% (44/120) of serum samples from asymptomatic dogs
(clinical score<2) were rK39 dipstick positive, compared with 79% (38/48) samples
from oligosymptomatic animals (score 3-6) and 94% (34/36) samples from
polysymptomatic (score >6) animals (χ
2=50.4; P≤0.001: χ2 for trend). Clinical
examination results from 6 sample time points were unavailable. The sensitivity of
CLA ELISA was significantly superior to rK39 dipsticks in asymptomatic and
oligosymptomatic dogs (though the difference was less striking in the latter), whereas
in polysymptomatic dogs the sensitivity of the two tests was similar. Both CLA
ELISA and rK39 dipsticks were more sensitive in PCR positive dogs (89% and 61%,
respectively) compared with PCR negative animals (79% and 32%, respectively),
though CLA ELISA was the more sensitive test in both PCR groups.
All 30 UK non-endemic dogs were negative by rK39 dipsticks (specificity =100%),
though specificity was not tested here in dogs with non-Leishmania parasitic
infections.
6.3.2 Longitudinal analysis
In longitudinal follow-up, rK39 dipstick and CLA ELISA sensitivity increased with
time from patent infection as shown in Figure 12. Sensitivities of both CLA ELISA
and rK39 dipstick were low at 4-6 months before the time of parasitological detection
of infection t0, though CLA ELISA (42%) was superior to rK39 dipstick (4%). CLA
ELISA was significantly more sensitive than the rK39 dipstick test at all subsequent
time points tested up to the end of the study (>16 months after t0), although larger
differences in sensitivity between the two tests were seen in the early stages of
infection from t-6 to t+4 months (χ
2
≥9.0; p≤0.003) than were seen after 6 months from
t0 (χ
2
≥4.6; p≤0.03). Maximum rK39 sensitivity was 76.3% (at t+6-8 months) in
comparison with maximum CLA sensitivity of 100% (>16 months post-t0).
In longitudinal follow up, 15 dogs remained asymptomatic throughout the study,
whereas 39 developed clinical signs. In clinical cases, the proportion of dogs with
signs of ZVL increased with time from t0 and declined somewhat after t+10 months,
a trend that was temporally associated with the proportion of these dogs which were
positive by rK39 dipsticks (Figure 13). Among animals which remained
asymptomatic throughout the period of follow-up, the proportion of dipstick positive
dogs at each time point was consistently low, though an isolated peak prevalence of
50% rK39 dipstick positivity was observed at t+10 months (Figure 13). Controlling
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for within-dog autocorrelation and duration of exposure to infection in the field, rK39
dipstick positivity was significantly associated with symptomatic infection (O.R.=
5.3; 95% C.I.= 2.17-12.63; z= 3.69; P≤0.001; n=47 dogs; 167 observations), and with
PCR positivity (O.R.= 3.9; 95% C.I.= 1.73-8.84; z= 3.27; P=0.001). In dogs which
tested positive by rK39 at ≥1 time point, 34/38 remained positive at all points after
rK39 seroconversion, whereas in 4 dogs, a single rK39 negative time point occurred
during the period of post rK39 seroconversion follow-up (mean 353 days; range 137-
472 days), showing the low frequency of reversion to rK39 seronegative.
Table 7. Cross-sectional analysis of rK39 dipstick and CLA ELISA test results
P-values shown are the results of χ2 tests comparing the raw proportions of positive
serum samples in each PCR/ clinical examination category by CLA ELISA and rK39
dipstick tests. Except where indicated, pre-t0 samples were excluded from analysis.
CLA ELISA + rK39 dipstick + P-value
Confirmed infections (post-t0) 88.1% (185/210) 55.7% (117/210) ≤0.001
Pre-t0 samples 54.0% (61/113) 14.2% (16/113) ≤0.001
PCR + 89.2% (99/111) 61.2% (68/111) ≤0.001
PCR - 79.4% (27/34) 32.4% (11/34) ≤0.001
Polysymptomatic 97.2% (35/36) 94.4% (34/36) 0.56
Oligosymptomatic 95.8% (46/48) 79.2% (38/48) 0.01
Asymptomatic 84.2% (101/120) 36.7% (44/120) ≤0.001
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Figure 10. rK39 dipstick positive serum samples (%) by log10 anti-CLA IgG titre.
CLA ELISA titre is expressed in log10 arbitrary units (relative to a positive control
symptomatic Brazil dog) calculated as described in Chapter 2.
Figure 11. Comparison between rK39 dipstick and rK39 ELISA results.
rK39 ELISA s/p ratios (see Chapter 4) were available from 181/323 dogs which were
tested with rK39 dipsticks. rK39 ELISA cut-off was calculated from the back-
transformed mean +3S.D. of the log10 s/p ratios of 30 UK negative dogs, as described
in Chapter 4.
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Figure 12. Test sensitivity (binomial 95% C.I.) of CLA ELISA and rK39 dipsticks.
Dogs (n=275) were aligned by time from first detection of infection by in vitro/in vivo
culture and/or PCR (t0). Binning by time points was used as indicated to equalize
group sizes. N.B. 40 samples from uninfected animals (i.e. without parasitologically
confirmed time of infection t0) were excluded, as were samples taken more than 6
months pre-t0 (n=8). Asterisks indicate significant differences between the sensitivity
of CLA ELISA and rK39 dipsticks.
n: no. of dogs tested at each time point.
** P≤0.01; * P≤0.05 (χ2 test).
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Figure 13. Temporal relationship between rK39 dipstick positivity and clinical
disease.
Open shapes show the proportion of samples positive by rK39 dipsticks, filled shapes
show the proportion of dogs with clinical signs of leishmaniasis (clinical score >2).
symp: dogs which developed clinical signs of disease (clinical score >2) at any time
point (n=39).
asymp: Dogs which never showed clinical signs of ZVL throughout the entire period
of follow-up (clinical score ≤2) (n=15).
6.4 Discussion
Published figures for rK39 dipstick sensitivity in dogs vary from 71% to 96%,
differences which were partly due to differing selection criteria for ‘true’ positive
dogs for calculation of test sensitivity in these previous studies. For example,
Reithinger et al. estimated rK39 dipstick sensitivity as 72% using crude parasite
ELISA and/or buffy coat PCR to define positives (Reithinger et al., 2002), whereas in
dogs with microscopically parasite-positive lymph node smears (a ‘gold’ standard of
comparatively low sensitivity), rK39 dipstick sensitivity was 97% (Otranto et al.,
2005). However, in two previous cross-sectional studies which used similar selection
criteria for ‘true’ positive dogs (clinical signs of ZVL and serology) widely differing
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estimates of sensitivity were again obtained: rK39 dipsticks were 71% sensitive in a
study of dogs in Iran (Mohebali et al., 2004b), whereas in dogs sampled in Brazil,
rK39 dipsticks were 94% sensitive (da Costa et al., 2003). It is likely that variations in
rK39 dipstick sensitivity also reflect differences in infection duration (which cannot
be quantified in cross-sectional studies). In human VL patients, reports of varying
rK39 dipstick sensitivity (71-100% (Jelinek et al., 1999; Brandonisio et al., 2002;
Guimaraes Carvalho et al., 2003; Sundar et al., 2006) have also resulted from
analyses of cross-sectional samples of patients with infections of unknown duration.
The present study is the first to report longitudinal analysis of rK39 dipstick results in
naturally infected dogs for which the time course of infection was well characterized.
As described above, rK39 dipstick sensitivity was low in the early stages of infection
(<10% sensitivity in samples taken before t0), and increased with time from t0 to a
maximum of 76% 6-8 months post-t0. This provides a partial explanation for the large
differences in sensitivity estimates obtained from previous cross-sectional surveys.
Another possible cause of inconsistent results in previous studies is variation in rK39
dipstick sensitivity in geographically distinct strains of Leishmania: such variations in
dipstick sensitivity for diagnosis of human VL have been recorded between East
Africa and the Indian subcontinent (Boelaert et al., 2008), and further investigation is
needed to determine if similar diagnostically relevant differences exist between Old
and New world L. infantum strains in dogs. Comparison between studies is further
complicated by the use of rK39 dipsticks from several different manufacturers in the
previously reported work. Unfortunately in the present study, it was not possible to
source rK39 dipsticks from more than one manufacturer to allow direct comparisons
of sensitivity to be made.
In the present study, CLA ELISA was significantly more sensitive than the rK39
dipstick test in Leishmania-infected dogs at all time points, though differences
between the two tests were less marked at  6 months from t0, due to the relative
improvement of rK39 sensitivity over time. Similarly high estimates of crude parasite
ELISA sensitivity in previous canine research (do Rosario et al., 2005; Mettler et al.,
2005; Ferreira et al., 2007) (range 95%-100%) tend to confirm the results shown here.
Sensitivity of the rK39 ELISA described in Chapter 4 was also superior to that of the
rK39 dipstick, which contrasts with a previous cross-sectional study which found no
significant difference in the sensitivity of rK39 ELISA when compared to Diamed-
Vet-IT Leish assay (Mettler et al., 2005), though the number of dogs tested in that
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study was comparatively low. As shown in Chapter 4, rK39 ELISA was itself inferior
to CLA ELISA. Thus, CLA ELISA is still the most appropriate test for accurate
detection of early stage infection and hence calculation of infection incidence in dogs
enrolled in vaccine trials, subject to the considerations discussed in Chapter 4.
Previous studies employing the rK39 antigen have suggested an association between
rK39 positive test results and presence of active clinical disease in both humans
(Badaro et al., 1996) and in dogs (Rhalem et al., 1999; do Rosario et al., 2005;
Mettler et al., 2005; Porrozzi et al., 2007; Lemos et al., 2008) and confirmed by our
results reported here. In longitudinal analysis, the increase in the proportion of
symptomatic dogs after t0 was temporally associated with the proportion positive by
rK39 dipsticks, which was followed by a decline in both proportions from t+10
months, due to recovery or death of diseased animals. The low frequency of reversion
to rK39 negative in animals with ≥1 positive rK39 dipstick result suggests that the
latter explanation is more likely. rK39 dipstick sensitivity increased in association
with the severity of clinical signs to 94% sensitivity in polysymptomatic dogs, and
dipstick sensitivity was also highly associated with anti-CLA IgG titre, which is an
important prognostic indicator of disease severity in dogs (Reis et al., 2006b). rK39
dipstick test positivity was restricted to those samples with high rK39 ELISA s/p
ratios, which is of interest in view of evidence from human VL cases that anti-rK39
IgG is a prognostic indicator for relapse after therapy (Kumar et al., 2001). Thus, in a
veterinary clinical setting, rK39 dipsticks are likely to be highly sensitive for
detection of clinically symptomatic cases of canine leishmaniasis, which present a
diagnostic challenge for veterinarians due to the non-specific nature of canine clinical
signs of ZVL, and may also be useful for identifying relapses. The dipstick test format
allows rapid and straightforward testing of animals in the field, which will be useful
for busy veterinarians in practice, and provides an immediate result without the delays
associated with laboratory testing of samples. Where dog culling is the primary
control measure, delays in sample processing have been identified as one reason for
failure of this strategy to reduce disease incidence (Courtenay et al., 2002b), and the
use of dipstick tests could help to improve this situation. There may also be
significant improvements in owner compliance when presented with an unequivocal,
visually interpretable result at the time of testing. The rK39 antigen also has the
potential advantage of lower cross-reactivity with other pathogens likely to be co-
endemic in areas affected by ZVL. The specificity of the Inbios rK39 dipsticks tested
87
here was 100% in 30 UK negative dogs. However, false positive rK39 dipstick
results have previously been detected in small numbers of dogs with Ehrlichia canis
or Trypanasoma cruzi infection (Lemos et al., 2008), and in negative control dogs
from areas that are not endemic for Leishmania or either of these diseases (Reithinger
et al., 2002). In other work, the specificity of anti-rK39 antibodies for infection with
the visceralizing L. donovani complex (Burns Jr et al., 1993) has been questioned due
to cross-reactions in rK39 ELISA with sera from 3/9 dogs infected with cutaneous
leishmaniasis (L. braziliensis (Porrozzi et al., 2007)). More extensive characterization
of rK39 antigen specificity is therefore required, before recommendations can be
made for the use of these tests in areas where co-infection with the above pathogens is
likely. In conclusion, we have shown that rK39 dipstick sensitivity was inferior to
that of CLA and rK39 ELISA in naturally infected dogs in longitudinal follow-up,
and that rK39 dipstick positivity is highly associated with clinical disease, making
this test more appropriate for clinical diagnosis than for use in vaccine trials against
canine ZVL.
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Chapter 7: Comparison of Leishmania OligoC-TesT PCR
with conventional and real-time PCR for the detection of
canine Leishmania infantum infection
7.1 Introduction
For accurate measurement of infection incidence in vaccine trials against canine
leishmaniasis, the ideal diagnostic test should show high sensitivity in early stage
infections, and should also be cost-effective, technically simple and robust.
Serological methods are the most technically straightforward of the available tests for
diagnosis of canine ZVL infection, but these methods have been reported to lack
sensitivity in asymptomatic and early stage infection (Dye et al., 1993; Quinnell et
al., 1997; Miró et al., 2008). Detection of Leishmania parasites in canine clinical
samples has traditionally been performed by means of microscopic examination of
stained tissue specimens, or by parasitological culture, which are known to be
insensitive. Polymerase chain reaction (PCR) for amplification of defined parasite
DNA sequences is highly sensitive in animals with clinical disease, and has higher
sensitivity than serology in asymptomatic animals and early-stage infections, as
reported in Chapters 4&6, and in previous research (Quinnell et al., 2001a; Solano-
Gallego et al., 2001; Iniesta et al., 2002; Lachaud et al., 2002a; Oliva et al., 2006).
However, the technical complexity of PCR and the requirement for trained laboratory
personnel may reduce its practicality for use in developing countries most affected by
ZVL. Furthermore, there is a lack of standardization in the selection of target
Leishmania DNA sequences and experimental PCR protocols used in laboratories
worldwide, which complicates objective comparisons of test sensitivity and
specificity. In order to address some of these issues, a commercially available PCR
test kit (Leishmania OligoC-TesT) has been developed and validated for detection of
Leishmania parasite DNA in human specimens (Deborggraeve et al., 2008; Espinosa
et al., 2009). Sensitivity of the test ranged from 77.8%-100% in clinical samples from
patients with visceral leishmaniasis in Sudan and Kenya, with a limit of detection of 1
parasite in 180µl blood (Deborggraeve et al., 2008). The OligoC-TesT has not yet
been independently validated for use in dogs. The aims of this study were therefore:
(1) to measure the sensitivity of the OligoC-TesT compared with three conventional
PCR procedures (nested PCR for amplification of kinetoplast DNA (kDNA), nested
PCR of internal transcribed spacer region-1 (ITS-1) of the ribosomal RNA (rRNA)
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gene, and kDNA/rRNA PCR followed by hybridization with specific oligonucleotide
probes), and compared with real-time quantitative PCR (qPCR), (2) to compare the
sensitivity of the OligoC-TesT, and PCR methods listed above, in samples from
infected dogs in the presence or absence of clinical signs of leishmaniasis, and (3) to
determine the analytical sensitivity of the OligoC-TesT relative to canine bone
marrow parasite burdens measured by real-time qPCR. Here we use samples collected
in a previous longitudinal study on a cohort of L. infantum naturally infected domestic
dogs in Brazil.
7.2 Methods
7.2.1 Sampling and selection of dogs
Bone marrow samples from naturally exposed outbred dogs were tested. These
samples came from a previous longitudinal field study in Brazil, described in Chapter
2 and previously (Quinnell et al., 1997). Bone marrow samples (for PCR followed by
hybridization with specific oligonucleotide probes, and in vitro/in vivo parasitological
culture, as described in Chapter 2) were obtained at approximately 2 month intervals.
Dogs were clinically examined at each time point and assigned a semi-quantitative
clinical score: dogs with total scores 0-2 were considered asymptomatic, scores 3-6
were defined as oligosymptomatic, and scores 7-18 were defined as polysymptomatic
(Quinnell et al., 2001a). In the current study we used archived bone marrow samples
from dogs which showed evidence of infection at any time after initial exposure,
where infection was defined as positivity by serology (crude parasite ELISA) and/or
in vitro/in vivo culture. Samples were aligned by time point of first detection of
infection (t0). The criteria for defining t0 in the current chapter (serology and/or
parasitological culture) were different from those used in Chapters 4&6 (PCR and/or
parasitological culture), which was necessary to ensure independence of the defining
criteria for infection from the experimental methods on test. Thus, the ‘gold standard’
for defining infection was, in each case, an amalgam of all other available
independent methods. The number of OligoC-TesT kits available allowed testing of
163 samples (from 67 infected dogs), with a mean 2.4 time points per dog (range 1-5
time points), from 2 months before first detection of infection (t-2) to 12 months post
infection (t+12). 147 samples were from dogs with confirmed infection (i.e. samples
taken on or after t0) and 15 samples were taken 2 months before confirmed infection,
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when dogs are likely to be in the pre-patent period (Quinnell et al., 1997). 1 sample
was not included in the subsequent data analysis due to PCR inhibition (see below).
Clinical scores were unavailable for 2.5% (4/163) of the samples.
7.2.2 DNA extraction
In the present study, DNA extraction was performed on 100µl aliquots of bone
marrow, using a phenol-chloroform protocol as described in Chapter 2. The median
Abs260/280 of DNA extracts was 1.81 (interquartile range=1.74-1.85), indicating high
purity of the extracted DNA.
7.2.3 Nested ITS-1 and kDNA PCR
In the present study, DNA extracts were subjected to nested PCR targeting the ITS-1
region of the rRNA gene of all Leishmania species, as described in Chapter 2 (Parvizi
et al., 2005; Parvizi et al., 2008). A nested PCR was used to amplify a variable region
of Leishmania kDNA, as described in Chapter 2. The latter PCR protocol was not
species-specific for L. infantum, however species can be discriminated based on
product size (Noyes et al., 1998). Positive and negative controls were as described
previously.
7.2.4 Real-time quantitative PCR
LEISH-1 and LEISH-2 primers and the fluorophore-labelled Leishprobe were used in
a previously validated protocol specific for a conserved region of L. infantum kDNA,
as described in Chapter 2 and previously (Francino et al., 2006). All bone marrow
DNA samples were amplified in duplicate at 1:10 dilution in water (appropriate
dilution factors were identified from serial 10-fold dilutions in preliminary
optimization experiments). Quantification of Leishmania DNA was performed using
an absolute method, by comparison of Ct values with those from a standard curve
constructed from 10-fold dilutions of L. infantum DNA extracted from cultured
parasites, from 1×106 to 0.1 parasite equivalents/ml (strain MHOM/MA/67/ITMAP-
263), which were run in triplicate on every plate. Parasite burdens were log10 (n+1)
transformed for analysis.
Pre-developed TaqMan Assay reagents (Applied Biosystems, UK) were used to
amplify the 18S rRNA gene as an internal reference of canine genomic DNA, to
detect PCR inhibition. Negative controls were DNA extracted from blood samples of
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10 UK dogs with no history of foreign travel. The inter-assay coefficient of variability
(CV) of the Leishmania real-time qPCR, estimated by running a reference sample in
duplicate on every plate, was 1.90%. The mean intra-assay CV of reference sample
duplicates was 0.29% (range 0.12%-0.52%).
7.2.5 OligoC-TesT kit
Kits were provided by the manufacturer (Coris Bioconcept, Gembloux, Belgium) and
were used according to product recommendations, for genus-specific detection of
Leishmania DNA, as described in detail in Chapter 2, and previously (Deborggraeve
et al., 2008). Briefly, pre-formulated master mix was used to amplify sample DNA in
a single round conventional PCR protocol. This step was followed by detection of
specific PCR product using double-sided dipsticks which replace the requirement for
gel electrophoresis. An internal positive control sequence co-amplifies with the target
to allow detection of PCR inhibition, while migration control lines indicate correct
running of the test strip buffer. A single inconclusive OligoC-TesT result (1/163) due
to PCR inhibition was excluded from further data analysis.
7.3 Results
7.3.1 Overall test sensitivity in infected dogs
In bone marrow samples taken from dogs on or after the time of first detection of
infection by serology and/or in vitro/in vivo culture (t0), the overall sensitivity of the
OligoC-TesT was 70.3% (102/145) (Table 8). The proportion of positive samples by
the OligoC-TesT was significantly greater than the proportion detected by the
PCR/hybridization method (60.7% (88/145); McNemar’s χ
2=8.17; P=0.007) and by
the ITS-1 nested PCR (53.8% (78/145); McNemar’s χ
2=22.2; P<0.001), but was not
significantly different to the proportion positive by kDNA nested PCR (72.4%
(105/145); McNemar’s χ
2=0.36, P=0.69). The most sensitive method was real-time
qPCR, which detected L. infantum DNA in 91.0% (132/145) of the samples tested,
significantly more than any of the other procedures (McNemar’s χ
2
≥25.14, P<0.001
in all pairwise comparisons).
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7.3.2 Sensitivity in symptomatic and asymptomatic dogs
The proportions of positive test results in bone marrow samples from dogs which
were stratified into 3 clinical groups (oligo- poly- and asymptomatic, as defined
above) are shown in Table 8. Comparing symptomatic (oligo- and polysymptomatic
groups combined) with asymptomatic dogs, test sensitivity was significantly higher in
bone marrow samples from the former group, using OligoC-TesT, kDNA PCR, ITS-1
PCR and PCR/hybridization ( χ
2
≥3.91; P≤0.05), but was not significantly different
between clinical groups for real-time qPCR (χ
2=2.41, P=0.12) (Table 8). Controlling
for autocorrelation, there was a significant positive association between the severity
of clinical signs of leishmaniasis in infected dogs (total clinical score, range 0-18) and
the probability of testing positive, using any of the diagnostic PCR methods including
real-time qPCR (z≥2.66, P≤0.008). Similarly, total clinical score in infected dogs was
positively correlated with log-transformed Leishmania parasite burdens measured in
bone marrow samples by real-time qPCR (z=4.33, P<0.001).
93
Table 8. Percentage of canine bone marrow samples positive by conventional and nested PCRs, OligoC-TesT and real-time qPCR.
95% binomial C.I. are indicated in italics. Samples were taken from dogs with L. infantum infection confirmed by ELISA and/or in vitro/in
vivo culture. The clinical status of dogs was defined as asymptomatic (asymp: total clinical score (ts) ≤2), oligosymptomatic (oligosymp: ts=3-
6), or polysymptomatic (polysymp: ts=7-18). Samples taken from dogs with no clinical score data were excluded.
PCR tests which showed higher sensitivity in samples from dogs with clinical signs of ZVL (oligo- and polysymptomatic groups combined)
compared with asymptomatic dogs are indicated by asterisks (χ
2 test: *P≤0.05; **P≤0.01).
Results of pairwise comparison of the overall sensitivity of each test with the OligoC-TesT are shown (McNemar’s χ
2 test: +, more sensitive
than OligoC-TesT; -, less sensitive than OligoC-TesT; =, no significant difference between tests).
Test Polysymp
(n=29)
Oligosymp
(n=34)
Asymp
(n=82)
Overall
(n=145)
Real-time qPCR 100
(88.1-100)
91.2
(76.3-98.1)
87.8
(78.7-94.0)
91.0
(85.2-95.1)
+
kDNA PCR 96.6
(82.2-99.9)
76.5
(58.8-89.3)
62.2
(50.1-72.7)
72.4
(64.4-79.5)
= **
OligoC-TesT 93.1
(77.2-99.2)
73.5
(55.6-87.1)
61.0
(49.6-71.6)
70.3
(62.2-77.6)
**
PCR/hybridization 82.8
(64.2-94.2)
58.8
(40.7-75.4)
53.7
(42.3-64.7)
60.7
(52.2-68.7)
- *
ITS-1 PCR 89.7
(72.6-97.8)
52.9
(35.1-70.2)
41.5
(30.7-52.9)
53.8
(45.3-62.1)
- **
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7.3.3 Test agreement
Pairwise agreement between different PCR tests in individual samples was only
moderate between OligoC-TesT and both ITS-1 (k=0.57, S.E.=0.07, P<0.01) and
PCR/hybridization (k=0.59, S.E.=0.08, P<0.01), reflecting the superior sensitivity of
the OligoC-TesT. Agreement was weak between OligoC-TesT and real-time qPCR
(k=0.38, S.E.=0.06, P<0.01), due to superior sensitivity of real-time qPCR. Despite
similar sensitivity of the OligoC-TesT and kDNA PCR, their pairwise agreement was
only moderate: 16 samples were kDNA positive/ OligoC-TesT negative whereas for
14 samples the reverse was true (k=0.56, S.E.=0.08, P<0.01). In 29/30 of these
apparently discordant samples, parasite burden estimated by real-time qPCR was low
(<100 parasites/ml; mean=19.5, 95% C.I.=13.5-25.5; one outlier excluded).
A single bone marrow sample that tested negative by real-time qPCR was positive by
the OligoC-TesT, PCR/ hybridization and kDNA PCR. Specificity of the procedures
on test was not measured in dogs from the endemic area, since all Brazilian dogs in
the present study were selected on the criteria of infection at some time point.
However, using a small number of non-endemic healthy UK control dogs (n=10)
specificity was 100% for all tests. As expected, positive OligoC-TesT results were
obtained when testing control DNA from a range of Leishmania species: L. infantum
MHOM/FR/78/LEM75, L. tropica MHOM/SU/74/K27, L. major MHOM/SU/73/5-
ASKH, and L. donovani MHOM/IN/80/DD8.
7.3.4 Analytical sensitivity
The detection limit of the OligoC-TesT, as stated by the manufacturer is 0.05
Leishmania parasites per PCR (Deborggraeve et al., 2008). The analytical sensitivity
of both kDNA nested PCR and ITS-1 PCR, estimated here from 10-fold serial
dilutions of DNA from cultured L. infantum promastigotes (MHOM/MA/67/ITMAP-
263), was 0.2 parasites per PCR, though subjective signal strength (band intensity) in
end point PCR was stronger in kDNA PCR. Analytical sensitivity for the previously
performed PCR/hybridization reaction was not determined here. In our hands, the
detection limit for real-time qPCR was 0.005 parasites per PCR, similar to the
previously published estimate of 0.001 parasites per PCR (Francino et al., 2006).
When tested in clinical samples (Figure 14), the OligoC-TesT gave positive results in
100% of canine bone marrow DNA samples with estimated Leishmania burdens ≥74
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parasites/ml (i.e. ≥0.4 parasites/PCR); its sensitivity to detect 10-100 parasites/ml
(0.05-0.5 parasites/PCR) and <10 parasites/ml (<0.05parasites/PCR) was 50.0% and
21.1% respectively (Figure 15). kDNA PCR showed a slightly lower cut-off of 49
parasites/ml (0.1 parasites/PCR) in bone marrow samples, missing only one positive
sample above this threshold (i.e. 98.9% sensitivity), and detecting 57.9% and 21.1%
positive samples at 10-100 and <10 parasites/ml, respectively. PCR/hybridization and
ITS-1 PCR were less sensitive at low parasite burdens in clinical samples, and did not
reach 90% sensitivity until parasite concentration exceeded 1000 per ml sample.
7.3.5 Test sensitivity and time course of infection
Longitudinal results of the three conventional PCR tests, OligoC-TesT, and real-time
qPCR on bone marrow samples from the time of detection of infection t0 are shown
in Figure 16A. The most striking differences in test sensitivity occurred at t-2 months,
when the proportions positive by ITS-1 and PCR/hybridization were both zero,
whereas real-time qPCR, OligoC-TesT and kDNA PCR were positive in 73.3%,
53.3% and 46.7%, respectively. The proportion positive was highest in the first 6
months after confirmed infection, and decreased thereafter. Excluding samples at t-2
months, and controlling for clinical score, there was a significant negative correlation
between the proportion of positive samples and increasing time from confirmed
infection when tested by the OligoC-TesT (z=-2.71, P=0.007), kDNA PCR (z=-2.93,
P=0.003), PCR/hybridization (z=-4.05, P<0.001 or real-time qPCR (z=-2.52,
P=0.01), a trend which was borderline significant in the case of ITS-1 PCR (z=-1.70,
P=0.09). This trend for lower sensitivity with increasing duration of infection, was
associated with a similar negative correlation between bone marrow parasite burdens
measured by real-time qPCR and increasing duration of infection, also controlling for
clinical score (z=-4.48, P<0.001) (Figure 16B).
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Figure 14. Detection threshold of OligoC-TesT and conventional nested PCRs.
The distribution of positive and negative results in individual bone marrow samples is
shown according to parasite burden measured by real-time qPCR.
Samples are sorted in ascending order with respect to parasite burden, truncated at
1000 parasites/ml for clarity.
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Figure 15. Sensitivity of OligoC-TesT and conventional PCR (95% upper binomial
C.I.) in bone marrow samples across a 7- log10 range of parasite burdens.
Samples are grouped by parasite burdens measured by real-time qPCR.
n: no. of samples
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Figure 16. Sensitivity of OligoC-TesT, conventional PCR and real-time qPCR
with varying time from infection.
(A) Percentage of positive canine bone marrow samples (95% upper binomial
C.I.) by conventional and nested PCRs, OligoC-TesT and real-time qPCR, at time
t after first detection of L. infantum infection by culture and/or serology (t0). (B)
Median parasite burden (parasites/ml sample) measured by real-time qPCR at
time t.
Error bars show interquartile range (25%-75%).
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7.4 Discussion
This study shows that the overall sensitivity of the OligoC-TesT to detect
Leishmania DNA in bone marrow aspirates from infected dogs (70%) is comparable
to or greater than the sensitivity of the conventional PCR methods tested (range 54-
72%). In polysymptomatic clinical cases of canine ZVL, the sensitivity of the
OligoC-TesT was 93%, in comparison with 83-97% sensitivity of the conventional
PCR methods. This is comparable to previously reported OligoC-TesT sensitivity in
humans with symptomatic visceral leishmaniasis (78%-100%) (Deborggraeve et al.,
2008). The positive correlation reported here between parasite burdens in canine
bone marrow samples and the severity of clinical signs of ZVL was consistent with
our finding that the OligoC-TesT was significantly more sensitive in symptomatic
compared to asymptomatic dogs. This was similar to the trend shown by the other
conventional PCR tests, and corroborates previous work which demonstrated similar
relationships (Rodriguez-Cortes et al., 2007; Manna et al., 2009). For the diagnosis
of ZVL in suspected clinical cases by veterinarians, therefore, the OligoC-TesT is
likely to be highly sensitive. The ease of use of the OligoC-TesT will be an
advantage in both veterinary diagnostic and public health contexts. In particular,
OligoC-TesT provides high sensitivity without the need for nested PCR protocols,
which are prone to contamination problems, or hybridization steps, which increase
the processing time and in some cases do not improve sensitivity (Lachaud et al.,
2002b).
OligoC-TesT and kDNA PCR, despite similar overall sensitivity, showed only
moderate agreement indicating a degree of discordance. Importantly, almost all these
instances (29/30) occurred in samples with low parasite burdens (<100 parasites/ml),
which is likely to reflect lower analytical sensitivity at the detection limit of both
these tests. The apparent lower sensitivity of the PCR/hybridization method could
have resulted from a lower DNA extraction efficiency when carried out during the
previous study (Quinnell et al., 2001a), whereas all other tests here were performed
on repeat DNA extractions from the same archived bone marrow samples. In
addition, the PCR/hybridization method relied on agreement between rRNA and
kDNA PCR, thus any samples which were positive in one test but not the other
would have been classed as negative.
Despite the wide range of PCR protocols that have been used to detect Leishmania
infection, relatively few studies have directly compared the sensitivity of different
100
protocols. More sensitive conventional methods than the ones used here have been
described (Lachaud et al., 2002a; Lachaud et al., 2002b). Detection limits of 10-3
parasites/ml seeded canine blood have been reported using primers targeting kDNA
sequences, though as previously discussed, theoretical analytical sensitivity does not
always reflect diagnostic performance in clinical samples (Lachaud et al., 2002b).
For example, in other work comparing the sensitivity of conventional kDNA PCR
with real-time qPCR in canine bone marrow, only samples with parasite loads in
excess of 30 parasites/ml were positive by kDNA PCR (Francino et al., 2006). In
blood samples from human patients suffering from visceral leishmaniasis, nested
PCR was 100% sensitive when parasitaemia exceeded 22 parasites/ml, though
parasite burdens as low as 0.12 parasites/ml were detected sporadically (Mary et al.,
2004). The nested kDNA PCR tested here showed 99% sensitivity at parasite
burdens above 49 parasites/ml (Figure 14), compared with the OligoC-TesT which
reliably produced positive results when parasite density exceeded 74 parasites/ml
sample. In contrast, sensitivity of nested ITS-1 PCR and PCR/hybridization remained
low until bone marrow parasite burdens were 10-100 fold higher. The diagnostic
advantage of the OligoC-TesT and kDNA PCR was most apparent in samples with
low parasite burden, such as samples from asymptomatic dogs, and dogs in the early
stages of infection (2 months before the first detection of infection by serology
and/or parasitological culture). The most sensitive test was real-time qPCR which is
likely to become the gold standard for parasite detection in population (prevalence)
studies, although it is not necessarily the best method for veterinary clinical
diagnostic use. As pointed out by others (Lachaud et al., 2002b), the advantages of a
highly sensitive test are offset by a reduced positive predictive value for clinically
patent disease, which has been correlated with increased transmission of parasites
from dogs to sand flies in previous studies (Courtenay et al., 2002b). Conversely, the
OligoC-TesT would be appropriate for detection of infection incidence in vaccine
trials against ZVL, though the high cost of the test kit (approx. 6-9 GBP per sample
(S. Deborggraeve, personal communication)) may make large scale use financially
prohibitive until retail costs are reduced.
A negative relationship between the sensitivity of conventional PCR and the duration
of infection has been reported in previously published results using the
PCR/hybridization test, carried out in larger numbers of samples from these Brazilian
dogs. That study showed a decline to c. 50% sensitivity after 300 days post-infection
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(Quinnell et al., 2001a). In the present study, we confirmed a similar trend for lower
test sensitivity with increasing duration of infection, in three out of the four
qualitative PCR methods tested. The fall in sensitivity with increasing time from
confirmed infection was associated with lower bone marrow parasite burdens, and a
consequent decrease in the number of samples with parasite levels above the
detection limit for each test. Lower parasite burdens are likely to reflect both parasite
clearance from more resistant animals and loss of highly parasite-positive susceptible
dogs from the population through increased mortality rate (Quinnell et al., 2001a).
This trend shows interesting parallels with the results of rK39 dipstick serological
tests reported in Chapter 6, which showed a similar decline in sensitivity in the later
stages of infection.
Species of Leishmania other than L. infantum, such as L. amazonensis and L.
braziliensis have previously been isolated from dogs (Delgado et al., 1993; Llanos-
Cuentas et al., 1999; Reithinger and Davies, 2002; Tolezano et al., 2007; Quaresma
et al., 2009), although the epidemiological significance of the dog as a reservoir host
for these parasites is unclear. Mixed infections with L. braziliensis and L. infantum
have also been documented (Madeira et al., 2006). It is necessary to confirm that the
comparative high sensitivity of OligoC-TesT and kDNA did not result from detection
of species of Leishmania other than L. infantum, since both the OligoC-TesT and
kDNA PCR show broad specificity for all Leishmania spp. However, product sizes
in kDNA PCR were in all cases consistent with L. infantum, and enabled exclusion
of L. amazonensis (but not L. braziliensis) (Noyes et al., 1998), and previously
reported identification of cultured parasites in 34 canine bone marrow samples from
the current study population yielded only L. infantum (Quinnell et al., 1997).
Moreover, examination of health records from several decades of monitoring the
human population in the study site does not provide any evidence to support
autochthonous transmission of cutaneous leishmaniasis in this study area (Dr.
Lourdes Garcez, Instituto Evandro Chagas, Brazil; personal communication).
In conclusion, we have validated the use of the OligoC-TesT for detection of L.
infantum DNA in the reservoir host of ZVL, and have shown that the test has
comparable or superior sensitivity to the conventional PCR methods tested. Due to
the speed and ease of operation and interpretation, and standardized methodology, it
is highly suitable for use in endemic areas for veterinary diagnostic purposes and for
public health authorities. In regions where multiple species of Leishmania are
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(potentially) circulating, direct sequencing of PCR product may be necessary to
allow species identification (Deborggraeve et al., 2008), however prototype
Leishmania species-specific oligochromatographic kits are also in development.
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Chapter 8: Comparison of quantitative and qualitative
PCR as proxy measures for the evaluation of
infectiousness and incrimination of potential reservoirs of
leishmaniasis
8.1 Introduction
From a public health perspective, strategies targeted at blocking the transmission of
vector-borne diseases between hosts require information on the infectiousness of the
reservoir host. In the case of ZVL, this requires measurement of the infectiousness of
domestic dogs to phlebotomine sand flies which transmit the disease. Unfortunately,
to estimate infectiousness directly requires time consuming and labour-intensive
xenodiagnosis experiments (Molina et al., 1994; Courtenay et al., 2002b) which
involve feeding colony-raised sand flies on infected animals, a procedure which is not
amenable to scaling up for use in large-scale survey work. No consensus currently
exists as to the best choice of canine tissue sample or test procedure to use as a viable
proxy measure of infectiousness, though it is sometimes assumed that infectiousness
to biting sand flies correlates with parasite load in skin (Silva et al., 2001). Indeed,
previous investigations have suggested that PCR-negative canine skin, lymph node
and blood samples are evidence of a successful transmission blocking vaccine
(Nogueira et al., 2005), however there is limited data to support such a claim;
similarly, the use of parasitological methods (e.g. microscopy,
immunohistochemistry, or PCR) as a proxy measure of infectiousness to sand flies
has yet to be validated. The increasing accessibility of real-time quantitative PCR
(qPCR) offers another potential tool to investigate levels of tissue parasitism.
Although previous studies show that parasite burdens differ between simultaneously
sampled tissues such as skin, bone marrow and peripheral blood (Manna et al., 2006;
Quaresma et al., 2009), it is a reasonable hypothesis that parasitaemia or parasite
DNA levels in skin correlate with increased likelihood of parasite uptake by biting
sand flies. There is no published data testing this hypothesis by using real-time qPCR
to correlate tissue parasite load with infectiousness by xenodiagnosis experiments,
and comparing the predictive value of real-time versus conventional PCR for
identification of infectious animals. A PCR based proxy measure of infectiousness
would be highly desirable for use in large-scale intervention trials including those for
up-and-coming experimental vaccines, in understanding the potential importance of
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wildlife reservoirs in transmission, and in investigating the entomological
mechanisms behind success or failure of interventions (Mazloumi Gavgani et al.,
2002; Jalouk et al., 2007). Our first aim was to determine the predictive value of the
presence and abundance of parasite DNA in canine tissues (detected by conventional
nested kinetoplast (kDNA) and internal transcribed spacer-1 (ITS-1) PCR, and real-
time qPCR) for infectiousness of dogs to Lutzomyia longipalpis sand flies. Canine
skin and bone marrow samples were collected in longitudinal follow-up of naturally
exposed dogs, stratified by their infectiousness to sand flies from the results of
previous longitudinal xenodiagnosis experiments (Courtenay et al., 2002b). Second,
we aimed to characterize the relationship between tissue parasite burdens, infectious
status and time since infection in naturally exposed dogs. Third, we aimed to compare
parasite burdens in dogs with those of a sympatric population of crab-eating foxes
(Cerdocyon thous: a putative wildlife reservoir), which showed similar contemporary
prevalence of ZVL infection but that were negative in xenodiagnosis experiments
(Courtenay et al., 2002a). This study compares the potential for real-time and
conventional PCR to contribute to measuring the impact of intervention trials against
canine Leishmania on disease transmission, and to aid studies seeking to quantify the
infectious role of suspected Leishmania reservoir hosts.
8.2 Methods
8.2.1 Canine samples
Samples were selected from naturally exposed outbred dogs, from a previously
described large-scale longitudinal field study in Brazil (Quinnell et al., 1997), in
which bone marrows and biopsies of ear skin were sampled repeatedly at
approximately 2 month intervals for up to 24 months post initial natural exposure.
For the present study, 157 bone marrow samples were available from 41 dogs, while
a subset of 31 dogs also had paired ear biopsy samples (n=102 samples).
Xenodiagnosis results were available from matched time points, for 81 bone marrow
samples and 51 ear biopsies. Dogs were also categorized as “ever-infectious” or
“never-infectious” to sandflies, as defined below (Section 8.2.3), based on all
xenodiagnosis experiments (1-12 per dog) conducted previously (Courtenay et al.,
2002b). Samples were aligned by the time of first detection of infection (t0), defined
as positivity by serology (crude parasite ELISA) and/or parasitological culture of
bone marrow in vitro or in vivo in hamsters, as described in Chapter 2 and previously
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(Quinnell et al., 1997). Blood samples from 10 UK dogs with no history of foreign
travel provided negative DNA controls for PCR tests in the current study.
8.2.2 Fox samples
Samples were selected from a concurrent longitudinal study of free ranging crab-
eating foxes (Cerdocyon thous), sympatric with the dog population detailed above, as
described (Courtenay et al., 2002a). We selected samples from 16 foxes, from which
paired bone marrows and ear biopsies were available on at least one occasion (n=26
pairs of samples), on the criterion of seropositivity by crude parasite ELISA at the
time of sampling. Anti-Leishmania IgG titres in the seropositive foxes selected were
lower than in dogs described above (Wilcoxon rank sum test: z=3.11; P=0.002).
Clinical signs of ZVL were detected in only one of these 16 foxes (sampled on two
occasions). In vivo xenodiagnosis experiments to measure fox infectiousness to Lu.
longipalpis sand flies were repeated on 1-3 occasions, in all 16 foxes. Negative
results were obtained in all xenodiagnosis experiments (Courtenay et al., 2002a).
8.2.3 Xenodiagnosis
Xenodiagnosis experiments on dogs and mark-recaptured foxes were carried out
previously, as described in Chapter 2 and elsewhere (Courtenay et al., 2002a;
Courtenay et al., 2002b). The number of positive (infectious) flies was recorded as a
proportion of total number of fed flies at the end of the experiment. The total
proportion of fed vs unfed flies was also recorded. The proportion of blood-fed flies
was similar for dogs (45%) and foxes (37%). Animals were defined as xenodiagnosis
positive (≥1 infectious sandfly detected by dissection) or negative (0 infectious flies)
at each individual time point, and also as never-infectious or ever-infectious based on
the results of repeated xenodiagnosis carried out on the same animal (ever-infectious
animals were those which were positive by xenodiagnosis at ≥ 1 time point).
8.2.4 DNA extraction, nested ITS-1 and kDNA PCR
DNA extraction was performed on 100µl aliquots of bone marrow, using a phenol-
chloroform protocol as described in Chapter 2. Ear biopsy samples were extracted
using a commercial kit (DNeasy: Qiagen, UK) following the manufacturer’s
recommendations. Mean Abs260/280 in dog and fox bone marrow extracts was 1.83 and
1.89 respectively, and in ear biopsies, 1.88 and 1.94, respectively, showing high
purity of the extracted DNA.
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DNA extracts were subjected to nested PCRs targeting a) the ITS-1 region of the
rRNA gene of all Leishmania species, and b) a variable region of Leishmania kDNA,
as described in Chapter 2. Detection PCR products was carried out by gel
electrophoresis to confirm second round reaction products of approximately 480bp
and 680bp, respectively. Positive and negative controls were as described in Chapter
2.
8.2.5 Real-time qPCR
Quantitative real-time PCR (qPCR) was carried out using LEISH-1 and LEISH-2
primers and FAM-labelled Leishprobe as described in Chapter 2. Sample DNA (5µl)
was added at 1:10 dilution (bone marrows) or 1:100 dilution (ear biopsies) in water
(appropriate dilution factors were identified from serial 10-fold dilutions in
preliminary optimization experiments). All DNA samples were amplified in
duplicate. Positive and negative controls were as described in Chapter 2.
Quantification of Leishmania DNA using real-time qPCR data was performed using
three different methods. Absolute quantification (parasites/ml) was carried out by
comparison of sample Ct values with those from a standard curve constructed from
10-fold dilutions of L. infantum DNA from 1×106 to 0.1 parasite equivalents/ml
(strain MHOM/MA/67/ITMAP-263), which were run in triplicate on every plate.
Parasite burdens calculated as above were also expressed relative to total DNA
concentration measured spectrophotometrically (parasites/ml/100ng DNA), to
provide a normalized measurement which could be referred to subsequent studies.
Thirdly, parasite load was normalized to the eukaryotic 18S rRNA gene as a
reference of total canine DNA, using the 2-ΔΔCt method (Livak and Schmittgen, 2001).
For this purpose, pre-developed 18S rRNA gene TaqMan Assay reagents (Applied
Biosystems, UK) were used, following the manufacturer’s recommendations. 2-ΔΔCt 
values were calculated using Ct values from Leishmania and rRNA real-time qPCR
for each sample, relative to a reference sample with the lowest parasite burden
relative to rRNA gene copy number, using the formula:
All data was log10 (n+1) transformed for analysis. The inter-assay coefficient of
variability (CV) of the Leishmania real-time qPCR, estimated by running a reference
   -ΔΔCt    - ( (Ctleish-CtrRNA) sample - (Ctleish-CtrRNA) reference )
2 = 2
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sample in duplicate on every plate, was 2.48%. The mean intra-assay CV of reference
sample duplicates was 0.40% (range 0.03%-1.44%).
8.3 Results
8.3.1 Real-time and conventional PCR for detection of infectious dogs
The sensitivity and specificity of bone marrow and ear biopsy real-time qPCR, kDNA
and ITS-1 conventional nested PCR for detection of xenodiagnosis-positive dogs at
the time of sampling are shown in Table 9. Results of previous serological tests
(crude parasite ELISA) are shown for comparison. Real time qPCR of bone marrow
and ear biopsies showed similarly high sensitivity to both of the conventional PCR
methods tested, and serology. Specificity of real-time qPCR was low, similar to
serology, and lower than the specificity of both the conventional nested PCRs in bone
marrows (McNemar’s χ
2
≥10.9; P≤0.001) and ear biopsies (McNemar’s χ2≥18;
P≤0.001).
Using parasite burdens (expressed as log10 parasites/ml/100ng DNA) measured by
real-time qPCR, categorized as low (0-4.9), medium (5-9.9) and high (≥10) (Figure
17), the probability of xenodiagnosis-positivity was highest in the latter group when
sampling bone marrows (χ
2
≥9.66; P=0.002) and ear biopsies (χ2 ≥9.05; P=0.003).
Optimum cut-off points of 9 & 15 log10 parasites/ml/100ng DNA (arrowed, Figure
18, A&B) were selected to give the maximum combined value for sensitivity and
specificity for identification of xenodiagnosis-positive dogs, using bone marrow and
ear biopsy samples, respectively. These cut-offs improved the diagnostic value of
bone marrow real-time qPCR by increasing specificity to approximately the same
value as ITS-1 PCR (McNemar’s χ
2=2.7; P=0.22) and superior to kDNA PCR
(McNemar’s χ
2=18.2; P<0.001: Table 9). Specificity of ear biopsy real-time qPCR
using the optimum cut-off point was higher than ITS-1 PCR, though not significantly
so (McNemar’s χ
2=4.45; P=0.07), and was superior to kDNA PCR (McNemar’s
χ
2=9.0; P=0.004). However, the use of cut-off parasite burdens in bone marrows and
ear biopsies reduced the sensitivity of real-time qPCR to 89% and 88%, respectively,
not significantly different to the sensitivities of ITS-1 and kDNA PCR. ROC curves
(1-specificity vs sensitivity) plotted from varying parasite burden cut-off values, gave
area under the curve (AUC) values of 0.86 (bone marrows) and 0.94 (ear biopsies),
indicating good to excellent diagnostic value of real-time qPCR for detecting
infectious dogs at the time of sampling.
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Parasite burdens in tissue samples were also estimated from Ct values measured in
real-time qPCR using two alternative quantification methods, as log10 parasites/ml,
and log10 2-ΔΔCt values, calculated as described above. Parasite burdens calculated by
all three procedures were highly correlated (adjusted r2=0.92-0.98; Table 10), thus
statistical associations were similar when data were analyzed using the alternative
quantification methods (Figures 19 & 20). All subsequent analysis has been carried
out on parasite burdens normalized to total DNA (parasites/ml/100ng DNA), and for
clarity all parasite burdens will be reported in these units.
8.3.2 Predictive value of parasite burden to identify highly infectious dogs.
We next determined whether tissue parasite burdens were associated with the
proportion of fed sandflies that became infected in xenodiagnosis experiments
performed at the time of sampling (Figure 18, A&B). The purpose of this analysis
was to attempt to identify highly infectious dogs responsible for the majority of
disease transmission. There was a poor correlation between the proportion of total fed
flies that were infected in xenodiagnosis at a single time point, and parasite burdens
in simultaneously sampled bone marrows (adjusted r2=0.24) and ear biopsies
(adjusted r2=0.27). Ranking dogs by their cumulative contribution to transmission
(Figure 21, A&B) illustrates that the dogs identified by the described real-time qPCR
cut-off points in bone marrow and ear biopsy samples (arrowed, Figure 18, A&B)
were together responsible for 99.4% and 97% of transmission events, respectively.
Conventional kDNA PCR of bone marrows and ear biopsies identified dogs
responsible 99.7% and 100% of transmission events, respectively, while ITS-1 PCR
identified 99.7% and 67.6% (one highly infectious dog was ear biopsy ITS-1 PCR
negative). Crude parasite ELISA serology carried out in the previous survey was
positive in all infectious dogs.
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Table 9. Sensitivity and specificity of conventional and real-time qPCR for detection
of infectious dogs.
Columns headed ITS-1 and kDNA show sensitivity and specificity of ITS-1 and
kDNA conventional nested PCRs respectively, for identification of xenodiagnosis
positive dogs at the time of sampling. Figures in parentheses show 95% C.I.
CLA ELISA: sensitivity and specificity of crude parasite ELISA, for detection of
infectiousness in dogs at the time of bone marrow or ear biopsy sampling.
Leishmania real-time qPCR results are shown for dichotomous outcome (qPCR +/-),
and using the optimum cut-off bone marrow and ear biopsy parasite burdens (qPCR
cut-off: 9 & 15 log10 parasites/ml/100ng DNA, respectively) which were selected to
produce the highest combined figure for sensitivity and specificity. AUC: Area under
ROC curve (1-specificity vs sensitivity) for varying parasite burden cut-off points to
classify dogs as infectious based on results of real-time qPCR. An AUC value of 1
indicates a perfect test, 0.5 indicates a test with no diagnostic value.
Dogs ITS-1 kDNA CLA ELISA qPCR +/- qPCR cut-off n
Bone marrow
Sensitivity (%) 94 (73-100) 94 (73-100) 100 (82-100) 94 (73-100) 89 (66-99) 18
Specificity (%) 71 (59-82) 46 (33-59) 22 (13-34) 24 (14-36) 78 (66-87) 63
AUC=0.86
Ear biopsy
Sensitivity (%) 75 (35-97) 100 (63-100) 100 (63-100) 100 (63-100) 88 (47-100) 8
Specificity (%) 74 (59-87) 63 (47-77) 26 (14-41) 21 (10-36) 91 (78-97) 43
AUC=0.94
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Figure 17. Relationships between bone marrow and ear biopsy parasite burdens and
infectiousness to sand flies (1).
Probability of xenodiagnosis-positivity in dogs stratified by parasite burdens in bone
marrows and ear biopsies, measured by real-time qPCR in samples taken at the time
of xenodiagnosis. Asterisks indicate statistically significant differences between the
indicated proportions positive by xenodiagnosis (**: P≤0.01; *:P≤0.05; χ
2 test).
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Figure 18. Relationships between bone marrow and ear biopsy parasite burdens and
infectiousness to sand flies (2).
Proportion of total fed Lu. longipalpis sandflies that were infected in xenodiagnosis
experiments, in relation to (A) bone marrow and (B) ear biopsy parasite burdens.
Arrows indicate optimum cut-off points selected to maximize real-time qPCR
sensitivity and specificity for identification of xenodiagnosis positive dogs based on
their bone marrow and ear biopsy parasite burdens (cut-off=9 and 15 log10
parasites/ml/100ng DNA, respectively).
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Table 10. Correlation between parasite burdens estimated using absolute and relative
quantification methods.
Correlation (adjusted Pearson’s r2 value) between estimates of parasite burden
calculated from real-time qPCR data, using absolute parasite burden expressed as
log10 parasites/ml, quantification relative to total DNA quantity measured
spectrophotometrically (log10 parasites/ml/100ng DNA), and quantification relative to
the copy number of the canine rRNA gene (log10 2-ΔΔCt).
Quantification method Bone marrow Ear Biopsy
log10 parasites/ml
log10 2-ΔΔCt
log10 parasites/ml/100ng DNA
0.92
0.97
0.93
0.95
0.92
0.98
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Figure 19. Relationships between tissue parasite burdens measured using alternative
quantification methods, and infectiousness to sand flies (1).
(A) & (B) Probability of xenodiagnosis-positivity in dogs stratified by parasite
burdens in bone marrows and ear biopsies, measured by real-time qPCR, quantified
by the log10 2-ΔΔCt method (A) and as log10 parasites/ml (B).
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Figure 20. Relationships between tissue parasite burdens measured using alternative
quantification methods, and infectiousness to sand flies (2).
Proportion of total fed Lu. longipalpis sandflies that were infected in xenodiagnosis
experiments, in relation to parasite burdens quantified by real-time qPCR using:
(A) & (B) log10 2-ΔΔCt method, and
(C) & (D) log10 parasites/ml
Bone marrow samples are indicated by circles and ear biopsies by squares.
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Figure 21. Proportion of transmission events in dogs identified by real-time and
conventional PCR positivity
Dogs are ranked from left to right in order of their contribution to total transmission
events (no. of sand flies infected overall). Dotted lines indicate the proportion of
transmission events attributable to real-time qPCR positive dogs, defined using the
cut-off points described above, in bone marrows (A) and ear biopsies (B). Horizontal
bars indicate the results of conventional kDNA and ITS-1 PCR, and serology on bone
marrows and ear biopsies respectively.
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8.3.3 Parasite burden, infectiousness and time since infection.
L. infantum parasite loads in bone marrow and ear biopsy samples estimated by real-
time qPCR (median +/- interquartile range), stratified by the infectious status of dogs
as ever-infectious or never-infectious, with time from first detection of infection (t0)
are shown in Figure 22(A). Parasite levels in samples from ever-infectious animals
were higher than never-infectious dogs in bone marrow samples (n=157) at t0 to t+6
mo and t+8 to t+12 mo (Wilcoxon rank sum test: z=-2.95; P=0.003; z=-2.99; P=
0.003), and in ear biopsies (n=102) at the same time points (Wilcoxon rank sum test:
z=-2.28; P=0.02; z=-3.88; P<0.001, respectively). Controlling for within-dog
autocorrelation, there was a significant positive correlation between tissue parasite
burden in infected dogs and the probability of being ever-infectious to sand flies,
when testing either bone marrows (z=2.11; P=0.04) or ear biopsies (z=2.85;
P=0.004). In fox samples, parasite levels in both bone marrows and ear biopsies were
lower than in ever-infectious dogs (Wilcoxon rank sum test: z=-5.39; P<0.001; z=-
5.71; P<0.001, respectively) and were also lower than in never-infectious dogs
(Wilcoxon rank sum test: z=-3.64; P<0.001; z=-4.17; P<0.001, respectively) (Figure
22). The sensitivity and specificity of conventional and real-time PCR for identifying
ever- and never-infectious dogs according to time post-infection are shown in Figure
22(B). Real-time qPCR of bone marrow and ear biopsy was the most sensitive (75-
97% and 60-100%, respectively) but least specific method (15-33% and 0-63%,
respectively) for detection of ever-infectious dogs. For detection of ever-infectious
animals using bone marrow samples, the maximum sensitivity of kDNA PCR was
79% (25% specificity) at 0-6 months post t0, and maximum sensitivity of ITS-1 PCR
was 75% (83% specificity) at 14-20 months post t0. Using ear biopsies, the maximum
sensitivity of kDNA PCR was 86% (43% specificity) at 8-12 months post t0, and
maximum sensitivity of ITS-1 PCR was 71% (67% specificity) at 8-12 months post
t0.
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Figure 22. Relationship between parasite burden and time from infection in ever- and
never- infectious dogs.
(A) Leishmania parasite load measured by real-time qPCR in bone marrow (n=157)
and ear biopsy (n=102) samples from ever-infectious and never–infectious dogs, and
bone marrow and ear biopsy samples (n=26 each) from non-infectious foxes. Parasite
counts are expressed as the median (+/- interquartile range) log10 parasite count per
ml DNA extract, normalized to 100ng total DNA (log10 parasites/ml/100ngDNA), by
time from first detection of infection (t0) defined as positivity by crude parasite
ELISA and /or in vitro/in vivo culture. Fox bone marrow (FBM) and fox ear biopsy
(FE) parasite counts in samples from ELISA positive foxes are shown for comparison
– time t0 was not determined in foxes.
Time points at which tissue parasite burdens were greater in ever-infectious dogs than
in never-infectious dogs are indicated (B: bone marrow; E: ear biopsy; **: P≤0.01;
*:P≤0.05; Wilcoxon rank sum test).
(B) Sensitivity (with specificity in parentheses) of conventional PCRs and real-time
qPCR for detection of ever-infectious dogs at the indicated time points. Fox samples
were all negative by xenodiagnosis, allowing calculation of specificity only.
118
Figure 22.
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8.4 Discussion
From the results reported here, the main challenge in adapting conventional or real-
time qPCR for use as a proxy measure of the infectiousness of ZVL-infected dogs to
sand flies appears to be lack of specificity of these tests in xenodiagnosis-negative
dogs. Real-time qPCR was highly sensitive for detection of xenodiagnosis-positive
dogs when PCR outcome was considered as a dichotomous result (0 or ≥1
parasites/ml/100ng DNA), however conventional nested ITS-1 and kDNA PCR
methods showed similar sensitivity to real-time qPCR, as did crude parasite serology.
The specificity of real-time qPCR was poor, equivalent to serology and inferior to
conventional PCR. However, quantification of parasite burdens allowed stratification
of dogs into groups, in which the group with the highest parasite burdens (>10 log10
parasites/ml/100ng DNA) showed the highest probability of being infectious to sand
flies, and allowed the selection of a cut-off point, below which the majority of dogs
were xenodiagnosis-negative. These findings show interesting parallels with previous
analyses of the distribution of anti-parasite antibody titres in infected dogs, which
demonstrated the existence of a similar cut-off point in IgG titre below which dogs
were mainly non-infectious (Courtenay et al., 2002b). In the present study, the use of
optimum cut-off parasite burdens to define xenodiagnosis-positive dogs improved the
specificity of bone marrow real-time qPCR, but only to equivalent performance with
ITS-1 PCR. In ear biopsy real-time qPCR, use of the optimum cut-off improved
specificity to >90%, although this figure was not significantly better than ITS-1 PCR
(74% specificity) due to limited sample size. The diagnostic performance of real-time
qPCR to predict xenodiagnosis positivity in dogs at the time of sampling, based on
ROC analysis, was superior in ear biopsies than in bone marrows. Ear skin biopsies
are technically straightforward and rapid to collect under local anaesthesia, though
even less invasive sampling methods than those used here could be investigated, for
example conjunctival swabs have shown some merit in previous work using
conventional PCR to identify infected dogs (Strauss-Ayali et al., 2004; Pilatti et al.,
2009), and are under investigation as a sampling technique for real time PCR studies
(Francino et al., 2006).
Previous studies, which have used a number of methods (though not real-time qPCR)
to detect parasites in canine tissues in relation to infectiousness, have produced
conflicting results. For example, in a small cross-sectional study of naturally infected
Brazilian dogs, an absence of microscopic evidence of amastigotes in skin samples
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from xenodiagnosis-negative animals was in contrast to large numbers of amastigotes
in xenodiagnosis-positive animals (Vercosa et al., 2008). Similarly, naturally infected
dogs treated with liposomal meglumine antimoniate showed reduced parasite burdens
(determined by counting immunolabelled amastigotes) in skin and bone marrow,
relative to untreated controls, in association with reduced infectiousness to Lu.
longipalpis (Ribeiro et al., 2008). Neither real-time nor conventional PCR analysis
was performed in either of those two studies. Conversely, and in agreement with our
results reported here, conventional PCR carried out on ear and abdomen biopsies of
Colombian dogs, and on skin, bone marrow and spleen samples from Brazilian dogs,
showed imperfect specificity for detection of infectiousness to Lu. longipalpis, with
positive PCR results in both infectious and non-infectious animals (Travi et al., 2001;
Michalsky et al., 2007). A principal aim of the present study was to determine
whether quantification of parasite burdens would enable incrimination of the small
proportion of highly infectious dogs which are responsible for the majority of
transmission. Where dog culling is the main control measure, this could improve
canine welfare by reducing the numbers of dogs culled needlessly. For example in the
present study, approximately 20% of all infectious dogs (4/18 in the bone marrow
group) were responsible for >75% of all transmission events. However, we found
poor correlation between tissue parasite burdens and the proportion of sand flies
infected by feeding on individual dogs (r2≤0.24; Figure 18 A & B), meaning that high
tissue parasite burdens were of limited use in separating out the most highly
infectious dogs. Although the use of the optimum cut-off bone marrow and ear
biopsy parasite burdens in real-time qPCR allowed identification of dogs responsible
for 99% and 97% of transmission events, respectively, both conventional PCRs
identified similarly high proportions of transmission events, though kDNA was
superior to ITS-1 in ear biopsies (Figure 21B). It is therefore hard to justify the
additional expense of real-time compared to conventional nested PCR for identifying
infectious dogs in large scale survey work, since quantification of parasite burdens
does not appear to offer any additional diagnostic advantage.
For future implementation of a successful vaccine, it seems intuitively obvious that
identification of highly infectious dogs or ‘super-spreaders’ would improve targeted
vaccination strategies. However, in this context it is interesting to consider the effects
of vaccinating populations which show heterogeneity in the infectiousness of
individuals, as is clearly the case for canine leishmaniasis (Figure 18). Mathematical
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modelling has shown that targeted vaccination aimed at super-spreaders does indeed
reduce the probability of disease emergence in a susceptible population to a greater
degree than random treatment (Yates et al., 2006). However, the effect is only
significant when resources (and hence vaccine coverage) are limited. In the model of
Yates et al., 2006, this was simulated by comparing the reduction of the basic
reproduction rate (R0) by random vaccine allocation (0-100% of the population), with
initial targeted vaccination of a sub-population of 5% super-spreaders (which were
10× more infectious than ‘normal’ individuals), followed by random allocation of
remaining vaccination coverage amongst the rest of the population. In that model, the
beneficial effect of targeting vaccination at super-spreaders was highest at low overall
vaccine coverage rates, and became less marked as coverage of the population
increased. Therefore it is recommended that prior to vaccine implementation by
public health authorities, cost/benefit analysis should compare the expense and
logistic difficulty of attempting to identify and vaccinate super-spreaders, as
compared with random vaccine distribution. For such calculations, it is also worth
noting that results obtained in the abovementioned mathematical models were
identical for a ‘perfect’ vaccine (i.e. conferring complete protection in vaccinated
individuals) applied to 70% of the population, and an imperfect vaccine (which
reduced susceptibility by 70%) with 100% population coverage. This emphasises the
point that a vaccine against canine leishmaniasis need not be completely protective in
order to impact on disease transmission.
All the PCR tests used, both conventional and real-time, showed low specificity due
to misclassification of a significant proportion of samples from highly parasite-
positive, but xenodiagnosis-negative dogs. Although we have interpreted
xenodiagnosis experiments as a ‘gold’ standard for defining infectiousness, some
previous research shows that the proportion of flies infected by an infectious dog can
vary from 0% to 100% between consecutive xenodiagnosis experiments even when
conducted over relatively short time intervals (mean 6 days (95% C.I.: 3 to 10 days)
(Dr. Orin Courtenay, unpublished data). Apparent low specificity of PCR in
xenodiagnosis-negative dogs reported here may have resulted from similar wide
fluctuations in xenodiagnosis positivity. Such high error margin in degree of
infectiousness by examination at a single time point can be reduced by repeated
measures from longitudinal sampling. To investigate this possibility, in the current
study we also used cumulative positivity from repeated xenodiagnosis experiments to
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define ever-infectious and never-infectious dogs. Our results from this analysis
suggest that a positive relationship does exist between parasite burdens in bone
marrow and ear biopsy samples measured by real-time qPCR, and infectiousness to
sandflies. However, the specificity of conventional and real-time qPCR in defining
dogs as ever- or never-infectious was not significantly better than their specificity in
point estimates of infectiousness. This may indicate that despite PCR evidence of
tissue parasitism, a sub-group of infected dogs remained non-infectious to sand flies,
or alternatively progressed to infectiousness at some later date, outside the period of
follow-up in the current study.
Quantifying the infectiousness of suspected wildlife reservoirs of ZVL is important to
allow assessment of their relative contribution to disease transmission by partitioning
R0, as has been done previously in studies of the crab-eating fox in Brazil (Courtenay
et al., 2002a). The difficulty of carrying out xenodiagnosis experiments on wild
animals would be alleviated by more straightforward PCR-based protocols to
estimate infectiousness. As reported here, tissue parasite burdens in infected foxes
were lower than in infected dogs (both ever and never-infectious groups). Our data
thus provides a plausible parasitological explanation for why these foxes did not
contribute to disease transmission. As previously described, anti-Leishmania IgG
titres in foxes selected for the present study were also lower than in dogs tested here,
and foxes were largely asymptomatic, which may reflect differences in exposure or
parasite clearance, between the species. The time course of infection in the small
number of foxes tested here was not fully characterized, and to validate real-time
qPCR as a means of detecting infectiousness in wildlife reservoirs would require
larger-scale longitudinal studies with an extended period of follow-up. Moreover, the
associations reported here describe the infectiousness of dogs and foxes in Brazil to
the locally important vector species, Lu. longipalpis. Geographical differences in
transmission dynamics of ZVL are likely to exist, for example in the Mediterranean it
has been suggested that Phlebotomus perniciosus may be a more permissive vector
than Lu. longipalpis, which can acquire infection from skin with lower parasite
burden (Molina et al., 1994). Thus, region-specific studies in both old and new
worlds will be required to compare the associations tested here.
In conclusion, for identification of infectiousness to sand flies in ZVL infected dogs,
tissue parasite burdens measured by real-time qPCR provided no clear advantage
over the dichotomous results of conventional nested PCR which would justify the
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expense of the former procedure. In the absence of a ‘gold’ standard for measuring
infectiousness, a moderately sensitive conventional PCR test is likely to identify
infectious animals with high sensitivity but low to moderate specificity, which has
implications for control programmes which aim to interrupt disease transmission by
culling infectious animals. Further longitudinal research is needed to characterize
variations in xenodiagnosis results in infected dogs over time, and their relationship
with tissue parasite burdens.
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Chapter 9: General discussion
DNA/MVA TRYP and LACK prime/boost vaccines are shown in this study to be safe
and immunogenic in uninfected, unexposed outbred dogs, with superior antigen-
specific levels of the signature type-1 cytokine IFN-γ, and in vivo delayed-type
hypersensitivity responses, in TRYP compared to LACK vaccinated dogs. The IgG
class profile in DNA/MVA TRYP vaccinated dogs was also consistent with protective
immunity, based on precedents established in previous canine research. However
subsequent comparison of the specificity of monoclonal and polyclonal antibodies
reported in Chapter 5 showed inconsistent associations between class levels and
parasitological outcome. For future canine vaccine studies, caution is advised in the
interpretation of IgG class profiles measured using currently available polyclonal
reagents, as a proxy for Th1/Th2 cellular immune response balance.
Characterization of vaccine-induced antibody responses in the target species is an
essential component of vaccine development, to ensure that natural exposure to disease
can be distinguished from vaccination. The lack of significant CLA and rK39-specific
IgG responses in vaccinated animals, in contrast to strong responses reported here in
infected animals, show the potential for differentiation of infected from vaccinated
animals (DIVA) (van Oirschot, 1999). Legislative requirements for import of
vaccinated animals to Leishmania non-endemic countries may require the development
of a marker vaccine which elicits serological responses against antigens not present in
the target pathogen, enabling detection of vaccinated animals by specific serological
tests. Modification of the experimental DNA/MVA vaccine used in the present study
by insertion of multi-epitope plasmids expressing TRYP in combination with a non-
Leishmania protein could meet this requirement. From the data reported here, ELISAs
incorporating either CLA or rK39 antigens would be appropriate serological tests for
measurement of infection incidence in DNA/MVA TRYP or LACK vaccinated
animals enrolled in field trials, though CLA ELISA was more sensitive in naturally
infected dogs than rK39 in early stage infections, and was also superior to a rapid
diagnostic dipstick test incorporating the rK39 antigen. Despite the sensitivity
advantage of CLA ELISA, the potential for cross-reactivity with antibodies against
other canine pathogens such as Ehrlichia canis, which may be co-endemic with
Leishmania infantum, means that CLA ELISA cannot be recommended as a standalone
test to determine infection incidence in vaccine trials, and should be combined with
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more specific molecular methods for diagnosis of ZVL.
Molecular methods tested here for detection of L. infantum infection were targeted at
DNA sequences not present in the experimental DNA/MVA TRYP and LACK
vaccines, and were therefore appropriate for measurement of infection incidence in
vaccinated animals. For use in large scale field trials where technical facilities are
limited, the OligoC-TesT kit was the most straightforward of the PCR protocols tested,
with the advantages of standardized pre-formulated reagents which would enable
comparison of results between different trials using the same kit. OligoC-TesT showed
high sensitivity for detection of infection, which was comparable to or greater than the
sensitivity of kDNA and ITS-1 nested PCR, respectively. However, the high price of
the kit is a current obstacle to its widespread adoption for large scale survey work.
From the perspective of public health, vaccine-induced sterile immunity against ZVL
in the reservoir host is not essential: a vaccine which reduced the infectiousness of
dogs to biting sand flies (ideally such that the basic reproductive rate of the disease
(R0) <1), would block or reduce transmission to humans. Investigation of molecular
methods, as potential proxy measures to replace time consuming xenodiagnosis,
highlighted a number of limitations of real-time and conventional PCR as measures of
transmission blocking effect of an experimental canine vaccine. The main challenge
was lack of specificity of these tests in xenodiagnosis-negative dogs. Conversely, real-
time qPCR was highly sensitive for detection of xenodiagnosis-positive dogs, however
conventional nested ITS-1 and kDNA PCR methods showed similar sensitivity to real-
time qPCR, as did serology. Despite this, quantification of parasite burdens allowed
stratification of dogs into groups with high and low infectiousness based on selection
of cut-off parasite burdens. Above the cut-off point, poor correlation between tissue
parasite burdens and the proportion of infected sand flies made it difficult to identify
the most highly infectious dogs, which could have improved targeted culling strategies
aimed at those animals responsible for the majority of transmission events. It is
therefore hard to justify the additional expense of real-time compared to conventional
nested PCR (4 GBP vs 1 GBP per sample, approx.) for identifying infectious dogs in
large scale survey work, since quantification of parasite burdens does not appear to
offer major diagnostic advantages. For implementation of a successful vaccine against
canine leishmaniasis, targeted vaccination strategies aimed at highly infectious dogs
would be of most benefit where resources and hence vaccine coverage are limited. A
cost/benefit analysis of the potential utility of molecular methods for this purpose
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would need to take the above issues into account, in addition to the logistic difficulties
of targeted (compared with random) vaccine allocation.
Future research efforts should be directed towards confirmation of vaccine safety and
immunogenicity in replicate cohorts of outbred dogs, with dosing-up trials of freeze-
dried vaccine formulations as discussed in Chapter 3. Subsequently, community-based
field trials will be required to measure vaccine efficacy to reduce canine ZVL
infection, disease and infectiousness in a genetically diverse population of dogs
exposed to natural infection with L. infantum. Outcomes would include clinical
disease, seroconversion, molecular detection of parasite DNA in canine tissue samples
(and potentially quantification by real-time qPCR, subject to the selection of
appropriate cut-off points) as a marker of infectiousness to sandflies, and
immunological correlates of these end points (in vitro cytokine stimulation assays, and
tissue cytokine mRNA expression). Analysis of these outcome measures would
quantify differences in the incidence of infection and disease between blinded and
randomized vaccine and control groups, and relate these to measured correlates of
protective immune responses. Measurement of the longevity of vaccine-induced
protective cellular immune responses is critical to determine optimum re-vaccination
frequency. In this way, a successful canine vaccine would be shown to provide long-
term protection of dogs against Leishmania infection and/or disease, and to reduce or
eliminate infectiousness of the reservoir host, thereby reducing or preventing
transmission to humans.
The end point of vaccine development is the licensing of a commercial product.
Potential markets for a canine vaccine against ZVL would be companion animal
owners mainly in developed world endemic areas and those who travel with their dogs
to such areas, and public health authorities in highly endemic countries where
alternative control measures against ZVL are failing, for example in Brazil (Courtenay
et al., 2002b). For all markets, a successful experimental vaccine against canine ZVL
would need to translate into a cost-effective product in comparison with other available
vaccines and disease control interventions. Insecticide-impregnated collars for dogs
have proven efficacy in reducing infective sandfly bites, thus ZVL transmission to
humans and dogs, and represent a potential competitor to a canine vaccine. However,
in the field the persistence of protection from these collars (theoretically 6 months) will
also depend on the rate that dogs lose their collars, as briefly discussed in Chapter 1. In
Brazilian trials, 17%-34% of collars were lost over 5 months (Oliveira-Lima et al.,
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2002; Reithinger et al., 2004), compared to 35% in 10 months in Italy (Foglia Manzillo
et al., 2006). Thus where transmission is year round, the average dog would require 2
or more collars per year for individual protection and to maintain theoretical herd
immunity. The minimum current costs of collars (e.g. c. US$10-15 in Brazil, €17-20 in
Europe) are high and conceived as unaffordable by most ZVL endemic communities,
whereas vaccine protection of significant duration would avoid problems associated
with loss of collars, and loss of protection, and would benefit from decreased inter-
intervention interval. Considering logistic constraints on community-wide delivery, the
frequency of intervention required for an effective DNA/MVA vaccine would be far
lower than that required to maintain dog coverage with collars.
A successful canine vaccine would be a step towards the development and delivery of
a future human vaccine against leishmaniasis. With significant potential for future
exploitation of DNA/MVA vaccines against leishmaniasis, it is important, even in the
initial stages of vaccine development, to be aware of issues surrounding patents and
intellectual property (IP). For example, the TRYP antigen used in the current study is
subject to claims in patent applications (described alternatively as TSA antigen, as
discussed in Chapter 1) which cover the use of the peptide as part of a fusion of more
than one antigen, and which cover the peptide as a vaccine component, though other
research describing the same antigen as TRYP has been cited as prior art which
undermines the novelty of the patent application. It is also clear that there is a complex
patent landscape in the area of the DNA/MVA prime boost technology, however,
rights to this technology are available for licensing, and would not necessarily impede
commercialization of an successful vaccine. The legal issues described above
emphasise the need for consideration of matters beyond the purely scientific in the
process of vaccine development from the academic to the commercial sectors.
The present study describes DNA/MVA vaccine trials against canine leishmaniasis and
validates diagnostic methods for use in future large scale trials to measure vaccine
efficacy. The general approaches used here have wide relevance to the development of
vaccines against other pathogens, and in other species of animals.
128
References
Abranches, P., Lopes, F. J., Silva, F. M., Ribeiro, M. M. and Pires, C. A. (1983).
Kala-azar in Portugal. III. Results of a survey on canine leishmaniasis performed
in the Lisbon region. Comparison of urban and rural zones Ann. Parasitol. Hum.
Comp. 58 (4): 307-315.
Abranches, P., Santos-Gomes, G., Rachamim, N., Campino, L., Schnur, L. F. and
Jaffe, C. L. (1991). An experimental model for canine visceral leishmaniasis.
Parasite Immunol. 13 (5): 537-550.
Acedo-Sanchez, C., Morillas-Marquez, F., Sanchiz-Marin, M. C. and Martin-
Sanchez, J. (1998). Changes in antibody titres against Leishmania infantum in
naturally infected dogs in southern Spain. Vet. Parasitol. 75 (1): 1-8.
Aguilar-Torrentera, F. and Carlier, Y. (2001). Immunological factors governing
resistance and susceptibility of mice to Leishmania major infection. Rev. Lat. Am.
Microbiol. 43 (3): 135-142.
Alexander, B. (2000). Sampling methods for phlebotomine sandflies. Med. Vet. Entomol.
14 (2): 109-122.
Altet, L., Francino, O., Solano-Gallego, L., Renier, C. and Sanchez, A. (2002).
Mapping and sequencing of the canine NRAMP1 gene and identification of
mutations in Leishmaniasis-susceptible dogs. Infect. Immun. 70 (6): 2763-2771.
Alvar, B. J., Molina, R., San Andres, M., Tesouro, M., Nieto, J., Vitutia, M.,
Gonzalez, F., San Andres, M. D., Boggio, J., Rodriguez, F., Sainz, A. and
Escacena, C. (1994). Canine leishmaniasis: Clinical, parasitological and
entomological follow-up after chemotherapy. Ann. Trop. Med. Parasitol. 88 (4):
371-378.
Alvar, J., Canavate, C., Molina, R., Moreno, J. and Nieto, J. (2004). Canine
leishmaniasis. Adv. Parasitol. 57: 1-88.
Alves, C. F., de Amorim, I. F. G., Moura, E. P., Ribeiro, R. R., Michalick, M. S.,
Kalapothakis, E., Bruna-Romero, O., Tafuri, W. L., Teixeira, M. M. and
Melo, M. N. (2009). Expression of IFN-gamma, TNF-alpha, IL-10 and TGF-beta
in lymph nodes associates with parasite load and clinical form of disease in dogs
naturally infected with Leishmania (Leishmania) chagasi. Vet. Immunol.
Immunopathol. 128 (4): 349-358.
Amara, R. R., Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. I.,
Montefiori, D. C., Xu, Y., Herndon, J. G., Wyatt, L. S., Candido, M. A.,
Kozyr, N. L., Earl, P. L., Smith, J. M., Ma, H. L., Grimm, B. D., Hulsey, M.
L., McClure, H. M., McNicholl, J. M., Moss, B. and Robinson, H. L. (2002).
Control of a mucosal challenge and prevention of AIDS by a multiprotein
DNA/MVA vaccine. Vaccine 20 (15): 1949-1955.
129
Andrade, R. A., Silva Araujo, M. S., Reis, A. B., Gontijo, C. M., Vianna, L. R.,
Mayrink, W. and Martins-Filho, O. A. (2009). Advances in flow cytometric
serology for canine visceral leishmaniasis: Diagnostic applications when distinct
clinical forms, vaccination and other canine pathogens become a challenge. Vet.
Immunol. Immunopathol. 128 (1-3): 79-86.
Araujo, M. S., de Andrade, R. A., Sathler-Avelar, R., Teixeira-Carvalho, A.,
Andrade, M. C., Vianna, L. R., Mayrink, W., Reis, A. B., Malaquias, L. C.,
Mello, M. N. and Martins-Filho, O. A. (2009). T-cell-derived cytokines, nitric
oxide production by peripheral blood monocytes and seric anti-Leishmania
(Leishmania) chagasi IgG subclass patterns following immunization against
canine visceral leishmaniasis using Leishvaccine and Leishmune. Vaccine 27 (7):
1008-1017.
Armijos, R. X., Weigel, M. M., Calvopina, M., Hidalgo, A., Cevallos, W. and Correa,
J. (2004). Safety, immunogenecity, and efficacy of an autoclaved Leishmania
amazonensis vaccine plus BCG adjuvant against New World cutaneous
leishmaniasis. Vaccine 22 (9-10): 1320-1326.
Badaro, R., Benson, D., Eulalio, M. C., Freire, M., Cunha, S., Netto, E. M., Pedral-
Sampaio, D., Madurcira, C., Burns, J. M., Houghton, R. L., David, J. R. and
Reed, S. G. (1996). rK39: A cloned antigen of Leishmania chagasi that predicts
active visceral leishmaniasis. J. Infect. Dis. 173 (3): 758-761.
Baneth, G., Koutinas, A. F., Solano-Gallego, L., Bourdeau, P. and Ferrer, L. (2008).
Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part
one. Trends Parasitol. 24 (7): 324-330.
Barbieri, C. L. (2006). Immunology of canine leishmaniasis. Parasite Immunol. 28 (7):
329-337.
Basu, R., Bhaumik, S., Basu, J. M., Naskar, K., De, T. and Roy, S. (2005).
Kinetoplastid membrane protein-11 DNA vaccination induces complete protection
against both pentavalent antimonial-sensitive and -resistant strains of Leishmania
donovani that correlates with inducible nitric oxide synthase activity and IL-4
generation: Evidence for mixed Th1- and Th2-like responses in visceral
leishmaniasis. J. Immunol. 174 (11): 7160-7171.
Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M. and Sacks, D. L. (2002a).
CD4+CD25+ regulatory T cells control Leishmania major persistence and
immunity. Nature 420 (6915): 502-507.
Belkaid, Y., Von Stebut, E., Mendez, S., Lira, R., Caler, E., Bertholet, S., Udey, M.
C. and Sacks, D. (2002b). CD8(+) T cells are required for primary immunity in
C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.
J. Immunol. 168 (8): 3992-4000.
Bhaumik, S., Basu, R., Sen, S., Naskar, K. and Roy, S. (2009). KMP-11 DNA
immunization significantly protects against L. donovani infection but requires
exogenous IL-12 as an adjuvant for comparable protection against L. major.
Vaccine 27 (9): 1306-1316.
130
Blackwell, J. M. (1996). Genetic susceptibility to leishmanial infections: Studies in mice
and man. Parasitology 112: S67-S74.
Blavier, A., Keroack, S., Denerolle, P., Goy-Thollot, I., Chabanne, L., Cadore, J. L.
and Bourdoiseau, G. (2001). Atypical forms of canine leishmaniosis. Vet. J. 162
(2): 108-120.
Boelaert, M., Criel, B., Leeuwenburg, J., Van Damme, W., Le Ray, D. and Van der
Stuyft, P. (2000). Visceral leishmaniasis control: a public health perspective.
Trans. R. Soc. Trop. Med. Hyg. 94 (5): 465-471.
Boelaert, M., El-Safi, S., Hailu, A., Mukhtar, M., Rijal, S., Sundar, S., Wasunna, M.,
Aseffa, A., Mbui, J., Menten, J., Desjeux, P. and Peeling, R. W. (2008).
Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39
strip test and KAtex in East Africa and the Indian subcontinent. Trans. R. Soc.
Trop. Med. Hyg. 102 (1): 32-40.
Borja-Cabrera, G. P., Mendes, A. C., de Souza, E. P., Okada, L. Y. H., Trivellato, F.
A. D., Kawasaki, J. K. A., Costa, A. C., Reis, A. B., Genaro, O., Batista, L. M.
M., Palatnik, M. and Palatnik-de-Sousa, C. B. (2004). Effective immunotherapy
against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22 (17-18):
2234-2243.
Borja-Cabrera, G. P., Pontes, N. N. C., da Silva, V. O., de Souza, E. P., Santos, W.
R., Gomes, E. M., Luz, K. G., Palatnik, M. and de Sousa, C. B. P. (2002). Long
lasting protection against canine kala-azar using the FML-QuilA saponin vaccine
in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 20 (27-
28): 3277-3284.
Borja-Cabrera, G. P., Santos, F. N., Bauer, F. S., Parra, L. E., Menz, I., Morgado, A.
A., Soares, I. S., Batista, L. M. M. and Palatnik-de-Sousa, C. B. (2008).
Immunogenicity assay of the Leishmune® vaccine against canine visceral
leishmaniasis in Brazil. Vaccine 26 (39): 4991-4997.
Bourdoiseau, G., Hugnet, C., Goncalves, R. B., Vezilier, F., Petit-Didier, E.,
Papierok, G. and Lemesre, J. L. (2009). Effective humoral and cellular
immunoprotective responses in Li ESAp-MDP vaccinated protected dogs. Vet.
Immunol. Immunopathol. 128 (1-3): 71-78.
Brandonisio, O., Fumarola, L., Maggi, P., Cavaliere, R., Spinelli, R. and Pastore, G.
(2002). Evaluation of a rapid immunochromatographic test for serodiagnosis of
visceral leishmaniasis. Eur. J. Clin. Microbiol. 21 (6): 461-464.
Brandonisio, O., Spinelli, R. and Pepe, M. (2004). Dendritic cells in Leishmania
infection. Microbes Infect. 6 (15): 1402-1409.
Burns Jr, J. M., Shreffler, W. G., Benson, D. R., Ghalib, H. W., Badaro, R. and
Reed, S. G. (1993). Molecular characterization of a kinesin-related antigen of
Leishmania chagasi that detects specific antibody in African and American
visceral leishmaniasis. Proc. Natl. Acad. Sci. U. S. A. 90 (2): 775-779.
131
Cabral, M., Ogrady, J. and Alexander, J. (1992). Demonstration of Leishmania
specific cell-mediated and humoral immunity in asymptomatic dogs. Parasite
Immunol. 14 (5): 531-539.
Campos-Neto, A., Porrozzi, R., Greeson, K., Coler, R. N., Webb, J. R., Seiky, Y. A.
W., Reed, S. G. and Grimaldi G, Jr. (2001). Protection against cutaneous
leishmaniasis induced by recombinant antigens in murine and nonhuman primate
models of the human disease. Infect. Immun. 69 (6): 4103-4108.
Campos-Neto, A., Webb, J. R., Greeson, K., Coler, R. N., Skeiky, Y. A. W. and Reed,
S. G. (2002). Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial
fusion proteins confers protection against Leishmania major infection in
susceptible BALB/c mice. Infect. Immun. 70 (6): 2828-2836.
Carcelen, J., Iniesta, V., Fernandez-Cotrina, J., Serrano, F., Parejo, J. C., Corraliza,
I., Gallardo-Soler, A., Maranon, F., Soto, M., Alonso, C. and Gomez-Nieto, C.
(2009). The chimerical multi-component Q protein from Leishmania in the
absence of adjuvant protects dogs against an experimental Leishmania infantum
infection. Vaccine 27 (43): 5964-5973.
Cardoso, L., Neto, F., Sousa, J. C., Rodrigues, M. and Cabral, M. (1998). Use of a
leishmanin skin test in the detection of canine Leishmania-specific cellular
immunity. Vet. Parasitol. 79 (3): 213-220.
Cardoso, L., Schallig, H. D. F. H., Cordeiro-da-Silva, A., Cabral, M., Alunda, J. M.
and Rodrigues, M. (2007). Anti-Leishmania humoral and cellular immune
responses in naturally infected symptomatic and asymptomatic dogs. Vet.
Immunol. Immunopathol. 117 (1-2): 35-41.
Carrillo, E., Ahmed, S., Goldsmith-Pestana, K., Nieto, J., Osorio, Y., Travi, B.,
Moreno, J. and McMahon-Pratt, D. (2007). Immunogenicity of the P-8
amastigote antigen in the experimental model of canine visceral leishmaniasis.
Vaccine 25 (8): 1534-1543.
Carson, C., Antoniou, M., Alcami, A., Ruiz-Argüello, M. B., Christodoulou, V.,
Messaritakis, I., Blackwell, J. M. and Courtenay, O. (2009). A prime/boost
DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania
DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of
zoonotic visceral leishmaniasis. Vaccine 27: 1080-1086.
Chamizo, C., Moreno, J. and Alvar, J. (2005). Semi-quantitative analysis of cytokine
expression in asymptomatic canine leishmaniasis. Vet. Immunol. Immunopathol.
103 (1-2): 67-75.
Champsi, J. and McMahon-Pratt, D. (1988). Membrane glycoprotein M-2 protects
against Leishmania amazonensis infection. Infect. Immun. 56 (12): 3272-3279.
Chappuis, F., Mueller, Y., Nguimfack, A., Rwakimari, J. B., Couffignal, S., Boelaert,
M., Cavailler, P., Loutan, L. and Piola, P. (2005). Diagnostic accuracy of two
132
rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral
leishmaniasis in northeastern Uganda. J. Clin. Microbiol. 43 (12): 5973-5977.
Chappuis, F., Rijal, S., Singh, R., Acharya, P., Karki, B. M. S., Das, M. L., Bovier, P.
A., Desjeux, P., Le Ray, D., Koirala, S. and Loutan, L. (2003). Prospective
evaluation and comparison of the direct agglutination test and an rK39-antigen-
based dipstick test for the diagnosis of suspected kala-azar in Nepal. Trop. Med.
Int. Health 8 (3): 277-285.
Coffman, R. L., Lebman, D. A. and Rothman, P. (1993). Mechanism and regulation of
immunoglobulin isotype switching. Adv. Immunol. 54: 229-270.
Cohen, J. (1968). Weighted kappa: Nominal scale agreement provision for scaled
disagreement or partial credit. Psychol. Bull. 70 (4): 213-220.
Coler, R. N. and Reed, S. G. (2005). Second-generation vaccines against leishmaniasis.
Trends Parasitol. 21 (5): 244-249.
Collin, N., Gomes, R., Teixeira, C., Cheng, L., Laughinghouse, A., Ward, J. M.,
Elnaiem, D. E., Fischer, L., Valenzuela, J. G. and Kamhawi, S. (2009). Sand
fly salivary proteins induce strong cellular immunity in a natural reservoir of
visceral leishmaniasis with adverse consequences for Leishmania. PLoS Pathog.
5 (5): 11.
Cordeiro-da-Silva, A., Cardoso, L., Araújo, N., Castro, H., Tomás, A., Rodrigues,
M., Cabral, M., Vergnes, B., Sereno, D. and Ouaissi, A. (2003). Identification
of antibodies to Leishmania silent information regulatory 2 (SIR2) protein
homologue during canine natural infections: pathological implications. Immunol.
Lett. 86 (2): 155-162.
Correa, A. P. F. L., Dossi, A. C. S., de Oliveira Vasconcelos, R., Munari, D. P. and de
Lima, V. M. F. (2007). Evaluation of transformation growth factor B1,
interleukin-10, and interferon-gamma in male symptomatic and asymptomatic
dogs naturally infected by Leishmania (Leishmania) chagasi. Vet. Parasitol. 143
(3-4): 267-274.
Courtenay, O., Quinnell, R. J., Garcez, L. M. and Dye, C. (2002a). Low infectiousness
of a wildlife host of Leishmania infantum: the crab-eating fox is not important for
transmission. Parasitology 125 (Pt 5): 407-414.
Courtenay, O., Quinnell, R. J., Garcez, L. M., Shaw, J. J. and Dye, C. (2002b).
Infectiousness in a cohort of Brazilian dogs: Why culling fails to control visceral
leishmaniasis in areas of high transmission. J. Infect. Dis. 186 (9): 1314-1320.
Cruz, A., Coburn, C. M. and Beverley, S. M. (1991). Double targeted gene replacement
for creating null mutants. Proc. Natl. Acad. Sci. U. S. A. 88 (16): 7170-7174.
Cruz, I., Morales, M. A., Noguer, I., Rodriguez, A. and Alvar, J. (2002). Leishmania
in discarded syringes from intravenous drug users. Lancet 359 (9312): 1124-1125.
133
Cupolillo, E., Grimaldi, G., Momen, H. and Beverley, S. M. (1995). Intergenic Region
Typing (IRT) - a rapid molecular approach to the characterization and evolution of
Leishmania. Mol. Biochem. Parasitol. 73 (1-2): 145-155.
da Costa-Val, A. P., Cavalcanti, R. R., de Figueiredo Gontijo, N., Marques
Michalick, M. S., Alexander, B., Williams, P. and Melo, M. N. (2007). Canine
visceral leishmaniasis: Relationships between clinical status, humoral immune
response, haematology and Lutzomyia (Lutzomyia) longipalpis infectivity. Vet. J.
174 (3): 636-643.
da Costa, R. T., Franca, J. C., Mayrink, W., Nascimento, E., Genaro, O. and
Campos-Neto, A. (2003). Standardization of a rapid immunochromatographic test
with the recombinant antigens K39 and K26 for the diagnosis of canine visceral
leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 97 (6): 678-682.
da Silva, E. S., van der Meide, W. F., Schoone, G. J., Gontijo, C. M. F., Schallig, H.
D. F. H. and Brazil, R. P. (2006). Diagnosis of canine leishmaniasis in the
endemic area of Belo Horizonte, Minas Gerais, Brazil by parasite, antibody and
DNA detection assays. Vet. Res. Commun. 30 (6): 637-643.
Da Silva, V. O., Borja-Cabrera, G. P., Correia Pontes, N. N., De Souza, E. P., Luz, K.
G., Palatnik, M. and Palatnik de Sousa, C. B. (2000). A phase III trial of
efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil
(Sao Goncalo do Amaranto, RN). Vaccine 19 (9-10): 1082-1092.
Dantas-Torres, F. (2006). Leishmune® vaccine: The newest tool for prevention and
control of canine visceral leishmaniosis and its potential as a transmission-
blocking vaccine. Vet. Parasitol. 141 (1-2): 1-8.
Davoudi, N., Tate, C. A., Warburton, C., Murray, A., Mahboudi, F. and McMaster,
W. R. (2005). Development of a recombinant Leishmania major strain sensitive to
ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical
trials. Vaccine 23 (9): 1170-1177.
Day, M. J. (2007). Immunoglobulin G subclass distribution in canine leishmaniosis: A
review and analysis of pitfalls in interpretation. Vet. Parasitol. 147 (1-2): 2-8.
de Luna, R., Vuotto, M. L., Ielpo, M. T. L., Ambrosio, R., Piantedosi, D.,
Moscatiello, V., Ciaramella, P., Scalone, A., Gradoni, L. and Mancino, D.
(1999). Early suppression of lymphoproliferative response in dogs with natural
infection by Leishmania infantum. Vet. Immunol. Immunopathol. 70 (1-2): 95-
103.
de Oliveira Mendes, C., Paraguai De Souza, E., Borja-Cabrera, G. P., Melo Batista,
L. M., Aparecida Dos Santos, M., Parra, L. E., Menz, I., Palatnik, M. and
Palatnik De Sousa, C. B. (2003). IgG1/IgG2 antibody dichotomy in sera of
vaccinated or naturally infected dogs with visceral leishmaniosis. Vaccine 21 (19-
20): 2589-2597.
Deborggraeve, S., Laurent, T., Espinosa, D., Van der Auwera, G., Mbuchi, M.,
Wasunna, M., El-Safi, S., Al-Basheer, A. A., Arevalo, J., Miranda-Verastegui,
134
C., Leclipteux, T., Mertens, P., Dujardin, J. C., Herdewijn, P. and Buscher, P.
(2008). A simplified and standardized polymerase chain reaction format for the
diagnosis of leishmaniasis. J. Infect. Dis. 198 (10): 1565-1572.
Delgado, O., Castes, M., White, A. C. and Kreutzer, R. D. (1993). Leishmania
columbiensis in Venezuela. Am. J. Trop. Med. Hyg. 48 (1): 145-147.
Deplazes, P., Smith, N. C., Arnold, P., Lutz, H. and Eckert, J. (1995). Specific IgG1
and IgG2 antibody responses of dogs to Leishmania infantum and other parasites.
Parasite Immunol. 17 (9): 451-458.
Desjeux, P. (2004). Leishmaniasis: current situation and new perspectives. Comp.
Immunol. Microbiol. Infect. Dis. 27 (5): 305-318.
Diro, E., Techane, Y., Tefera, T., Assefa, Y., Kebede, T., Genetu, A., Kebede, Y.,
Tesfaye, A., Ergicho, B., Gebre-Yohannes, A., Mengistu, G., Engers, H.,
Aseffa, A., Desjeux, P., Boelaert, M. and Hailu, A. (2007). Field evaluation of
FD-DAT, rK39 dipstick and KATEX (urine latex agglutination) for diagnosis of
visceral leishmaniasis in northwest Ethiopia. Trans. R. Soc. Trop. Med. Hyg. 101
(9): 908-914.
do Rosario, E. Y., Genaro, O., Franca-Silva, J. C., Da Costa, R. T., Mayrink, W.,
Reis, A. B. and Carneiro, M. (2005). Evaluation of enzyme-linked
immunosorbent assay using crude Leishmania and recombinant antigens as a
diagnostic marker for canine visceral leishmaniasis. Mem. Inst. Oswaldo Cruz
100 (2): 197-203.
Doe, B., Selby, M., Barnett, S., Baenziger, J. and Walker, C. M. (1996). Induction of
cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is
facilitated by bone marrow-derived cells. Proc. Natl. Acad. Sci. U. S. A. 93 (16):
8578-8583.
Dumonteil, E. (2007). DNA vaccines against protozoan parasites: Advances and
challenges. J. Biomed. Biotechnol.: Article 90520.
Dumonteil, E., McMahon-Pratt, D. and Price, V. L. (2001). Report of the fourth
TDR/IDRI meeting on second-generation vaccines against leishmaniasis.
Universidad Autonoma de Yucatan, Mexico, TDR publications.
Dunan, S., Frommel, D., Monjour, L., Ogunkolade, B. W., Cruz, A. and Quilici, M.
(1989). Vaccination trial against canine visceral leishmaniasis. Phocean
Veterinary Study Group on Visceral Leishmaniasis. Parasite Immunol. (Oxf.) 11
(4): 397-402.
Dye, C. (1996). The logic of visceral leishmaniasis control. Am. J. Trop. Med. Hyg. 55
(2): 125-130.
Dye, C., Vidor, E. and Dereure, J. (1993). Serological diagnosis of leishmaniasis - on
detecting infection as well as disease. Epidemiol. Infect. 110 (3): 647-656.
135
European Commission (1986). European Commission: Directive on the protection of
animals used for experimental and other scientific purposes.
http://ec.europa.eu/environment/chemicals/lab_animals/home_en.htm. Directive
86/609/EEC.
European Medicines Agency (1994). EMeA Evaluation of the safety of veterinary
medicinal products for the target animals: Document 7AE2a
European Medicines Agency (1995). EMeA Specific requirements for the production
and control of live and inactivated viral and bacterial vaccines for cats and dogs:
Document 7BIm13a
Elassad, A. M. S., Younis, S. A., Siddig, M., Grayson, J., Petersen, E. and Ghalib, H.
W. (1994). The significance of blood levels of IgM, IgA, IgG and IgG subclasses
in Sudanese visceral leishmaniasis patients. Clin. Exp. Immunol. 95 (2): 294-299.
Encke, J., Zu Putlitz, J. and Wands, J. R. (1999). DNA vaccines. Intervirology 42 (2-
3): 117-124.
Enserink, M. (2000). Infectious diseases - Has Leishmaniasis become endemic in the
US? Science 290 (5498): 1881-1883.
Espinosa, D., Boggild, A. K., Deborggraeve, S., Laurent, T., Valencia, C., Pacheco,
R., Miranda-Verastegui, C., Llanos-Cuentas, A., Leclipteux, T., Dujardin, J.
C., Buscher, P. and Arevalo, J. (2009). Leishmania OligoC-TesT as a simple,
rapid, and standardized tool for the molecular diagnosis of cutaneous
leishmaniasis in Peru. J. Clin. Microbiol. 47 (8): 2560-2563.
Feltquate, D. M. (1998). DNA vaccines: Vector design, delivery, and antigen
presentation. J. Cell. Biochem. (SUPPL. 30/31): 304-311.
Fernandes, A. P., Costa, M. M., Coelho, E. A., Michalick, M. S., de Freitas, E., Melo,
M. N., Luiz Tafuri, W., Resende Dde, M., Hermont, V., Abrantes Cde, F. and
Gazzinelli, R. T. (2008). Protective immunity against challenge with Leishmania
(Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.
Vaccine 26 (46): 5888-5895.
Ferreira, E. d. C., de Lana, M., Carneiro, M., Reis, A. B., Paes, D. V., Silva, E. S. d.,
Schallig, H. and Gontijo, C. M. F. (2007). Comparison of serological assays for
the diagnosis of canine visceral leishmaniasis in animals presenting different
clinical manifestations. Vet. Parasitol. 146 (3-4): 235-241.
Ferreira, J. H. L., Gentil, L. G., Dias, S. S., Fedeli, C. E. C., Katz, S. and Barbieri, C.
L. (2008). Immunization with the cysteine proteinase Ldccys1 gene from
Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits
protective immune responses in a murine model of visceral leishmaniasis. Vaccine
26 (5): 677-685.
Fisa, R., Gallego, M., Castillejo, S., Aisa, M. J., Serra, T., Riera, C., Carrio, J.,
Gallego, J. and Portus, M. (1999). Epidemiology of canine leishmaniosis in
Catalonia (Spain): The example of the Priorat focus. Vet. Parasitol. 83 (2): 87-97.
136
Foglia Manzillo, V., Oliva, G., Pagano, A., Manna, L., Maroli, M. and Gradoni, L.
(2006). Deltamethrin-impregnated collars for the control of canine leishmaniasis:
Evaluation of the protective effect and influence on the clinical outcome of
Leishmania infection in kennelled stray dogs. Vet. Parasitol. 142 (1-2): 142-145.
Francino, O., Altet, L., Sanchez-Robert, E., Rodriguez, A., Solano-Gallego, L.,
Alberola, J., Ferrer, L., Sanchez, A. and Roura, X. (2006). Advantages of real-
time PCR assay for diagnosis and monitoring of canine leishmaniosis. Vet.
Parasitol. 137 (3-4): 214-221.
Frommel, D., Ogunkolade, B. W., Vouldoukis, I. and Monjour, L. (1988). Vaccine-
induced immunity against cutaneous Leishmaniasis in BALB/c mice. Infect.
Immun. 56 (4): 843-848.
Fujiwara, R. T., Vale, A. M., Franca Da Silva, J. C., Da Costa, R. T., Quetz, J. D. S.,
Martins Filho, O. A., Reis, A. B., Correa Oliveira, R., Machado-Coelho, G. L.,
Bueno, L. L., Bethony, J. M., Frank, G., Nascimento, E., Genaro, O.,
Mayrink, W., Reed, S. and Campos-Neto, A. (2005). Immunogenicity in dogs of
three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates
for canine visceral leishmaniasis. Vet. Res. 36 (5-6): 827-838.
Gaafar, A., Kharazmi, A., Ismail, A., Kemp, M., Hey, A., Christensen, C. B. V.,
Dafalla, M., Elkadaro, A. Y., Elhassan, A. M. and Theander, T. G. (1995).
Dichotomy of the T-cell response to Leishmania antigens in patients suffering
from Cutaneous Leishmaniasis - Absence or scarcity of Th1 activity is associated
with severe infections. Clin. Exp. Immunol. 100 (2): 239-245.
Genaro, O., deToledo, V., DaCosta, C. A., Hermeto, M. V., Afonso, L. C. C. and
Mayrink, W. (1996). Vaccine for prophylaxis and immunotherapy Brazil. Clin.
Dermatol. 14 (5): 503-512.
Germann, T., Bongartz, M., Dlugonska, H., Hess, H., Schmitt, E., Kolbe, L., Kolsch,
E., Podlaski, F. J., Gately, M. K. and Rude, E. (1995). Interleukin-12
profoundly up-regulates the synthesis of antigen-specific complement-fixing
IgG2a, IgG2b and IgG3 antibody subclasses in-vivo. Eur. J. Immunol. 25 (3):
823-829.
Ghosh, A., Zhang, W. W. and Matlashewski, G. (2001). Immunization with A2 protein
results in a mixed Th1/Th2 and a humoral response which protects mice against
Leishmania donovani infections. Vaccine 20 (1-2): 59-66.
Gilbert, S. C., Moorthy, V. S., Andrews, L., Pathan, A. A., McConkey, S. J., Vuola,
J. M., Keating, S. M., Berthoud, T., Webster, D., McShane, H. and Hill, A. V.
S. (2006). Synergistic DNA-MVA prime-boost vaccination regimes for malaria
and tuberculosis. Vaccine 24 (21): 4554-4561.
Giunchetti, R. C., Correa-Oliveira, R., Martins, O. A., Teixeira-Carvalho, A., Roatt,
B. M., De Oliveira Aguiar-Soares, R. D., Juliana, V. D. S., Moreira, N. D. D.,
Malaquias, L. C. C., Castro, L., De Lana, M. and Reis, A. B. (2007).
137
Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs.
Vaccine 25: 7674-7686.
Giunchetti, R. C., Corriba-Oliveira, R., Martins-Filho, O. A., Teixeira-Carvalho, A.,
Roatt, B. M., Aguiar-Soares, R., Coura-Vital, W., de Abreu, R. T., Malaquias,
L. C. C., Gontijo, N. F., Brodskyn, C., de Oliveira, C. I., Costa, D. J., de Lana,
M. and Reis, A. B. (2008). A killed Leishmania vaccine with sand fly saliva
extract and saponin adjuvant displays immunogenicity in dogs. Vaccine 26 (5):
623-638.
Gonzalo, R. M., Rodriguez, J. R., Rodriguez, D., Gonzalez-Aseguinolaza, G.,
Larraga, V. and Esteban, M. (2001). Protective immune response against
cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia
virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in
combination with purified p36. Microbes Infect. 3 (9): 701-711.
Goto, Y., Bogatzki, L. Y., Bertholet, S., Coler, R. N. and Reed, S. G. (2007).
Protective immunization against visceral leishmaniasis using Leishmania sterol
24-c-methyltransferase formulated in adjuvant. Vaccine 25 (42): 7450-7458.
Gradoni, L. and Gramiccia, M. (2004). Leishmaniosis. In OIE manual of standards for
diagnostic tests and vaccines for terrestrial animals. pp. 803-812. Paris, France:
Office International des Epizooties.
Gradoni, L., Manzillo, V. F., Pagano, A., Piantedosi, D., De Luna, R., Gramiccia, A.,
Scalone, A., Di Muccio, T. and Oliva, G. (2005). Failure of a multi-subunit
recombinant leishmanial vaccine (MML) to protect dogs from Leishmania
infantum infection and to prevent disease progression in infected animals. Vaccine
23 (45): 5245-5251.
Gueirard, P., Laplante, A., Rondeau, C., Milon, G. and Desjardins, M. (2008).
Trafficking of Leishmania donovani promastigotes in non-lytic compartments in
neutrophils enables the subsequent transfer of parasites to macrophages. Cell.
Microbiol. 10 (1): 100-111.
Guimaraes Carvalho, S. F., Moreira Lemos, E., Corey, R. and Dietze, R. (2003).
Performance of recombinant K39 antigen in the diagnosis of Brazilian visceral
leishmaniasis. Am. J. Trop. Med. Hyg. 68 (3): 321-324.
Gurunathan, S., Klinman, D. M. and Seder, R. A. (2000). DNA vaccines:
Immunology, application, and optimization. Annu. Rev. Immunol. 18: 927-974.
Gurunathan, S., Prussin, C., Sacks, D. L. and Seder, R. A. (1998). Vaccine
requirements for sustained cellular immunity to an intracellular parasitic infection.
Nat. Med. 4 (12): 1409-1415.
Gurunathan, S., Sacks, D. L., Brown, D. R., Reiner, S. L., Charest, H., Glaichenhaus,
N. and Seder, R. A. (1997). Vaccination with DNA encoding the
immunodominant LACK parasite antigen confers protective immunity to mice
infected with Leishmania major. J. Exp. Med. 186 (7): 1137-1147.
138
Handman, E. (2001). Leishmaniasis: current status of vaccine development. Clin.
Microbiol. Rev. 14 (2): 229-243.
Handman, E., Symons, F. M., Baldwin, T. M., Curtis, J. M. and Scheerlinck, J. P.
(1995). Protective vaccination with promastigote surface antigen 2 from
Leishmania major is mediated by a TH1 type of immune response. Infect. Immun.
63 (11): 4261-4267.
Heinzel, F. P., Sadick, M. D., Holaday, B. J., Coffman, R. L. and Locksley, R. M.
(1989). Reciprocal expression of Interferon-gamma or Interleukin-4 during the
resolution or progression of murine Leishmaniasis - Evidence for expansion of
distinct helper T-Cell subsets. J. Exp. Med. 169 (1): 59-72.
Herrera-Najera, C., Pina-Aguilar, R., Xacur-Garcia, F., Ramirez-Sierra, M. J. and
Dumonteil, E. (2009). Mining the Leishmania genome for novel antigens and
vaccine candidates. Proteomics 9 (5): 1293-1301.
Houghton, R. L. (1998). A cloned antigen (recombinant K39) of Leishmania chagasi
diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1
patients and a prognostic indicator for monitoring patients undergoing drug
therapy. J. Infect. Dis. 177 (5): 1339-1344.
Huang, F. P., Xu, D., Esfandiari, E. O., Sands, W., Wei, X. Q. and Liew, F. Y. (1998).
Cutting edge: Mice defective in Fas are highly susceptible to Leishmania major
infection despite elevated IL-12 synthesis, strong Th1 responses, and enhanced
nitric oxide production. J. Immunol. 160 (9): 4143-4147.
Iniesta, L., Fernandez-Barredo, S., Bulle, B., Gomez, M. T., Piarroux, R., Gallego,
M., Alunda, J. M. and Portus, M. (2002). Diagnostic techniques to detect cryptic
leishmaniasis in dogs. Clin. Diagn. Lab. Immunol. 9 (5): 1137-1141.
Iniesta, L., Gallego, M. and Portus, M. (2005). Immunoglobulin G and E responses in
various stages of canine leishmaniosis. Vet. Immunol. Immunopathol. 103 (1-2):
77-81.
Iniesta, L., Gallego, M. and Portus, M. (2007). Idiotype expression of IgG1 and IgG2 in
dogs naturally infected with Leishmania infantum. Vet. Immunol. Immunopathol.
119 (3-4): 189-197.
Ivens, A. C. and Blackwell, J. M. (1996). Unravelling the Leishmania genome. Curr.
Opin. Genet. Dev. 6 (6): 704-710.
Jalouk, L., Al Ahmed, M., Gradoni, L. and Maroli, M. (2007). Insecticide-treated
bednets to prevent anthroponotic cutaneous leishmaniasis in Aleppo Governorate,
Syria: results from two trials. Trans. R. Soc. Trop. Med. Hyg. 101 (4): 360-367.
Janeway, C., Travers, P., Walport, M. and Shlomchik, M. (2001). Immunobiology 5:
The immune system in health and disease. 732pp. Philadelphia, Garland
publishing / Churchill Livingstone.
139
Jardim, A., Alexander, J., Teh, H. S., Ou, D. and Olafson, R. W. (1990).
Immunoprotective Leishmania major synthetic T cell epitopes. J. Exp. Med. 172
(2): 645-648.
Jelinek, T., Eichenlaub, S. and Loscher, T. (1999). Sensitivity and specificity of a rapid
immunochromatographic test for diagnosis of visceral leishmaniasis. Eur. J. Clin.
Microbiol. Infect. Dis. 18 (9): 669-670.
Jeronimo, S. M. B., Duggal, P., Ettinger, N. A., Nascimento, E. T., Monteiro, G. R.,
Cabral, A. P., Pontes, N. N., Lacerda, H. G., Queiroz, P. V., Gomes, C. E. M.,
Pearson, R. D., Blackwell, J. M., Beaty, T. H. and Wilson, M. H. (2007).
Genetic predisposition to self-curing infection with the protozoan Leishmania
chagasi: a genomewide scan. J. Infect. Dis. 196: 1261–1269.
Joshi, A. B., Das, M. L., Akhter, S., Chowdhury, R., Mondal, D., Kumar, V., Das, P.,
Kroeger, A., Boelaert, M. and Petzold, M. (2009). Chemical and environmental
vector control as a contribution to the elimination of visceral leishmaniasis on the
Indian subcontinent: cluster randomized controlled trials in Bangladesh, India and
Nepal. BMC Med. 7: 9.
Julia, V. and Glaichenhaus, N. (1999). CD4+ T cells which react to the Leishmania
major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host
in resistant B10.D2 mice. Infect. Immun. 67 (7): 3641-3644.
Kamil, A. A., Khalil, E. A. G., Musa, A. M., Modabber, F., Mukhtar, M. M.,
Ibrahim, M. E., Zijlstra, E. E., Sacks, D., Smith, P. G., Zicker, F. and El-
Hassan, A. M. (2003). Alum-precipitated autoclaved Leishmania major plus
bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety,
skin-delayed type hypersensitivity response and dose finding in healthy
volunteers. Trans. R. Soc. Trop. Med. Hyg. 97 (3): 365-368.
Karplus, T. M., Jeronimo, S. M. B., Chang, H., Helms, B. K., Burns, T. L., Murray,
J. C., Mitchell, A. A., Pugh, E. W., Braz, R. F. S., Bezerra, F. L. and Wilson,
M. E. (2002). Association between the tumor necrosis factor locus and the clinical
outcome of Leishmania chagasi infection. Infect. Immun. 70 (12): 6919-6925.
Kaye, P. M., Curry, A. J. and Blackwell, J. M. (1991). Differential production of Th1-
and Th2-derived cytokines does not determine the genetically controlled or
vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146
(8): 2763-2770.
Kemp, M. (1997). Regulator and effector functions of T-cell subsets in human
Leishmania infections. APMIS 105: 5-33.
Kemp, M., Handman, E., Kemp, K., Ismail, A., Mustafa, M. D., Kordofani, A. Y.,
Bendtzen, K., Kharazmi, A. and Theander, T. G. (1998). The Leishmania
promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in
humans with naturally acquired immunity to L. major. FEMS Immunol. Med.
Microbiol. 20 (3): 209-218.
140
Kemp, M., Kurtzhals, J. A. L., Bendtzen, K., Poulsen, L. K., Hansen, M. B., Koech,
D. K., Kharazmi, A. and Theander, T. G. (1993). Leishmania donovani reactive
Th1-like and Th2-like T-cell clones from individuals who have recovered from
Visceral Leishmaniasis. Infect. Immun. 61 (3): 1069-1073.
Khalil, E. A. G., El Hassan, A. M., Zijlstra, E. E., Mukhtar, M. M., Ghalib, H. W.,
Musa, B., Ibrahim, M. E., Kamil, A. A., Elsheikh, M., Babiker, A. and
Modabber, F. (2000). Autoclaved Leishmania major vaccine for prevention of
visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in
Sudan. Lancet 356 (9241): 1565-1569.
Khamesipour, A., Rafati, S., Davoudi, N., Maboudi, F. and Modabber, F. (2006).
Leishmaniasis vaccine candidates for development: A global overview. Indian J.
Med. Res. 123 (3): 423-438.
Kharazmi, A., Kemp, K., Ismail, A., Gasim, S., Gaafar, A., Kurtzhals, J. A. L., El
Hassan, A. M., Theander, T. G. and Kemp, M. (1999). T-cell response in
human leishmaniasis. Immunol. Lett. 65 (1-2): 105-108.
Kishore, K., Kumar, V., Kesari, S., Dinesh, D. S., Kumar, A. J., Das, P. and
Bhattacharya, S. K. (2006). Vector control in leishmaniasis. Indian J. Med. Res.
123 (3): 467-472.
Kornbluth, R. S. and Edgington, T. S. (1986). Tumor necrosis factor production by
human monocytes is a regulated event: induction of TNF-alpha-mediated cellular
cytotoxicity by endotoxin. J. Immunol. 137 (8): 2585-2591.
Kumar, R., Pai, K., Pathak, K. and Sundar, S. (2001). Enzyme-linked immunosorbent
assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral
leishmaniasis. Clin. Diagn. Lab. Immunol. 8 (6): 1220-1224.
Lachaud, L., Chabbert, E., Dubessay, P., Dereure, J., Lamothe, J., Dedet, J. P. and
Bastien, P. (2002a). Value of two PCR methods for the diagnosis of canine
visceral leishmaniasis and the detection of asymptomatic carriers. Parasitology
125 (3): 197-207.
Lachaud, L., Marchergui-Hammami, S., Chabbert, E., Dereure, J., Dedet, J. P. and
Bastien, P. (2002b). Comparison of six PCR methods using peripheral blood for
detection of canine visceral leishmaniasis. J. Clin. Microbiol. 40 (1): 210-215.
Lage, R. S., Oliveira, G. C., Busek, S. U., Guerra, L. L., Giunchetti, R. C., Correa-
Oliveira, R. and Reis, A. B. (2007). Analysis of the cytokine profile in spleen
cells from dogs naturally infected by Leishmania chagasi. Vet. Immunol.
Immunopathol. 115 (1-2): 135-145.
Landis, J. R. and Koch, G. G. (1977). The measurement of observer agreement for
categorical data. Biometrics 33 (1): 159-174.
Lanotte, G., Rioux, J. A., Croset, H. and Vollhardt, Y. (1978). Ecology of
leishmaniasis in the south of France. IX. Sampling methods in the study of the
canine enzootic. Ann. Parasitol. Hum. Comp. 53 (1): 33-45.
141
Lasri, S., Sahibi, H., Sadak, A., Jaffe, C. L. and Rhalem, A. (1999). Immune responses
in vaccinated dogs with autoclaved Leishmania major promastigotes. Vet. Res. 30
(5): 441-449.
Lemesre, J. L., Holzmuller, P., Cavaleyra, M., Goncalves, R. B., Hottin, G. and
Papierok, G. (2005). Protection against experimental visceral leishmaniasis
infection in dogs immunized with purified excreted secreted antigens of
Leishmania infantum promastigotes. Vaccine 23 (22): 2825-2840.
Lemesre, J. L., Holzmuller, P., Goncalves, R. B., Bourdoiseau, G., Hugnet, C.,
Cavaleyra, M. and Papierok, G. (2007). Long-lasting protection against canine
visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of
France: Double-blind randomised efficacy field trial. Vaccine 25 (21): 4223-4234.
Lemos, E. M., Laurenti, M. D., Moreira, M. A. B., Reis, A. B., Giunchetti, R. C. and
Dietze, R. (2008). Canine visceral leishmaniasis: performance of a rapid
diagnostic test (Kalazar Detect TM) in dogs with and without signs of the disease.
Acta Trop. 107 (2): 205-207.
Levick, M. P., Blackwell, J. M., Connor, V., Coulson, R. M. R., Miles, A., Smith, H.
E., Wan, K. L. and Ajioka, J. W. (1996). An expressed sequence tag analysis of
a full-length, spliced-leader cDNA library from Leishmania major promastigotes.
Mol. Biochem. Parasitol. 76 (1-2): 345-348.
Levick, M. P., Tetaud, E., Fairlamb, A. H. and Blackwell, J. M. (1998). Identification
and characterisation of a functional peroxidoxin from Leishmania major. Mol.
Biochem. Parasitol. 96 (1-2): 125-137.
Liew, F. Y., Hale, C. and Howard, J. G. (1985). Prophylactic immunization against
experimental Leishmaniasis: IV. Subcutaneous immunization prevents the
induction of protective immunity against fatal Leishmania major infection. J.
Immunol. 135 (3): 2095-2101.
Liew, F. Y., Li, Y. and Millott, S. (1990a). Tumor necrosis factor-alpha synergizes with
IFN-gamma in mediating killing of Leishmania major through the induction of
nitric oxide. J. Immunol. 145 (12): 4306-4310.
Liew, F. Y., Li, Y. and Millott, S. (1990b). Tumour necrosis factor (TNF-α) in
leishmaniasis. II. TNF-α-induced macrophage leishmanicidal activity is mediated
by nitric oxide from L-arginine. Immunology 71 (4): 556-559.
Liu, Y. (2007). Utilization of the venturi effect to introduce micro-particles for epidermal
vaccination. Med. Eng. Phys. 29 (3): 390-397.
Livak, K. J. and Schmittgen, T. D. (2001). Analysis of relative gene expression data
using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25 (4): 402-
408.
Llanos-Cuentas, E. A., Roncal, N., Villaseca, P., Paz, L., Ogusuku, E., Perez, J. E.,
Caceres, A. and Davies, C. R. (1999). Natural infections of Leishmania
142
peruviana in animals in the Peruvian Andes. Trans. R. Soc. Trop. Med. Hyg. 93
(1): 15-20.
MacGregor, R. R., Boyer, J. D., Ugen, K. E., Lacy, K. E., Gluckman, S. J.,
Bagarazzi, M. L., Chattergoon, M. A., Baine, Y., Higgins, T. J., Ciccarelli, R.
B., Coney, L. R., Ginsberg, R. S. and Weiner, D. B. (1998). First human trial of
a DNA-based vaccine for treatment of human immunodeficiency virus type 1
infection: Safety and host response. J. Infect. Dis. 178 (1): 92-100.
Madeira, M. F., Schubach, A., Schubach, T. M. P., Pacheco, R. S., Oliveira, F. S.,
Pereira, S. A., Figueiredo, F. B., Baptista, C. and Marzochi, M. C. A. (2006).
Mixed infection with Leishmania (Viannia) braziliensis and Leishmania
(Leishmania) chagasi in a naturally infected dog from Rio de Janeiro, Brazil.
Trans. R. Soc. Trop. Med. Hyg. 100 (5): 442-445.
Mancianti, F., Nardoni, S. and Melosi, M. (2002). Evaluation of the effectiveness of
commercial immunomigration tests in the diagnosis of canine leishmaniasis.
Parassitologia 44 (suppl) (1): 99.
Mancianti, F., Pedonese, F. and Poli, A. (1996). Evaluation of dot enzyme-linked
immunosorbent assay (dot-ELISA) for the serodiagnosis of canine leishmaniosis
as compared with indirect immunofluorescence assay. Vet. Parasitol. 65 (1-2): 1-
9.
Manna, L., Reale, S., Viola, E., Vitale, F., Manzillo, V. F., Michele, P. L., Caracappa,
S. and Gravino, A. E. (2006). Leishmania DNA load and cytokine expression
levels in asymptomatic naturally infected dogs. Vet. Parasitol. 142 (3-4): 271-
280.
Manna, L., Reale, S., Vitale, F. and Gravino, A. E. (2009). Evidence for a relationship
between Leishmania load and clinical manifestations. Res. Vet. Sci. 87 (1): 76-78.
Manson-Bahr, P. (1987). Diagnosis [of leishmaniasis]. In The leishmaniases in biology
and medicine: Clinical aspects and control. Vol 2, pp. 703. W. Peters and R.
Killick-Kendick: London: Academic Press.
Maroli, M. and Khoury, C. (2006). Current approaches to the prevention and control of
leishmaniasis vectors. Vet. Res. Commun. 30 (Suppl. 1): 49-52.
Maroli, M., Rossi, L., Baldelli, R., Capelli, G., Ferroglio, E., Genchi, C., Gramiccia,
M., Mortarino, M., Pietrobelli, M. and Gradoni, L. (2008). The northward
spread of leishmaniasis in Italy: Evidence from retrospective and ongoing studies
on the canine reservoir and phlebotomine vectors. Trop. Med. Int. Health 13 (2):
256-264.
Martinez, A., Moreno, T., Martinez-Moreno, F. J., Acosta, I. and Hernandez, S.
(1995). Humoral and cell-mediated-immunity in natural and experimental canine
leishmaniasis. Vet. Immunol. Immunopathol. 48 (3-4): 209-220.
143
Mary, C., Faraut, F., Lascombe, L. and Dumon, H. (2004). Quantification of
Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J. Clin.
Microbiol. 42 (11): 5249-5255.
Masina, S., Gicheru, M. M., Demotz, S. O. and Fasel, N. J. (2003). Protection against
cutaneous leishmaniasis in outbred vervet monkeys, using a recombinant histone
H1 antigen. J. Infect. Dis. 188 (8): 1250-1257.
Mauricio, I. L., Stothard, J. R. and Miles, M. A. (2000). The strange case of
Leishmania chagasi. Parasitol. Today 16 (5): 188-189.
Mayr, A. and Danner, K. (1978). Vaccination against pox diseases under
immunosuppressive conditions. Dev. Biol. Stand. 41: 225-234.
Mayrink, W., Da Costa, C. A. and Magalhaes, P. A. (1979). A field trial of a vaccine
against American dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 73 (4):
385-387.
Mayrink, W., Genaro, O., Silva, J. C. F., daCosta, R. T., Tafuri, W. L., Toledo, V.,
daSilva, A. R., Reis, A. B., Williams, P. and daCosta, C. A. (1996). Phase I and
II open clinical trials of a vaccine against Leishmania chagasi infections in dogs.
Mem. Inst. Oswaldo Cruz 91 (6): 695-697.
Mazloumi Gavgani, A. S., Hodjati, M. H., Mohite, H. and Davies, C. R. (2002). Effect
of insecticide-impregnated dog collars on incidence of zoonotic visceral
leishmaniasis in Iranian children: A matched-cluster randomised trial. Lancet 360
(9330): 374-379.
Mazza, G., Duffus, W. P. H., Elson, C. J., Stokes, C. R., Wilson, A. D. and Whiting,
A. H. (1993). The separation and identification by monoclonal-antibodies of dog
IgG fractions. J. Immunol. Methods 161 (2): 193-203.
Mazza, G., Whiting, A. H., Day, M. J. and Duffus, W. P. (1994a). Development of an
enzyme-linked immunosorbent assay for the detection of IgG subclasses in the
serum of normal and diseased dogs. Res. Vet. Sci. 57 (2): 133-139.
Mazza, G., Whiting, A. H., Day, M. J. and Duffus, W. P. (1994b). Preparation of
monoclonal antibodies specific for the subclasses of canine IgG. Res. Vet. Sci. 57
(2): 140-145.
McShane, H., Brookes, R., Gilbert, S. C. and Hill, A. V. S. (2001). Enhanced
immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-
modified vaccinia virus Ankara prime-boost vaccination regimen for murine
tuberculosis. Infect. Immun. 69 (2): 681-686.
Melby, P. C. (1991). Experimental Leishmaniasis in humans - review. Rev. Infect. Dis.
13 (5): 1009-1017.
Melby, P. C., Yang, J., Zhao, W. G., Perez, L. E. and Cheng, J. (2001). Leishmania
donovani p36(LACK) DNA vaccine is highly immunogenic but not protective
against experimental visceral leishmaniasis. Infect. Immun. 69 (8): 4719-4725.
144
Mendez, S., Gurunathan, S., Kamhawi, S., Belkaid, Y., Moga, M. A., Skeiky, Y. A.
W., Campos-Neto, A., Reed, S., Seder, R. A. and Sacks, D. (2001). The potency
and durability of DNA- and protein-based vaccines against Leishmania major
evaluated using low-dose, intradermal challenge. J. Immunol. 166 (8): 5122-5128.
Mendonca-Previato, L., Gorin, P. A. J., Braga, A. F., Scharfstein, J. and Previato, J.
O. (1983). Chemical structure and antigenic aspects of complexes obtained from
epimastigotes of Trypanosoma cruzi. Biochemistry 22 (21): 4980-4987.
Mettler, M., Grimm, F., Capelli, G., Camp, H. and Deplazes, P. (2005). Evaluation of
enzyme-linked immunosorbent assays, an immunofluorescent- antibody test, and
two rapid tests (immunochromatographic-dipstick and gel tests) for serological
diagnosis of symptomatic and asymptomatic Leishmania infections in dogs. J.
Clin. Microbiol. 43 (11): 5515-5519.
Meyer, R. G., Britten, C. M., Siepmann, U., Petzold, B., Sagban, T. A., Lehr, H. A.,
Weigle, B., Schmitz, M., Mateo, L., Schmidt, B., Bernhard, H., Jakob, T.,
Hein, R., Schuler, G., Schuler-Thurner, B., Wagner, S. N., Drexler, I., Sutter,
G., Arndtz, N., Chaplin, P., Metz, J., Enk, A., Huber, C. and Wolfel, T.
(2005). A phase I vaccination study with tyrosinase in patients with stage II
melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).
Cancer Immunol. Immunother. 54 (5): 453-467.
Michalsky, E. M., Rocha, M. F., da Rocha Lima, A. C. V. M., Franca-Silva, J. C.,
Pires, M. Q., Oliveira, F. S., Pacheco, R. S., dos Santos, S. L., Barata, R. A.,
Romanha, A. J., Fortes-Dias, C. L. and Dias, E. S. (2007). Infectivity of
seropositive dogs, showing different clinical forms of leishmaniasis, to Lutzomyia
longipalpis phlebotomine sand flies. Vet. Parasitol. 147 (1-2): 67-76.
Miret, J., Nascimento, E., Sampaio, W., França, J. C., Fujiwara, R. T., Vale, A.,
Dias, E. S., Vieira, E., Costa, R. T. d., Mayrink, W., Neto, A. C. and Reed, S.
(2008). Evaluation of an immunochemotherapeutic protocol constituted of N-
methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-
110f® + MPL-SE® vaccine to treat canine visceral leishmaniasis. Vaccine 26
(12): 1585-1594.
Miró, G., Cardoso, L., Pennisi, M. G., Oliva, G. and Baneth, G. (2008). Canine
leishmaniosis - new concepts and insights on an expanding zoonosis: part two.
Trends Parasitol. 24 (8): 371-377.
Misra, A., Dube, A., Srivastava, B., Sharma, P., Srivastava, J. K., Katiyar, J. C. and
Naik, S. (2001). Successful vaccination against Leishmania donovani infection in
Indian langur using alum-precipitated autoclaved Leishmania major with BCG.
Vaccine 19 (25-26): 3485-3492.
Modabber, F. (2000). First generation leishmaniasis vaccines in clinical development:
Moving, but what next? Curr. Opin. Invest. Dr. 2 (1): 35-39.
145
Mohebali, M., Fallah, E., Jamshidi, S. and Hajjaran, H. (1998). Vaccine trial against
canine visceral leishmaniasis in the Islamic Republic of Iran. East. Mediterr.
Health J. 4 (2): 234-238.
Mohebali, M., Khamesipour, A., Mobedi, I., Zarei, Z. and Hashemi-Fesharki, R.
(2004a). Double-blind randomized efficacy field trial of alum precipitated
autoclaved Leishmania major vaccine mixed with BCG against canine visceral
leishmaniasis in Meshkin-Shahr district, IR Iran. Vaccine 22 (29-30): 4097-4100.
Mohebali, M., Taran, M. and Zarei, Z. (2004b). Rapid detection of Leishmania
infantum infection in dogs: comparative study using an immunochromatographic
dipstick rk39 test and direct agglutination. Vet. Parasitol. 121 (3-4): 239-245.
Molano, I., Garcia Alonso, M., Miron, C., Redondo, E., Requena, J. M., Soto, M.,
Gomez Nieto, C. and Alonso, C. (2003). A Leishmania infantum multi-
component antigenic protein mixed with live BCG confers protection to dogs
experimentally infected with L. infantum. Vet. Immunol. Immunopathol. 92 (1-2):
1-13.
Molina, R., Amela, C., Nieto, J., San-Andres, M., Gonzalez, F., Castillo, J. A.,
Lucientes, J. and Alvar, J. (1994). Infectivity of dogs naturally infected with
Leishmania infantum to colonized Phlebotomus perniciosus. Trans. R. Soc. Trop.
Med. Hyg. 88 (4): 491-493.
Momeni, A. Z., Jalayer, T., Emamjomeh, M., Khamesipour, A., Zicker, F.,
Ghassemi, R. L., Dowlati, Y., Sharifi, I., Aminjavaheri, M., Shafiei, A.,
Alimohammadian, M. H., Hashemi-Fesharki, R., Nasseri, K., Godal, T.,
Smith, P. G. and Modabber, F. (1999). A randomised, double-blind, controlled
trial of a killed L. major vaccine plus BCG against zoonotic cutaneous
leishmaniasis in Iran. Vaccine 17 (5): 466-472.
Monjour, L., Vouldoukis, I., Ogunkolade, B. W., Hetzel, C., Ichen, M. and Frommel,
D. (1988). Vaccination and treatment trials against murine leishmaniasis with
semi-purified Leishmania antigens. Trans. R. Soc. Trop. Med. Hyg. 82 (3): 412-
415.
Moorthy, V. S., Pinder, M., Reece, W. H. H., Watkins, K., Atabani, S., Hannan, C.,
Bojang, K., McAdam, K. P. W. J., Schneider, J., Gilbert, S. and Hill, A. V. S.
(2003). Safety and immunogenicity of DNA/modified vaccinia virus Ankara
malaria vaccination in African adults. J. Infect. Dis. 188 (8): 1239-1244.
Moreno, J., Nieto, J., Masina, S., Canavate, C., Cruz, I., Chicharro, C., Carrillo, E.,
Napp, S., Reymond, C., Kaye, P. M., Smith, D. F., Fasel, N. and Alvar, J.
(2007). Immunization with H1, HASPB1 and MML Leishmania proteins in a
vaccine trial against experimental canine leishmaniasis. Vaccine 25 (29): 5290-
5300.
Mosmann, T. R. and Sad, S. (1996). The expanding universe of T-cell subsets: Th1, Th2
and more. Immunol. Today 17 (3): 138-146.
146
Mougneau, E., Altare, F., Wakil, A. E., Zheng, S. C., Coppola, T., Wang, Z. E.,
Waldmann, R., Locksley, R. M. and Glaichenhaus, N. (1995). Expression
cloning of a protective Leishmania antigen. Science 268 (5210): 563-566.
Muller, I., Pedrazzini, T., Kropf, P., Louis, J. and Milon, G. (1991). Establishment of
resistance to Leishmania major infection in susceptible BALB/c mice requires
parasite-specific CD8+ T cells. Int. Immunol. 3 (6): 587-597.
Nadim, A., Javadian, E., Tahvildar Bidruni, G. and Ghorbani, M. (1983).
Effectiveness of leishmanization in the control of cutaneous leishmaniasis. B. Soc.
Pathol. Exot. 76 (4): 377-383.
Naucke, T. J., Menn, B., Massberg, D. and Lorentz, S. (2008). Sandflies and
leishmaniasis in Germany. Parasitol. Res. 103 Suppl 1: 65-68.
Nieto, C. G., Garcia-Alonso, M., Requena, J. M., Miron, C., Soto, M., Alonso, C. and
Navarrete, I. (1999). Analysis of the humoral immune response against total and
recombinant antigens of Leishmania infantum: correlation with disease
progression in canine experimental leishmaniasis. Vet. Immunol. Immunopathol.
67 (2): 117-130.
Nogueira, F. S., Moreira, M. A. B., Borja-Cabrera, G. P., Santos, F. N., Menz, I.,
Parra, L. E., Xu, Z., Chu, H. J., Palatnik-de-Sousa, C. B. and Luvizotto, M. C.
R. (2005). Leishmune® vaccine blocks the transmission of canine visceral
leishmaniasis - Absence of Leishmania parasites in blood, skin and lymph nodes
of vaccinated exposed dogs. Vaccine 23 (40): 4805-4810.
Noli, C. and Auxilia, S. T. (2005). Treatment of canine Old World visceral
leishmaniasis: a systematic review. Vet. Dermatol. 16 (4): 213-232.
Noyes, H. A., Reyburn, H., Bailey, J. W. and Smith, D. (1998). A nested-PCR-based
schizodeme method for identifying Leishmania kinetoplast minicircle classes
directly from clinical samples and its application to the study of the epidemiology
of Leishmania tropica in Pakistan. J. Clin. Microbiol. 36 (10): 2877-2881.
Ogunkolade, B. W., Vouldoukis, I., Frommel, D., Davoust, B., Rhodes-Feuillette, A.
and Monjour, L. (1988). Immunization of dogs with a Leishmania infantum-
derived vaccine. Vet. Parasitol. 28 (1-2): 33-41.
Oliva, G., Scalone, A., Manzillo, V. F., Gramiccia, M., Pagano, A., Di Muccio, T. and
Gradoni, L. (2006). Incidence and time course of Leishmania infantum infections
examined by parasitological, serologic, and nested-PCR techniques in a cohort of
naive dogs exposed to three consecutive transmission seasons. J. Clin. Microbiol.
44 (4): 1318-1322.
Oliveira-Lima, J. W., Sousa, R. N., Teixeira, M. J., Pompeu, M., Killick-Kendrick,
R. and David, J. R. (2002). Preliminary results of a field trial to evaluate the
value of deltamethrin-impregnated collars for the control of canine Leishmaniasis
in northeast Brazil. Proceedings of the Second International Canine Leishmanasis
Forum Sevilla, Spain, Intervet.
147
Oliveira, T. M., Mineo, T. W., Bason, M., Day, M. J. and Machado, R. Z. (2009). IgG
subclass profile of serum antibodies to Leishmania chagasi in naturally infected
and vaccinated dogs. Vet. Parasitol. 162 (1-2): 16-22.
Otranto, D., Capelli, G. and Genchi, C. (2009a). Changing distribution patterns of
canine vector borne diseases in Italy: leishmaniosis vs. dirofilariosis. Parasite.
Vector. 2: Suppl 1: S2.
Otranto, D., Paradies, P., de Caprariis, D., Stanneck, D., Testini, G., Grimm, F.,
Deplazes, P. and Capelli, G. (2009b). Toward diagnosing Leishmania infantum
infection in asymptomatic dogs in an area where leishmaniasis is endemic. Clin.
Vaccine Immunol. 16 (3): 337-343.
Otranto, D., Paradies, P., Sasanelli, M., Leone, N., De Caprariis, D., Chirico, J.,
Spinelli, R., Capelli, G. and Brandonisio, O. (2005). Recombinant K39 dipstick
immunochromatographic test: A new tool for the serodiagnosis of canine
leishmaniasis. J. Vet. Diagn. Invest. 17 (1): 32-37.
Otranto, D., Paradies, P., Sasanelli, M., Spinelli, R. and Brandonisio, O. (2004).
Rapid immunochromatographic test for serodiagnosis of canine leishmaniasis. J.
Clin. Microbiol. 42 (6): 2769-2770.
Ozensoy, S., Ozbel, Y., Turgay, N., Alkan, M. Z., Gul, K., Gilman-Sachs, A., Chang,
K. P., Reed, S. G. and Ozcel, M. A. (1998). Serodiagnosis and epidemiology of
visceral leishmaniasis in Turkey. Am. J. Trop. Med. Hyg. 59 (3): 363-369.
Palatnik-de-Sousa, C. B., Paraguai-de-Souza, E., Gomes, E. M. and Borojevic, R.
(1994). Experimental murine Leishmania donovani infection: immunoprotection
by the fucose-mannose ligand (FML). Braz. J. Med. Biol. Res. 27 (2): 547-551.
Palmowski, M. J., Choi, E. M. L., Hermans, I. F., Gilbert, S. C., Chen, J. L., Gileadi,
U., Salio, M., Van Pel, A., Man, S., Bonin, E., Liljestrom, P., Dunbar, P. R.
and Cerundolo, V. (2002). Competition between CTL narrows the immune
response induced by prime-boost vaccination protocols. J. Immunol. 168 (9):
4391-4398.
Papierok, G. and Lemesre, J. L. (2009). Protection against experimental visceral
leishmaniasis infection in dogs immunized with a peptidic vaccine: first results of
the 2nd generation of Cani Leish. WorldLeish 4, Lucknow, India.
Paraguai de Souza, E., Bernardo, R. R., Palatnik, M. and Palatnik de Sousa, C. B.
(2001). Vaccination of Balb/c mice against experimental visceral leishmaniasis
with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine 19 (23-24):
3104-3115.
Parra, L. E., Borja-Cabrera, G. P., Santos, F. N., Souza, L. O. P., Palatnik-de-Sousa,
C. B. and Menz, I. (2007). Safety trial using the Leishmune® vaccine against
canine visceral leishmaniasis in Brazil. Vaccine 25 (12): 2180-2186.
Parvizi, P., Mauricio, I., Aransay, A. M., Miles, M. A. and Ready, P. D. (2005). First
detection of Leishmania major in peridomestic Phlebotomus papatasi from
148
Isfahan province, Iran: Comparison of nested PCR of nuclear ITS ribosomal DNA
and semi-nested PCR of minicircle kinetoplast DNA. Acta Trop. 93 (1): 75-83.
Parvizi, P., Mazloumi-Gavgani, A. S., Davies, C. R., Courtenay, O. and Ready, P. D.
(2008). Two Leishmania species circulating in the Kaleybar focus of infantile
visceral leishmaniasis, northwest Iran: implications for deltamethrin dog collar
intervention. Trans. R. Soc. Trop. Med. Hyg. 102 (9): 891-897.
Parvizi, P. and Ready, P. D. (2008). Nested PCRs and sequencing of nuclear ITS-rDNA
fragments detect three Leishmania species of gerbils in sandflies from Iranian foci
of zoonotic cutaneous leishmaniasis. Trop. Med. Int. Health 13 (9): 1159-1171.
Peacock, C. S., Seeger, K., Harris, D., Murphy, L., Ruiz, J. C., Quail, M. A., Peters,
N., Adlem, E., Tivey, A., Aslett, M., Kerhornou, A., Ivens, A., Fraser, A.,
Rajandream, M. A., Carver, T., Norbertczak, H., Chillingworth, T., Hance,
Z., Jagels, K., Moule, S., Ormond, D., Rutter, S., Squares, R., Whitehead, S.,
Rabbinowitsch, E., Arrowsmith, C., White, B., Thurston, S., Bringaud, F.,
Baldauf, S. L., Faulconbridge, A., Jeffares, D., Depledge, D. P., Oyola, S. O.,
Hilley, J. D., Brito, L. O., Tosi, L. R. O., Barrell, B., Cruz, A. K., Mottram, J.
C., Smith, D. F. and Berriman, M. (2007). Comparative genomic analysis of
three Leishmania species that cause diverse human disease. Nat. Genet. 39 (7):
839-847.
Pedras, M. J., de Gouvea Viana, L., de Oliveira, E. J. and Rabello, A. (2008).
Comparative evaluation of direct agglutination test, rK39 and soluble antigen
ELISA and IFAT for the diagnosis of visceral leishmaniasis. Trans. R. Soc. Trop.
Med. Hyg. 102 (2): 172-178.
Perez-Jimenez, E., Kochan, G., Gherardi, M. M. and Esteban, M. (2006). MVA-
LACK as a safe and efficient vector for vaccination against leishmaniasis.
Microbes Infect. 8 (3): 810-822.
Perez-Victoria, J. M., Perez-Victoria, F. J., Parodi-Talice, A., Jimenez, I. A., Ravelo,
A. G., Castanys, S. and Gamarro, F. (2001). Alkyl-lysophospholipid resistance
in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-
glycoprotein-like transporter modulator. Antimicrob. Agents Chemother. 45 (9):
2468-2474.
Pertmer, T. M., Roberts, T. R. and Haynes, J. R. (1996). Influenza virus
nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited
by DNA vaccination are dependent on the route of vector DNA delivery. J. Virol.
70 (9): 6119-6125.
Peterman, J. H. and Butler, J. E. (1989). Application of theoretical considerations to the
analysis of ELISA data. BioTechniques 7 (6): 608-615.
Peters, N. C., Kimblin, N., Secundino, N., Kamhawi, S., Lawyer, P. and Sacks, D. L.
(2009). Vector transmission of Leishmania abrogates vaccine-induced protective
immunity. PLoS Pathog. 5 (6): 11.
149
Pilatti, M. M., Ferreira, S. D., de Melo, M. N. and de Andrade, A. S. R. (2009).
Comparison of PCR methods for diagnosis of canine visceral leishmaniasis in
conjunctival swab samples. Res. Vet. Sci. 87 (2): 255-257.
Pinelli, E., Gonzalo, R. M., Boog, C. J. P., Rutten, V., Gebhard, D., Delreal, G. and
Ruitenberg, E. J. (1995). Leishmania infantum-specific T-Cell lines derived from
asymptomatic dogs that lyse infected macrophages in a Major Histocompatibility
Complex-restricted manner. Eur. J. Immunol. 25 (6): 1594-1600.
Pinelli, E., Killick-kendrick, R., Wagenaar, J., Bernadina, W., Delreal, G. and
Ruitenberg, J. (1994). Cellular and humoral immune-responses in dogs
experimentally and naturally infected with Leishmania infantum. Infect. Immun.
62 (1): 229-235.
Pinelli, E., Van Der Kaaij, S. Y., Slappendel, R., Fragio, C., Ruitenberg, E. J.,
Bernadina, W. and Rutten, V. P. M. G. (1999). Detection of canine cytokine
gene expression by reverse transcription- polymerase chain reaction. Vet.
Immunol. Immunopathol. 69 (2-4): 121-126.
Pinheiro, P. H. D., Dias, S. D., Eulalio, K. D., Mendonca, I. L., Katz, S. and Barbieri,
C. C. (2005). Recombinant cysteine proteinase from Leishmania (Leishmania)
chagasi implicated in human and dog T-cell responses. Infect. Immun. 73 (6):
3787-3789.
Poot, J., Janssen, L. H., van Kasteren-Westerneng, T. J., van der Heijden-Liefkens,
K. H., Schijns, V. E. and Heckeroth, A. (2009). Vaccination of dogs with six
different candidate leishmaniasis vaccines composed of a chimerical recombinant
protein containing ribosomal and histone protein epitopes in combination with
different adjuvants. Vaccine 27 (33): 4439-4446.
Poot, J., Rogers, M. E., Bates, P. A. and Vermeulen, A. (2005). Detailed analysis of an
experimental challenge model for Leishmania infantum (JPC strain) in dogs. Vet.
Parasitol. 130 (1-2): 41-53.
Poot, J., Spreeuwenberg, K., Sanderson, S. J., Schijns, V., Mottram, J. C., Coombs,
G. H. and Vermeulen, A. N. (2006). Vaccination with a preparation based on
recombinant cysteine peptidases and canine IL-12 does not protect dogs from
infection with Leishmania infantum. Vaccine 24 (14): 2460-2468.
Porrozzi, R., Santos da Costa, M. V., Teva, A., Falqueto, A., Ferreira, A. L., dos
Santos, C. D., Fernandes, A. P., Gazzinelli, R. T., Campos-Neto, A. and
Grimaldi Jr, G. (2007). Comparative evaluation of enzyme-linked
immunosorbent assays based on crude and recombinant leishmanial antigens for
serodiagnosis of symptomatic and asymptomatic Leishmania infantum visceral
infections in dogs. Clin. Vaccine Immunol. 14 (5): 544-548.
Precopio, M. L., Betts, M. R., Parrino, J., Price, D. A., Gostick, E., Ambrozak, D. R.,
Asher, T. E., Douek, D. C., Harari, A., Pantaleo, G., Bailer, R., Graham, B. S.,
Roederer, M. and Koup, R. A. (2007). Immunization with vaccinia virus induces
polyfunctional and phenotypically distinctive CD8(+) T cell responses. J. Exp.
Med. 204 (6): 1405-1416.
150
Qu, J. Q., Zhong, L., Masoom-Yasinzai, M., Abdur-Rab, M., Aksu, H. S. Z., Reed, S.
G., Chang, K. P. and Gilman-Sachs, A. (1994). Serodiagnosis of Asian
leishmaniasis with a recombinant antigen from the repetitive domain of a
Leishmania kinesin. Trans. R. Soc. Trop. Med. Hyg. 88 (5): 543-545.
Quaresma, P. F., Murta, S. M., Ferreira Ede, C., da Rocha-Lima, A. C., Xavier, A.
A. and Gontijo, C. M. (2009). Molecular diagnosis of canine visceral
leishmaniasis: identification of Leishmania species by PCR-RFLP and
quantification of parasite DNA by real-time PCR. Acta Trop. 111 (3): 289-294.
Quinnell, R. J., Courtenay, O., Davidson, S., Garcez, L., Lambson, B., Ramos, P.,
Shaw, J. J., Shaw, M. A. and Dye, C. (2001a). Detection of Leishmania infantum
by PCR, serology and cellular immune response in a cohort study of Brazilian
dogs. Parasitology 122 (3): 253-261.
Quinnell, R. J., Courtenay, O., Garcez, L. and Dye, C. (1997). The epidemiology of
canine leishmaniasis: Transmission rates estimated from a cohort study in
Amazonian Brazil. Parasitology 115 (2): 143-156.
Quinnell, R. J., Courtenay, O., Garcez, L. M., Kaye, P. M., Shaw, M. A., Dye, C. and
Day, M. J. (2003a). IgG subclass responses in a longitudinal study of canine
visceral leishmaniasis. Vet. Immunol. Immunopathol. 91 (3-4): 161-168.
Quinnell, R. J., Courtenay, O., Shaw, M. A., Day, M. J., Garcez, L. M., Dye, C. and
Kaye, P. M. (2001b). Tissue cytokine responses in canine visceral leishmaniasis.
J. Infect. Dis. 183 (9): 1421-1424.
Quinnell, R. J., Kennedy, L. J., Barnes, A., Courtenay, O., Dye, C., Garcez, L. M.,
Shaw, M. A., Carter, S. D., Thomson, W. and Ollier, W. E. R. (2003b).
Susceptibility to visceral leishmaniasis in the domestic dog is associated with
MHC class II polymorphism. Immunogenetics 55 (1): 23-28.
Rafati, S., Kariminia, A., Seyde-Eslami, S., Narimani, M., Taheri, T. and Lebbatard,
M. (2002). Recombinant cysteine proteinases-based vaccines against Leishmania
major in BALB/c mice: The partial protection relies on interferon gamma
producing CD8+ T lymphocyte activation. Vaccine 20 (19-20): 2439-2447.
Rafati, S., Nakhaee, A., Taheri, T., Taslimi, Y., Darabi, F., Eravani, D., Sanos, S.,
Kaye, P., Taghikhani, M., Jamshidi, S. and Rad, M. A. (2005). Protective
vaccination against experimental canine visceral leishmaniasis using a
combination of DNA and protein immunization with cysteine proteinases type I
and II of L. infantum. Vaccine 23 (28): 3716-3725.
Rafati, S., Salmanian, A. H., Taheri, T., Vafa, M. and Fasel, N. (2001). A protective
cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding
cysteine proteinases of Leishmania major. Vaccine 19 (25-26): 3369-3375.
Ramiro, M. J., Zarate, J. J., Hanke, T., Rodriguez, D., Rodriguez, J. R., Esteban, M.,
Lucientes, J., Castillo, J. A. and Larraga, V. (2003). Protection in dogs against
visceral leishmaniasis caused by Leishmania infantum is achieved by
151
immunization with a heterologous prime-boost regime using DNA and vaccinia
recombinant vectors expressing LACK. Vaccine 21 (19-20): 2474-2484.
Ramos, I., Alonso, A., Marcen, J. M., Peris, A., Castillo, J. A., Colmenares, M. and
Larraga, V. (2008). Heterologous prime-boost vaccination with a non-replicative
vaccinia recombinant vector expressing LACK confers protection against canine
visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine
26 (3): 333-344.
Ramos, I., Alonso, A., Peris, A., Marcen, J. M., Abengozar, M. A., Alcolea, P. J.,
Castillo, J. A. and Larraga, V. (2009). Antibiotic resistance free plasmid DNA
expressing LACK protein leads towards a protective Th1 response against
Leishmania infantum infection. Vaccine 27 (48): 6695-6703.
Reed, S. G., Badaro, R. and Lloyd, R. M. (1987). Identification of specific and cross-
reactive antigens of Leishmania donovani chagasi by human infection sera. J.
Immunol. 138 (5): 1596-1601.
Reed, S. G., Coler, R. N. and Campos-Neto, A. (2003). Development of a leishmaniasis
vaccine: the importance of MPL. Expert Rev. Vaccines 2 (2): 239-252.
Reed, S. G. and Scott, P. (1993). T-cell and cytokine responses in leishmaniasis. Curr.
Opin. Immunol. 5 (4): 524-531.
Reiner, S. L. and Locksley, R. M. (1992). Lessons from Leishmania - a model for
investigations of CD4+ subset differentiation. Infect. Agents Dis. 1 (1): 33-42.
Reiner, S. L. and Locksley, R. M. (1995). The regulation of immunity to Leishmania
major. Annu. Rev. Immunol. 13: 151-177.
Reis, A. B., Teixeira-Carvalho, A., Giunchetti, R. C., Guerra, L. L., Carvalho, M. G.,
Mayrink, W., Genaro, O., Correa-Oliveira, R. and Martins, O. A. (2006a).
Phenotypic features of circulating leucocytes as immunological markers for
clinical status and bone marrow parasite density in dogs naturally infected by
Leishmania chagasi. Clin. Exp. Immunol. 146 (2): 303-311.
Reis, A. B., Teixeira-Carvalho, A., Vale, A. M., Marques, M. J., Giunchetti, R. C.,
Mayrink, W., Guerra, L. L., Andrade, R. A., Correa-Oliveira, R. and
Martins-Filho, O. A. (2006b). Isotype patterns of immunoglobulins: Hallmarks
for clinical status and tissue parasite density in brazilian dogs naturally infected by
Leishmania (Leishmania) chagasi. Vet. Immunol. Immunopathol. 112 (3-4): 102-
116.
Reithinger, R., Coleman, P. G., Alexander, B., Vieira, E. P., Assis, G. and Davies, C.
R. (2004). Are insecticide-impregnated dog collars a feasible alternative to dog
culling as a strategy for controlling canine visceral leishmaniasis in Brazil? Int. J.
Parasitol. 34 (1): 55-62.
Reithinger, R. and Davies, C. R. (2002). American cutaneous leishmaniasis in domestic
dogs: an example of the use of the polymerase chain reaction for mass screening
in epidemiological studies. Trans. R. Soc. Trop. Med. Hyg. 96 Suppl 1: S123-126.
152
Reithinger, R., Quinnell, R. J., Alexander, B. and Davies, C. R. (2002). Rapid
detection of Leishmania infantum infection in dogs: Comparative study using an
immunochromatographic dipstick test, enzyme-linked immunosorbent assay, and
PCR. J. Clin. Microbiol. 40 (7): 2352-2356.
Rhalem, A., Sahibi, H., Guessous-Idrissi, N., Lasri, S., Natami, A., Riyad, M. and
Berrag, B. (1999). Immune response against Leishmania antigens in dogs
naturally and experimentally infected with Leishmania infantum. Vet. Parasitol.
81 (3): 173-184.
Ribeiro, R. R., Moura, E. P., Pimentel, V. M., Sampaio, W. M., Silva, S. M.,
Schettini, D. A., Alves, C. F., Melo, F. A., Tafuri, W. L., Demicheli, C., Melo,
M. N., Frezard, F. and Michalick, M. S. M. (2008). Reduced tissue parasitic
load and infectivity to sand flies in dogs naturally infected by Leishmania
(Leishmania) chagasi following treatment with a liposome formulation of
meglumine antimoniate. Antimicrob. Agents Chemother. 52 (7): 2564-2572.
Rioux, J. A., Killick-Kendrick, R., Leaney, A. J., Young, C. J., Turner, D. P.,
Lanotte, G. and Bailly, M. (1979). Ecology of leishmaniasis in the south of
France. 11. Canine leishmaniasis: successful experimental transmission from dog
to dog by the bite of Phlebotomus ariasi Tonnoir, 1921. Ann. Parasitol. Hum.
Comp. 54 (4): 401-407.
Ritter, U., Lechner, A., Scharl, K., Kiafard, Z., Zwirner, J. and Korner, H. (2008).
TNF controls the infiltration of dendritic cells into the site of Leishmania major
infection. Med. Microbiol. Immunol. 197 (1): 29-37.
Roberts, M. T. M. (2005). Current understandings on the immunology of leishmaniasis
and recent developments in prevention and treatment. Br. Med. Bull. 75-76: 115-
130.
Rodriguez-Cortes, A., Ojeda, A., Lopez-Fuertes, L., Timon, M., Altet, L., Solano-
Gallego, L., Sanchez-Robert, E., Francino, O. and Alberola, J. (2007). A long
term experimental study of canine visceral leishmaniasis. Int. J. Parasitol. 37 (6):
683-693.
Rodríguez-Cortés, A., Ojeda, A., López-Fuertes, L., Timón, M., Altet, L., Solano-
Gallego, L., Sánchez-Robert, E., Francino, O. and Alberola, J. (2007).
Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does
not protect dogs against Leishmania infantum experimental challenge. Vaccine 25
(46): 7962-7971.
Rogers, M. E., Ilg, T., Nikolaev, A. V., Ferguson, M. A. J. and Bates, P. A. (2004).
Transmission of cutaneous leishmaniasis by sand flies is enhanced by
regurgitation of fPPG. Nature 430 (6998): 463-467.
Rogers, M. E., Sizova, O. V., Ferguson, M. A. J., Nikolaev, A. V. and Bates, P. A.
(2006). Synthetic glycovaccine protects against the bite of Leishmania-infected
sand flies. J. Infect. Dis. 194 (4): 512-518.
153
Rosati, M., Bergamaschi, C., Valentin, A., Kulkarni, V., Jalah, R., Alicea, C., Patel,
V., von Gegerfelt, A. S., Montefiori, D. C., Venzon, D. J., Khan, A. S.,
Draghia-Akli, R., Van Rompay, K. K. A., Felber, B. K. and Pavlakis, G. N.
(2009). DNA vaccination in rhesus macaques induces potent immune responses
and decreases acute and chronic viremia after SIVmac251 challenge. Proc. Natl.
Acad. Sci. U. S. A. 106 (37): 15831-15836.
Rosypal, A. C., Troy, G. C., Duncan, R. B., Zajac, A. M. and Lindsay, D. S. (2005).
Utility of diagnostic tests used in diagnosis of infection in dogs experimentally
inoculated with a North American isolate of Leishmania infantum infantum. J. Vet.
Intern. Med. 19 (6): 802-809.
Russell, W. M. S. and Burch, R. L. (1959). The principles of humane experimental
technique. 238pp. London, Methuen.
Russo, R., Laguna, F., Lopez-Velez, R., Medrano, F. J., Rosenthal, E., Cacopardo, B.
and Nigro, L. (2003). Visceral leishmaniasis in those infected with HIV: clinical
aspects and other opportunistic infections. Ann. Trop. Med. Parasit. 97: 99-105.
Saldarriaga, O. A., Travi, B. L., Park, W., Perez, L. E. and Melby, P. C. (2006).
Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis
in dogs. Vaccine 24 (11): 1928-1940.
Santos-Gomes, G. M., Capela, M. J. R., Ramada, J. and Campino, L. (2003).
Experimental canine leishmaniasis: evolution of infection following re-challenge
with Leishmania infantum. Acta Trop. 87 (2): 235-244.
Santos-Gomes, G. M., Rosa, R., Leandro, C., Cortes, S., Romao, P. and Silveira, H.
(2002). Cytokine expression during the outcome of canine experimental infection
by Leishmania infantum. Vet. Immunol. Immunopathol. 88 (1-2): 21-30.
Santos, F. N., Borja-Cabrera, G. P., Miyashiro, L. M., Grechi, J., Reis, A. B.,
Moreira, M. A. B., Martins Filho, O. A., Luvizotto, M. C. R., Menz, I., Pessoa,
L. M., Goncalves, P. R., Palatnik, M. and Palatnik-de-Sousa, C. B. (2007).
Immunotherapy against experimental canine visceral leishmaniasis with the
saponin enriched-Leishmune® vaccine. Vaccine 25 (33): 6176-6190.
Santos, W. R., de Lima, V. M. F., de Souza, E. P., Bernardo, R. R., Palatnik, M. and
de Sousa, C. B. P. (2002). Saponins, IL12 and BCG adjuvant in the FML-vaccine
formulation against murine visceral leishmaniasis. Vaccine 21 (1-2): 30-43.
Santos, W. R., Paraguai de Souza, E., Palatnik, M. and Palatnik de Sousa, C. B.
(1999). Vaccination of Swiss Albino mice against experimental visceral
leishmaniasis with the FML antigen of Leishmania donovani. Vaccine 17 (20-21):
2554-2561.
Scalone, A., De Luna, R., Oliva, G., Baldi, L., Satta, G., Vesco, G., Mignone, W.,
Turilli, C., Mondesire, R. R., Simpson, D., Donoghue, A. R., Frank, G. R. and
Gradoni, L. (2002). Evaluation of the Leishmania recombinant K39 antigen as a
diagnostic marker for canine leishmaniasis and validation of a standardized
enzyme-linked immunosorbent assay. Vet. Parasitol. 104 (4): 275-285.
154
Schallig, H. D. F. H., Canto-Cavalheiro, M. and Da Silva, E. S. (2002). Evaluation of
the direct agglutination test and the rK39 dipstick test for the sero-diagnosis of
visceral leishmaniasis. Mem. Inst. Oswaldo Cruz 97 (7): 1015-1018.
Schetters, T. P. M., Kleuskens, J., Scholtes, N. C. and Pasman, J. W. (1994).
Vaccination of dogs against Babesia canis infection using antigens from culture
supernatants with emphasis on clinical babesiosis. Vet. Parasitol. 52 (3-4): 219-
233.
Scrimgeour, E. M., Barker, D. C., al-Waily, A., Idris, M., Lambson, B., Nirmala, V.
and Windsor, J. J. (1998). First identification of a species of Leishmania causing
visceral leishmaniasis in the Sultanate of Oman, in a patient with AIDS. Trans. R.
Soc. Trop. Med. Hyg. 92 (3): 356-357.
Sepulveda, P., Hontebeyrie, M., Liegeard, P., Mascilli, A. and Norris, K. A. (2000).
DNA-based immunization with Trypanosoma cruzi complement regulatory
protein elicits complement lytic antibodies and confers protection against
Trypanosoma cruzi infection. Infect. Immun. 68 (9): 4986-4991.
Sharifi, I., Fekri, A. R., Aflatonian, M. R., Khamesipour, A., Nadim, A., Ahmadi
Mousavi, M. R., Momeni, A. Z., Dowlati, Y., Godal, T., Zicker, F., Smith, P.
G. and Modabber, F. (1998). Randomised vaccine trial of single dose of killed
Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in
Bam, Iran. Lancet 351 (9115): 1540-1543.
Shaw, S. E., Langton, D. A. and Hillman, T. J. (2009). Canine leishmaniosis in the
United Kingdom: a zoonotic disease waiting for a vector? Vet. Parasitol. 163 (4):
281-285.
Sheets, R. L., Stein, J., Manetz, T. S., Andrews, C., Bailer, R., Rathmann, J. and
Gomez, P. L. (2006a). Toxicological safety evaluation of DNA plasmid vaccines
against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is
similar despite differing plasmid backbones or gene-inserts. Toxicol. Sci. 91 (2):
620-630.
Sheets, R. L., Stein, J., Manetz, T. S., Duffy, C., Nason, M., Andrews, C., Kong, W.
P., Nabel, G. J. and Gomez, P. L. (2006b). Biodistribution of DNA plasmid
vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile
virus is similar, without integration, despite differing plasmid backbones or gene
inserts. Toxicol. Sci. 91 (2): 610-619.
Shifrine, M., Taylor, N. J., Rosenblatt, L. S. and Wilson, F. D. (1978). Comparison of
whole-blood and purified canine lymphocytes in a lymphocyte-stimulation
microassay. Am. J. Vet. Res. 39 (4): 687-690.
Sideris, V., Karagouni, E., Papadopoulou, G., Garifallou, A. and Dotsika, E. N.
(1996). Canine visceral leishmaniasis in the great Athens area, Greece. Parasite 3
(2): 125-130.
155
Sideris, V., Papadopoulou, G., Dotsika, E. and Karagouni, E. (1999). Asymptomatic
canine leishmaniasis in Greater Athens area, Greece. Eur. J. Epidemiol. 15 (3):
271-276.
Silva, E. S., Gontijo, C. M., Pacheco, R. S., Fiuza, V. O. and Brazil, R. P. (2001).
Visceral leishmaniasis in the metropolitan region of Belo Horizonte, state of
Minas Gerais, Brazil. Mem. Inst. Oswaldo Cruz 96 (3): 285-291.
Singh, S., Gilman-Sachs, A., Chang, K. P. and Reed, S. G. (1995). Diagnostic and
prognostic value of K39 recombinant antigen in Indian leishmaniasis. J. Parasitol.
81 (6): 1000-1003.
Skeiky, Y. A. W., Coler, R. N., Brannon, M., Stromberg, E., Greeson, K., Crane, R.
T., Campos-Neto, A. and Reed, S. G. (2002). Protective efficacy of a tandemly
linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in
MPL® adjuvant. Vaccine 20 (27-28): 3292-3303.
Smyth, A. J., Ghosh, A., Hassan, M. Q., Basu, D., De Bruijn, M. H. L., Adhya, S.,
Mallik, K. K. and Barker, D. C. (1992). Rapid and sensitive detection of
Leishmania kinetoplast DNA from spleen and blood samples of kala-azar patients.
Parasitology 105 (2): 183-192.
Snapper, C. M. and Paul, W. E. (1987). Interferon-gamma and B-cell stimulatory
factor-I reciprocally regulate Ig isotype production. Science 236 (4804): 944-947.
Solano-Gallego, L., Koutinas, A., Miro, G., Cardoso, L., Pennisi, M. G., Ferrer, L.,
Bourdeau, P., Oliva, G. and Baneth, G. (2009). Directions for the diagnosis,
clinical staging, treatment and prevention of canine leishmaniosis. Vet. Parasitol.
165 (1-2): 1-18.
Solano-Gallego, L., Llull, J., Osso, M., Hegarty, B. and Breitschwerdt, E. (2006). A
serological study of exposure to arthropod-borne pathogens in dogs from
northeastern Spain. Vet. Res. 37 (2): 231-244.
Solano-Gallego, L., Llull, J., Ramis, A., Fernandez-Bellon, H., Rodriguez, A., Ferrer,
L. and Alberola, J. (2005). Longitudinal study of dogs living in an area of Spain
highly endemic for leishmaniasis by serologic analysis and the leishmanin skin
test. Am. J. Trop. Med. Hyg. 72 (6): 815-818.
Solano-Gallego, L., Llull, J., Ramos, G., Riera, C., Arboix, M., Alberola, J. and
Ferrer, L. (2000). The Ibizian hound presents a predominantly cellular immune
response against natural Leishmania infection. Vet. Parasitol. 90 (1-2): 37-45.
Solano-Gallego, L., Morell, P., Arboix, M., Alberola, J. and Ferrer, L. (2001).
Prevalence of Leishmania infantum infection in dogs living in an area of canine
Leishmaniasis endemicity using PCR on several tissues and serology. J. Clin.
Microbiol. 39 (2): 560-563.
Spreng, D. (1993). Leishmanial polyarthritis in two dogs. J. Small Anim. Pract. 34: 559-
563.
156
Stager, S., Smith, D. F. and Kaye, P. M. (2000). Immunization with a recombinant
stage-regulated surface protein from Leishmania donovani induces protection
against visceral leishmaniasis. J. Immunol. 165 (12): 7064-7071.
StataCorp (2005). STATA Statistical Software: Release 9.0. College Station, TX: Stata
Corporation.
Stittelaar, K. J., Kuiken, T., de Swart, R. L., van Amerongen, G., Vos, H. W.,
Niesters, H. G., van Schalkwijk, P., van der Kwast, T., Wyatt, L. S., Moss, B.
and Osterhaus, A. D. (2001). Safety of modified vaccinia virus Ankara (MVA) in
immune-suppressed macaques. Vaccine 19 (27): 3700-3709.
Stober, C. B., Lange, U. G., Roberts, M. T. M., Alcami, A. and Blackwell, J. M.
(2005). IL-10 from regulatory T cells determines vaccine efficacy in murine
Leishmania major infection. J. Immunol. 175 (4): 2517-2524.
Stober, C. B., Lange, U. G., Roberts, M. T. M., Alcami, A. and Blackwell, J. M.
(2007). Heterologous priming-boosting with DNA and modified vaccinia virus
Ankara expressing tryparedoxin peroxidase promotes long-term memory against
Leishmania major in susceptible BALB/c Mice. Infect. Immun. 75 (2): 852-860.
Stober, C. B., Lange, U. G., Roberts, M. T. M., Gilmartin, B., Francis, R., Almeida,
R., Peacock, C. S., McCann, S. and Blackwell, J. M. (2006). From genome to
vaccines for leishmaniasis: Screening 100 novel vaccine candidates against murine
Leishmania major infection. Vaccine 24 (14): 2602-2616.
Strauss-Ayali, D., Baneth, G. and Jaffe, C. L. (2007). Splenic immune responses during
canine visceral leishmaniasis. Vet. Res. 38 (4): 547-564.
Strauss-Ayali, D., Jaffe, C. L., Burshtain, O., Gonen, L. and Baneth, G. (2004).
Polymerase chain reaction using noninvasively obtained samples, for the detection
of Leishmania infantum DNA in dogs. J. Infect. Dis. 189 (9): 1729-1733.
Streit, J. A., Oonelson, J. E. and Wilson, M. E. (1996). A recombinant BCG vaccine
expressing the Leishmania chagasi antigen LCR1. J. Investig. Med. 44 (3): A320.
Streit, J. A., Recker, T. J., Donelson, J. E. and Wilson, M. E. (2000). BCG expressing
LCR1 of Leishmania chagasi induces protective immunity in susceptible mice.
Exp. Parasitol. 94 (1): 33-41.
Sundar, S., Maurya, R., Singh, R. K., Bharti, K., Chakravarty, J., Parekh, A., Rai,
M., Kumar, K. and Murray, H. W. (2006). Rapid, noninvasive diagnosis of
visceral leishmaniasis in India: Comparison of two immunochromatographic strip
tests for detection of anti-K39 antibody. J. Clin. Microbiol. 44 (1): 251-253.
Sundar, S., Pai, K., Kumar, R., Pathak-Tripathi, K., Gam, A. A., Ray, M. and
Kenney, R. T. (2001). Resistance to treatment in Kala-azar: Speciation of isolates
from northeast India. Am. J. Trop. Med. Hyg. 65 (3): 193-196.
157
Sundar, S., Reed, S. G., Singh, V. P., Kumar, P. C. K. and Murray, H. W. (1998).
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 351
(9102): 563-565.
Sundar, S., Singh, R. K., Bimal, S. K., Gidwani, K., Mishra, A., Maurya, R., Singh,
S. K., Manandhar, K. D., Boelaert, M. and Rai, M. (2007). Comparative
evaluation of parasitology and serological tests in the diagnosis of visceral
leishmaniasis in India: A phase III diagnostic accuracy study. Trop. Med. Int.
Health 12 (2): 284-289.
Swihart, K., Fruth, U., Messmer, N., Hug, K., Behin, R., Huang, S., Delgiudice, G.,
Aguet, M. and Louis, J. A. (1995). Mice from a genetically resistant background
lacking the Interferon-gamma receptor are susceptible to infection with
Leishmania major but mount a polarized T-helper cell 1-type CD4(+) T-cell
response. J. Exp. Med. 181 (3): 961-971.
Talmi-Frank, D., Strauss-Ayali, D., Jaffe, C. L. and Baneth, G. (2006). Kinetics and
diagnostic and prognostic potential of quantitative Western blot analysis and
antigen-specific enzyme-linked immunosorbent assay in experimental canine
leishmaniasis. Clin. Vaccine Immunol. 13 (2): 271-276.
Tape, T. G. (2004) Interpreting laboratory tests. http://gim.unmc.edu/dxtests/Default.htm.
University of Nebraska Medical Center
Tapia, E., Perez-Jimenez, E., Lopez-Fuertes, L., Gonzalo, R., Gherardi, M. M. and
Esteban, M. (2003). The combination of DNA vectors expressing IL-12 + IL-18
elicits high protective immune response against cutaneous leishmaniasis after
priming with DNA-p36/LACK and the cytokines, followed by a booster with a
vaccinia virus recombinant expressing p36/LACK. Microbes Infect. 5 (2): 73-84.
Taran, M., Mohebali, M., Modaresi, M. H., Mamishi, S., Mahmoudi, M. and
Mojarad, M. (2007). Diagnosis of canine visceral leishmaniasis by ELISA using
K39sub recombinant antigen. Iran. J. Public Health 36 (2): 1-6.
Tijssen, P. (1985). Practice and theory of enzyme immunoassays. 549pp. Amsterdam
Elsevier Science Publishers B.V.
Titus, R. G., Gueiros-Filho, F. J., De Freitas, L. A. R. and Beverley, S. M. (1995).
Development of a safe live Leishmania vaccine line by gene replacement. Proc.
Natl. Acad. Sci. U. S. A. 92 (22): 10267-10271.
Titus, R. G., Lima, G. C., Engers, H. D. and Louis, J. A. (1984). Exacerbation of
murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T
cell populations capable of mediating Leishmania major-specific delayed-type
hypersensitivity. J. Immunol. 133 (3): 1594-1600.
Tolezano, J. E., Uliana, S. R. B., Taniguchi, H. H., Araújo, M. F. L., Barbosa, J. A.
R., Barbosa, J. E. R., Floeter-Winter, L. M. and Shaw, J. J. (2007). The first
records of Leishmania (Leishmania) amazonensis in dogs (Canis familiaris)
diagnosed clinically as having canine visceral leishmaniasis from Araçatuba
County, São Paulo State, Brazil. Vet. Parasitol. 149 (3-4): 280-284.
158
Tolson, D. L., Jardim, A., Schnur, L. F., Stebeck, C., Tuckey, C., Beecroft, R. P.,
Teh, H. S., Olafson, R. W. and Pearson, T. W. (1994). The kinetoplastid
membrane protein 11 of Leishmania donovani and African trypanosomes is a
potent stimulator of T-lymphocyte proliferation. Infect. Immun. 62 (11): 4893-
4899.
Toz, S. O., Chang, K. P., Ozbel, Y. and Alkan, M. Z. (2004). Diagnostic value of rK39
dipstick in zoonotic visceral leishmaniasis in Turkey. J. Parasitol. 90 (6): 1484-
1486.
Travi, B. L., Tabares, C. J., Cadena, H., Ferro, C. and Osorio, Y. (2001). Canine
visceral leishmaniasis in Colombia: Relationship between clinical and
parasitologic status and infectivity for sand flies. Am. J. Trop. Med. Hyg. 64 (3-4):
119-124.
Trotz-Williams, L. A. and Trees, A. J. (2003). Systematic review of the distribution of
the major vector-borne parasitic infections in dogs and cats in Europe. Vet. Rec.
152 (4): 97-105.
Trujillo, C., Ramirez, R., Velez, I. D. and Berberich, C. (1999). The humoral immune
response to the kinetoplastid membrane protein-11 in patients with American
Leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of
epitopes. Immunol. Lett. 70 (3): 203-209.
UK Home Office (1989). Code of practice for the housing and care of animals used in
scientific procedures. http://scienceandresearch.homeoffice.gov.uk/animal-
research.
Van Eys, G. J. J. M., Schoone, G. J., Kroon, N. C. M. and Ebeling, S. B. (1992).
Sequence analysis of small subunit ribosomal RNA genes and its use for detection
and identification of Leishmania parasites. Mol. Biochem. Parasitol. 51 (1): 133-
142.
van Oirschot, J. T. (1999). Diva vaccines that reduce virus transmission. J. Biotechnol.
73 (2-3): 195-205.
Veeken, H., Ritmeijer, K., Seaman, J. and Davidson, R. (2003). Comparison of an
rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the
diagnosis of kala-azar in Sudan. Trop. Med. Int. Health 8 (2): 164-167.
Velez, I. D., der Pilar Agudelo, S., Arbelaez, M. P., Gilchrist, K., Robledo, S. M.,
Puerta, J. A., Zicker, F., Berman, J. and Modabber, F. (2000). Safety and
immunogenicity of a killed Leishmania (L.) amazonensis vaccine against
cutaneous leishmaniasis in Colombia: A randomized controlled trial. Trans. R.
Soc. Trop. Med. Hyg. 94 (6): 698-703.
Veras, P. S. T., Brodskyn, C. I., Balestieri, F. M. P., De Freitas, L. A. R., Ramos, A.
P. S., Queiroz, A. R. P., Barral, A., Beverley, S. M. and Barral-Netto, M.
(1999). A DHFR TS Leishmania major knockout mutant cross-protects against
Leishmania amazonensis. Mem. Inst. Oswaldo Cruz 94 (4): 491-496.
159
Vercosa, B. B., Melo, C. C., Mendonca, II, Silva, S. S., Carvalho, S. S., Goto, H. H.
and Costa, F. F. (2008). Transmission potential, skin inflammatory response, and
parasitism of symptomatic and asymptomatic dogs with visceral leishmaniasis.
BMC Vet. Res. 4 (1): 45.
Wang, R. B., Doolan, D. L., Le, T. P., Hedstrom, R. C., Coonan, K. M., Charoenvit,
Y. P., Jones, T. R., Hobart, P., Margalit, M., Ng, J., Weiss, W. R., Sedegah,
M., de Taisne, C., Norman, J. A. and Hoffman, S. L. (1998). Induction of
antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.
Science 282 (5388): 476-480.
Wang, Z. E., Reiner, S. L., Zheng, S. C., Dalton, D. K. and Locksley, R. M. (1994).
CD4+ effector cells default to the Th2 pathway in Interferon gamma deficient
mice infected with Leishmania major. J. Exp. Med. 179 (4): 1367-1371.
Webb, J. R., Campos-Neto, A., Ovendale, P. J., Martin, T. I., Stromberg, E. J.,
Badaro, R. and Reed, S. G. (1998). Human and murine immune responses to a
novel Leishmania major recombinant protein encoded by members of a multicopy
gene family. Infect. Immun. 66 (7): 3279-3289.
Weyer, J., Rupprecht, C. E., Mans, J., Viljoen, G. J. and Nel, L. H. (2007).
Generation and evaluation of a recombinant modified vaccinia virus Ankara
vaccine for rabies. Vaccine 25 (21): 4213-4222.
Whitley, E. and Ball, J. (2002). Statistics review 4: sample size calculations. Crit. Care
6 (4): 335-341.
WHO (2002). Urbanization: an increasing risk factor for leishmaniasis. Weekly
epidemiological record. World Health Organization 77 (44): 365-370.
WHO (2006) Leishmaniasis: WHO Initiative for Vaccine Research (IVR):
http://www.who.int/vaccine_research/diseases/soa_parasitic/en/index3.html.
Wilson, M. E., Jeronimo, S. M. B. and Pearson, R. D. (2005). Immunopathogenesis of
infection with the visceralizing Leishmania species. Microb. Pathog. 38 (4): 147-
160.
Wilson, M. E., Young, B. M., Andersen, K. P., Weinstock, J. V., Metwali, A., Ali, K.
M. and Donelson, J. E. (1995). A recombinant Leishmania chagasi antigen that
stimulates cellular immune responses in infected mice. Infect. Immun. 63 (5):
2062-2069.
Wolff, J. A., Malone, R. W., Williams, P., Wang, C., Acsadi, G., Jani, A. and Felgner,
P. L. (1990). Direct gene transfer into mouse muscle in vivo. Science 247 (4949
I): 1465-1468.
WorldBank (2006) Disease Control Priorities Project:
http://www.dcp2.org/main/Home.html.
160
Wyllie, S., Vickers, T. J. and Fairlamb, A. H. (2008). Roles of trypanothione S-
transferase and tryparedoxin peroxidase in resistance to antimonials. Antimicrob.
Agents Chemother. 52 (4): 1359-1365.
Xu, D. and Liew, F. Y. (1994). Genetic vaccination against leishmaniasis. Vaccine 12
(16): 1534-1536.
Yang, D. M., Fairweather, N., Button, L. L., McMaster, W. R., Kahl, L. P. and Liew,
F. Y. (1990). Oral Salmonella typhimurium (AroA-) vaccine expressing a major
leishmanial surface protein (gp63) preferentially induces T helper 1 cells and
protective immunity against leishmaniasis. J. Immunol. 145 (7): 2281-2285.
Yates, A., Antia, R. and Regoes, R. R. (2006). How do pathogen evolution and host
heterogeneity interact in disease emergence? Proc. R. Soc. B-Biol. Sci. 273
(1605): 3075-3083.
Zadeh-Vakili, A., Taheri, T., Taslimi, Y., Doustdari, F., Salmanian, A. H. and Rafati,
S. (2004). Immunization with the hybrid protein vaccine, consisting of Leishmania
major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects
against leishmaniasis. Vaccine 22 (15-16): 1930-1940.
Zerpa, O., Ulrich, M., Negron, E., Rodriguez, N., Centeno, M., Rodriguez, V.,
Barrios, R. M., Belizario, D., Reed, S. and Convit, J. (2000). Canine visceral
leishmaniasis on Margarita Island (Nueva Esparta, Venezuela). Trans. R. Soc.
Trop. Med. Hyg. 94 (5): 484-487.
Zijlstra, E. E., Daifalla, N. S., Kager, P. A., Khalil, E. A. G., El-Hassan, A. M., Reed,
S. G. and Ghalib, H. W. (1998). rK39 enzyme-linked immunosorbent assay for
diagnosis of Leishmania donovani infection. Clin. Diagn. Lab. Immunol. 5 (5):
717-720.
Zijlstra, E. E., Nur, Y., Desjeux, P., Khalil, E. A. G., El-Hassan, A. M. and Groen, J.
(2001). Diagnosing visceral leishmaniasis with the recombinant K39 strip test:
Experience from the Sudan. Trop. Med. Int. Health 6 (2): 108-113.
161
Appendix I. Trials of experimental vaccines against zoonotic visceral leishmaniasis in dogs
Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Purified
parasite
fraction
L. infantum fraction
LiF2.
3 intravenous or
subcutaneous injections
at 1 month intervals,
with 5 different
adjuvants
Moderate anti-
Leishmania titres
in all vaccinated
dogs. Sera blocked
L. infantum
replication.
No exposure No exposure:
immunogenicity
trial only
3 months 12 German
shepherd dogs.
No side effects
recorded
(Ogunkolade et
al., 1988)
Purified
parasite
fraction
L. infantum fraction
LiF2 with Muramyl
Dipeptide adjuvant.
3 subcutaneous
injections at 1 month
intervals
None recorded None recorded Natural exposure 2 years 400 dogs
(natural
population,
randomly
assigned to
vaccine or
control groups)
Infection rate in
vaccinated dogs
higher than
control group in
1st year. No
between-group
difference in 2nd
year.
(Dunan et al.,
1989)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Killed
whole
parasite
Merthiolated sonicated
promastigotes of L.
braziliensis + BCG
adjuvant.
600ug by 3 intradermal
doses at 21 day
intervals.
No detectable anti-
Leishmania IgG
response to
vaccination.
Lymphoproliferative
response to
Leishmania antigen
in vaccinees. No
detectable anti-
Leishmania IgG in
9/10 vaccinees, high
titres in
unvaccinated dogs.
Experimental:
2.3x106 L.
braziliensis
promastigotes
intravenously , 2
months post
vaccination
26
months
19 laboratory-
reared mongrel
dogs
1/10 vaccinated
and 9/9 control
dogs developed
patent infection.
Vaccinated dogs
developed
injection site skin
ulcer.
(Mayrink et al.,
1996)
Killed
whole
parasite
Autoclaved L. infantum
or autoclaved L. major
with BCG
Positive
intradermal test in
vaccinated dogs
Positive intradermal
test in vaccinated
dogs, negative in
controls
Experimental:
2.5 × 106 L.
infantum
promastigotes, 90
days post vaccine
by intraperitoneal
challenge
5 months 16 dogs in four
groups
All dogs in
unvaccinated
groups positive
by culture and
microscopy, only
one vaccinated
dog infected.
(Mohebali et
al., 1998)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Killed
whole
parasite
Autoclaved L. major
promastigotes (ALM)
with either saponin or
BCG adjuvant.
Three doses: second
dose after 4 weeks,
third dose after 6
weeks.
High anti-
Leishmania
antibody titres in
ALM / saponin
vaccinated dogs,
low lymphocyte
proliferation.
ALM/BCG dogs
showed opposite
trends.
No exposure No exposure:
immunogenicity
trial only
10
months
18 mixed
breed dogs.
No side effects
recorded
(Lasri et al.,
1999)
Purified
parasite
fraction
FML enriched purified
fraction of L. donovani
in saline.
Three subcutaneous
doses 21 days apart,
None recorded 100% vaccinees
seropositive to FML
ELISA.
Positive intradermal
test 7 months post
vaccine.
Natural exposure
to L. chagasi
2 years 58 vaccinees
59 controls
Domestic
mongrel dogs
92% protection.
76% efficacy.
33% control dogs
developed
clinical or fatal
disease. 8%
vaccinated dogs
showed mild
non-fatal disease.
(Da Silva et al.,
2000)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Purified
parasite
fraction
FML enriched purified
fraction of L.
donovani+ QuilA
adjuvant.
Three subcutaneous
doses 21 days apart.
None recorded 100% vaccinees
seropositive to FML
ELISA.
Positive intradermal
test 2 months post
vaccine.
Natural exposure
to L. chagasi
3.5 years 44 vaccinees
41 controls
Domestic dogs
95% protection.
80% vaccine
efficacy
25% fatality rate
in control dogs
and 5% in
vaccinees.
(Borja-Cabrera
et al., 2002)
Purified
parasite
fraction
FML enriched purified
fraction of L. donovani
Three subcutaneous
doses 21 days apart.
70% seropositive
to FML ELISA.
IgG2 predominated
in normal pre-
immune and
vaccinated animals,
whereas IgG1
response greater in
infected animals.
Natural exposure
to L. chagasi
63 days 68 vaccinees,
121 naturally
infected
controls.
Comparison with
infected dogs,
hence protective
efficacy not
recorded.
(de Oliveira
Mendes et al.,
2003)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
DNA/rVV
prime/
boost
Heterologous
prime/boost with DNA-
LACK and Western
Reserve rVV
expressing LACK, by
subcutaneous injection
15 days apart.
Coincident IL-4
and IFN-γ mRNA 
peaks 2-4 weeks
post vaccination.
Vaccinated dogs
expressed IL-4, IFN-
γ and IL-12 mRNA 
(suggestive of mixed
Th1/Th2 response),
lymphoproliferation
response, and a high
ratio of anti-LACK
IgG2:IgG1.
Experimental:
(1x108 L.
infantum
promastigotes
intravenously), 2
weeks post
vaccine.
17
months
20 laboratory
Beagles
60% vaccine
efficacy for
prevention of
disease.
Reduction of
visceral parasite
load in partially
protected dogs.
(Ramiro et al.,
2003)
Recombinant
protein
Recombinant multi
component chimeric
Protein Q plus live
BCG
3 intra peritoneal
injections at 21 day
intervals.
Low positive anti-
Protein Q IgG
response 21 days
after 1st vaccine.
Control dogs
negative.
Positive intradermal
test in 8/ 10
vaccinated dogs and
1/10 control dogs,
21 months post
infection.
Vaccinees had lower
anti-Leishmania IgG
titres.
Experimental :
5 x 105L.
infantum
intravenously, 2
months post-
vaccination
2 years 20 laboratory
beagles
90% protection
against infection.
Vaccinated dogs
asymptomatic,
controls diseased.
N.B. safety
concerns re: live
BCG use (Poot et
al., 2009).
(Molano et al.,
2003)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Purified
parasite
fraction
FML enriched purified
fraction of L. donovani
+ QuilA adjuvant: (as
immunotherapy)
3 subcutaneous doses
3-6 weeks apart.
None recorded All seropositive to
FML ELISA at 2
months post
infection.
Experimental:
1x108
amastigotes of L.
donovani
intravenously
3 months before
vaccination.
1 year 5 mongrel
dogs (siblings)
3/5 vaccinees
remained
asymptomatic,
with positive
intradermal test,
and were parasite
negative.
(Borja-Cabrera
et al., 2004)
Purified
parasite
fraction
FML enriched purified
fraction of L.
donovani+ Saponin R
adjuvant:
3 subcutaneous doses
21 days apart
None recorded Increasing anti-FML
IgG2 levels and
75%-95% positive
intradermal reaction
in vaccinated dogs.
Naturally
infected pre-
vaccination
22
months
21 vaccinees
and
46 controls, all
asymptomatic
FML-ELISA
seropositive
outbred dogs.
Delay of clinical
disease: 90%
vaccinated dogs
and 37% controls
remained
asymptomatic at
end of trial.
(Borja-Cabrera
et al., 2004)
Killed
whole
parasite
Autoclaved whole L.
major promastigotes
with AlOH adjuvant
plus BCG
Single dose by
intradermal injection.
No anti-
Leishmania IgG at
4 months post
vaccine (before
t/m season).
High titre anti-
Leishmania IgG in
6/162 vaccinated
dogs and 17/141
controls at 16 mo
post vaccination.
Natural exposure
to L. infantum
16
months
182 vaccinees.
165 controls.
Outbred dogs.
Vaccine efficacy
69.3%, for
prevention of
seroconversion.
Local skin ulcer
at vaccine site in
64% of vaccines.
(Mohebali et
al., 2004a)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Purified
parasite
fraction
FML enriched purified
fraction of L. donovani
+ Riedel de Hahn
saponin adjuvant.
3 subcutaneous doses
21 days apart.
None recorded 100% vaccinated
dogs seropositive to
FML ELISA
Natural exposure 11
months
32 vaccinees
40 controls
Outbred dogs
Controls 25%
symptomatic,
57% lymph node
PCR positive,
16% blood PCR
positive, 25%
skin positive.
Vaccinees
negative by all
tests.
(Nogueira et
al., 2005)
Purified
fraction of
promastigote
culture
supernatant
L. infantum
excreted/secreted
antigens (LiESAp)+
muramyl dipeptide
adjuvant.
2 subcutaneous
injections 3 weeks
apart.
Anti-LiESAp IgG2
and lymphocyte
proliferative
responses higher
in vaccinated dogs
than controls.
IFN-γ levels  
higher in cytokine
assays of PBMC
from vaccinated
dogs.
Anti-LiESAp IgG2
and lymphocyte
proliferative
responses higher in
vaccinated dogs than
controls.
Experimental:
1x108 L. infantum
promastigotes
intravenously, 2
months and 8
months post
vaccine
14
months
18 dogs in four
groups.
Laboratory
Beagles.
100% protection
against
homologous and
heterologous
challenge
Mild local
reaction in many
dogs to second
vaccine dose.
(Lemesre et al.,
2005)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
DNA /
recombinant
protein
DNA/protein prime
boost 30 days apart
with a mix of Cysteine
proteinase type I (CPa)
and II (CPb), by
intramuscular injection.
Elevated anti-CPa
and CPb IgG1 and
IgG2 in vaccinated
dogs.
Elevated IFN-γ: IL-
10 mRNA ratio,
lymphoproliferation
response and Ag-
specific IgG and
IgG2 from
vaccinated dogs
compared to
controls.
Strong intradermal
response in
vaccinated dogs.
Experimental:
5x106 L. infantum
promastigotes
intravenously, 3
months post
vaccine.
12
months
15 dogs in four
groups.
Mixed breed
dogs.
1/10 of
vaccinated dogs
bone marrow
PCR positive in
contrast with 3/4
controls.
(Rafati et al.,
2005)
Recombinant
protein
Multi subunit
recombinant
polyprotein MML
(TSA, LmSTI1, and
LeIF), plus MPL-SE or
Adjuprime.
3 subcutaneous
injections, 28 days
apart, boost at 1 year.
Anti-MML
antibody response
in 13/15 MPL-SE
vaccinated dogs
and 8/15
Adjuprime
vaccinated dogs.
Weak
lymphoproliferative
response. Lack of
non-specific ConA
response in dogs co-
infected with
Ehrlichia.
Natural exposure
to L. infantum
2 years 3 groups of 15
dogs.
Laboratory
Beagles
Not protective to
clinical disease (?
due to concurrent
ehrlichiosis).
Cumulative
incidence 87%
(MPL-SE), 100%
(Adjuprime), and
100% (control)
(Gradoni et al.,
2005)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Recombinant
protein and
killed whole
parasite
Mixture of TSA,
LmSTI1, and LeIF
proteins, with MPL-SE
or Adjuprime
adjuvants, or killed L
amazonensis/L.
braziliensis with BCG
adjuvant.
3 doses by
subcutaneous injection
at 4 week intervals.
Antigen –specific
antibody response
in vaccinated dogs
particularly to
LmSTI1, maximal
after 3rd
vaccination then
declined for 6
weeks.
MPL-SE vaccinated
animals showed
IgG2 dominated
response to
infection.
Adjuprime and
whole parasite
vaccinated groups
produced low
IgG2 :IgG1 ratios.
Experimental :
1x106L. chagasi
promastigotes
intravenously, 4
months post
vaccine.
15
months
7 groups of 5
dogs.
Laboratory
beagles
Protection and
efficacy against
clinical disease
not reported –
immunogenicity
trial only.
(Fujiwara et
al., 2005)
DNA Multivalent 10 plasmid
DNA vaccine including
L. donovani Histone
proteins, LACK, PSA-
2, TSA, STI1, ARP-1,
H1. Three injections at
30 day intervals of
DNA plasmids by
intradermal or
intramuscular injection.
Antigen specific
lymphocyte
proliferative
response and
increased IFN-γ 
mRNA level in
PBMC of i/m
vaccinated dogs.
No detectable IgG
titre
DTH response to
viable L. donovani
promastigotes.-
Experimental:
Cutaneous
challenge 1x106
L. donovani
promastigotes
60 days 2 groups of 4
dogs:
Foxhounds
Inhibition of
parasite
replication in
draining LN after
cutaneous
challenge, and in
vitro. No
difference in
splenic parasite
burden.
(Saldarriaga et
al., 2006)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Recombinant
protein
Recombinant cysteine
proteinases (CPa and
CPbs) of L. infantum +
IL-12, with or without
QuilA saponin.
2 subcutaneous
injections at 4 week
interval.
Elevation of
antigen specific
anti-CP antibodies
in vaccinated
dogs.
High anti-CP and
anti-Leishmania
titres in vaccine and
control groups.
No DTH response in
any dogs.
Experimental:
5x107
promastigotes of
L. infantum
intravenously, 3
weeks post
vaccine.
13
months
3 groups of 5
dogs.
Laboratory
Beagles.
0% protection –
all vaccinated
dogs and all
controls became
clinically and
parasite positive
by lymph node
and bone marrow
culture.
(Poot et al.,
2006)
Purified
fraction of
promastigote
culture
supernatant
L. infantum
excreted/secreted
antigens (LiESAp)+
muramyl dipeptide
adjuvant.
2 subcutaneous
injections 3 weeks
apart, with third dose
12 months later.
None recorded Increased IgG2
reactivity and
enhanced NO
mediated anti-
leishmanial activity
of canine
macrophages in vitro
was seen in
vaccinated dogs
.
Natural exposure 24
months
Approx 400
IFAT negative
outbred
domestic dogs
in endemic
area
(randomized to
vaccine and
control groups)
Lower number of
bone marrow
PCR positives in
vaccinated group
than placebo
group. (1/165 cf
12/175)
(Lemesre at
al.,2007)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Purified
parasite
fraction
FML enriched purified
fraction of L.
donovani+ saponin
adjuvant:
3 subcutaneous doses
21 days apart
None recorded No exposure No exposure:
Safety trial only
14 days 600 outbred
dogs
Outcomes of
vaccine
administration:
Local pain (40%)
Anorexia (20%)
Apathy (24%)
Swelling (15.9%)
Vomiting (2.4%)
Diarrhoea (1.5%)
(Parra et al.,
2007)
Recombinant
protein
Recombinant L.
infantum Histone 1
(H1) and L. donovani
HASPB1, together and
separately, with
adjuvant (Montanide).
3 intradermal doses at
30 day intervals
High levels of
antigen specific
IgG detected in all
vaccinees. No
lymphocyte
proliferative
response seen in
any animals post
immunization.
Increase in anti-
HASPB1 IgG in
vaccinated groups.
No lymphocyte
proliferative
response seen in any
animals post
challenge.
Experimental:
1 x 108 L.
infantum
promastigotes
intravenously, 45
days post
vaccine.
16
months
7 groups of 8
dogs.
Laboratory
beagles.
No clinical
symptoms in 5/8
H1, 4/8 HASPB1
and 4/8
H1/HASPB1
dogs, compared
with 2/8 control
dogs. Adjuvant
related local skin
inflammation.
Moreno et al.,
2007
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Purified
parasite
fraction
FML enriched purified
fraction of L.
donovani+ Saponin
adjuvant (at double
normal adjuvant
concentration) :as
immunotherapy.
3 subcutaneous doses
21 days apart
None recorded Vaccine treated dogs
showed higher anti-
FML IgG titres than
controls with higher
IgG2 and decreasing
IgG1 over time.
75% vaccine dogs
showed positive
intra dermal test cf
50% controls.
Experimental:
2 x 108 L. chagasi
amastigotes
intravenously,
6 months before
vaccination
15
months
24 mixed
breed dogs,
previously
infected and
randomized to
treatment or
control groups.
Immuno-
therapeutic
effect:
Lower clinical
score in
vaccinees
compared to
controls, with
normal CD4+
lymphocyte
count cf
subnormal CD4+
count in controls.
(Santos et al.,
2007)
Killed whole
parasite
L. braziliensis
promastigote protein +
saponin adjuvant
(LBSap).
3 subcutaneous
injections at intervals
of 4 weeks.
Increased anti-
Leishmania IgG1
and IgG2 levels,
CD4+ and CD8+
cell counts, NO
production and
lymphocyte
proliferation.
No exposure No exposure:
immunogenicity
trial only
12 weeks 25 mixed
breed dogs in 4
groups
Vaccine side
effects: mild
local induration
at injection site.
Protective
efficacy not
recorded.
(Giunchetti et
al., 2007)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
DNA Multiantigenic plasmid
DNA encoding KMPII,
TRYP, LACK and
GP63
4 injections of vaccine
intradermally at 15-day
intervals
Sporadic detection
of anti-LACK IgG
in two dogs.
No cellular or
humoral response
to Leishmania
antigen in any
dogs.
Delay in production
of anti-Leishmania
IgG IgA and IgM in
vaccinated dogs
compared to
controls.
Experimental:
5 x 107 L.
infantum
promastigotes
intravenously,
1 month post
vaccination
16
months
2 groups of 6
dogs
Similar
development of
clinical signs in
both vaccine and
control groups –
high amounts of
Leishmania DNA
in visceral organs
- no evidence of
vaccine induced
protection.
(Rodríguez-
Cortés et al.,
2007)
Killed whole
parasite
L. braziliensis
promastigote protein
(LB) +/- saponin
(Sap) +/- L.
longipalpis salivary
gland extract (Sal).
3 subcutaneous
injections at intervals
of 4 weeks
Increased anti-
saliva and anti-L.
chagasi IgG, and
increased CD4+
and CD8+ counts,
NO production
and lymphocyte
proliferation in
LBSapSal group.
No exposure No exposure:
immunogenicity
trial only
12 weeks 25 mixed
breed dogs in 4
groups
Vaccine side
effects: mild
local induration
at injection site.
Protective
efficacy not
recorded-
immunogenicity
trial only.
(Giunchetti et
al., 2008)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Recombinant
protein
antigen
Recombinant A2
antigen
Three subcutaneous
doses at days 0, 21 and
42 with A2 + saponin
Increased IFN-γ, 
total IgG and
IgG2, and anti-A2
antibodies, with
low IL-10 levels
in vaccinated
animals compared
to controls.
Increased IFN-γ and 
low IL-10 levels
in vaccinated
animals compared to
controls.
Experimental:
5×107 L. chagasi
promastigotes
intravenously
four weeks after
last vaccine dose.
14
months
3 groups of 7
dogs
(laboratory
beagles).
5 out of 7
vaccinated dogs
remained
asymptomatic.
Whereas 5/7
control dogs
developed
disease
symptoms.
(Fernandes et
al., 2008)
DNA/rVV
prime/boost
Heterologous
prime/boost with DNA-
LACK and Western
Reserve rVV or
modified Vaccinia
virus Ankara (MVA)
expressing LACK, by
subcutaneous injection
15 days apart.
None reported Both IgG1 and IgG2
increased, though
rise in IgG2 was
more marked in
vaccinated dogs.
Total IgG was lower
in vaccinated than in
unvaccinated
infected dogs.
Increased IFN-γ 
mRNA expression in
vaccinees.
Experimental:
1×108 L.
infantum
metacyclic
promastigotes
intravenously 2
weeks after last
vaccine dose.
10
months
16 dogs in four
groups.
Laboratory
Beagles.
Fewer dogs
boosted with
MVA rVV
showed disease
symptoms than
Western Reserve
strain rVV
vaccinees (75%
cf 50% were
asymptomatic,
respectively)
(Ramos et al.,
2008)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Recombinant
protein
Recombinant vaccine
Leish-110f
(incorporating
recombinant antigens
TSA, LmSI1 and LeIF)
for immunotherapy +
adjuvant MPL-SE +/-
meglumine antimoniate
(Glucantime®)
None reported Higher Leishmania-
specific lymphocyte
proliferation in
groups receiving
Leish-110f than in
other groups.
Naturally
infected prior to
vaccination.
6 months 30
symptomatic
outbred dogs
in 5 groups.
Immuno-
therapeutic
effect: Animals
that received
Glucantime®, +/-
Leish-
110f®/MPL-
SE® showed
clinical
improvement.
(Miret et al.,
2008)
Purified
parasite
fraction
FML enriched purified
fraction of L.
donovani+ saponin
adjuvant
3 subcutaneous doses
21 days apart
None reported Anti-FML IgG
detected in 98%
vaccinated dogs, and
82% were positive
by intradermal test.
Natural exposure 2 years 550 outbred
dogs in 2
groups from
different
endemic areas.
99% vaccinated
dogs were
asymptomatic
compared to 79%
unvaccinated
dogs.
99% vaccinated
dogs survived to
2 years, cf 61%
unvaccinated
dogs.
(Borja-Cabrera
et al., 2008)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Purified
parasite
fraction, and
killed whole
parasite
Leishmune® or BCG-
adjuvanted killed L.
amazonensis
(“Leishvaccine”).
Three subcutaneous
doses Leishmune or
Leishvaccine at 21 day
intervals.
Leishmune® -
enhanced levels of
IFN-γ, NO and 
anti- L. chagasi
IgG2.
Leishvaccine-
Mixed IFN-γ and 
IL-4 response with
enhanced anti-L.
chagasi IgG1
No exposure No exposure:
immunogenicity
trial only
40 days 2 groups of 6
German
shepherd dogs.
Protection and
efficacy against
clinical disease
not reported –
immunogenicity
trial only.
(Araujo et al.,
2009)
Recombinant
chimerical
protein
antigen
Recombinant
JPCM5_Q protein with
adjuvants (muramyl
dipeptide, AlOH,
Matrix C or killed P.
acnes.)
2 subcutaneous
injections 21 days
apart.
IgG specific for Q
protein was
detected in all
vaccinated dogs.
AlOH and Matrix
C groups showed
greater
lymphocyte
proliferation assay
responses than
controls.
Leishmania- specific
IgG increased in all
vaccinated and
control groups post
exposure. DTH
responses did not
differ between
vaccinated and
control groups.
Experimental:
5 × 107 stationary
phase
promastigotes of
L. infantum JPC
strain via
intravenous
injection, 3-4
weeks after 2nd
vaccination.
10
months
43 laboratory
beagles.
No protection :
all vaccinated
dogs and controls
were parasite
positive and
showed clinical
disease by end of
study.
(Poot et al.,
2009)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
Recombinant
chimerical
protein
antigen
Recombinant Q
protein, single dose, or
2 doses of 100µg 21
days apart.
IgG2 specific for
Q protein
increased in
vaccinated dogs,
though
Leishmania-
specific IgG was
not elevated.
All challenged dogs
developed anti-
Leishmania titres
post exposure. NO
production in lymph
node cell cultures
from the Q and Q+Q
groups was
significantly higher
than controls.
Experimental:
5 × 105
promastigotes of
L. infantum via
intravenous
injection, 60 days
after 1st
vaccination.
11
months
21 laboratory
beagles
Q vaccination
reduced clinical
severity, and
reduced lymph
node and skin
positivity by
culture, qPCR
and microscopy.
Controls showed
gross pathology
in organs not
seen in
vaccinees.
(Carcelen et
al., 2009)
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Vaccine type Vaccine protocol Pre exposure
correlates of
protection / failure
Post exposure
correlates of
protection / failure
Exposure to
disease
Duration
of study
No of animals Clinical outcome Reference
DNA/rVV
prime/boost
Heterologous
prime/boost with DNA-
LACK (antibiotic
resistance gene free
plasmid) and modified
Vaccinia virus Ankara
(MVA) expressing
LACK, by two
subcutaneous injections
15 days apart.
Increase in IFN-γ 
mRNA expression
in PBMC pre-
challenge.
Lower production of
Leishmania-specific
IgG in vaccinees,
and Th1 response
indicated by increase
in IFN-γ mRNA in 
PBMC, and
corresponding
decrease in IL-10
expression. IL-4
higher in non-
vaccinated dogs.
Experimental:
1×108 L.
infantum
metacyclic
promastigotes
intravenously 2
weeks after last
vaccine dose.
10
months
16 dogs in
three groups.
Laboratory
Beagles.
Reduction in
clinical signs and
liver parasite
burden in
vaccinated dogs.
(Ramos et al.,
2009)
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Appendix II: Primer sequences
Oligonucleotide primer sequences used in the study are summarized below:
Primer Sequence (5’-3’) Reference
IR1 GCTGTAGGTGAACCTGCAGCAGCTGGATCATT Cupolillo et al.,1995;
Parvizi et al., 2005
IR2 GCGGGTAGTCCTGCCAAACACTCAGGTCTG Cupolillo et al.,1995;
Parvizi et al., 2005
ITS1F GCAGCTGGATCATTTTCC Parvizi et al., 2005
ITS2R4 ATATGCAGAAGAGAGGAGGC Parvizi et al., 2008
LEISH-1 AACTTTTCTGGTCCTCCGGGTAG Francino et al., 2006
LEISH-2 ACCCCCAGTTTCCCGCC Francino et al., 2006
Leishprobe (FAM-5’-AAAAATGGGTGCAGAAAT-
3’-non-fluorescent quencher-MGB
Francino et al., 2006
CSB2XF C/GA/GTA/GCAGAAAC/TCCCGTTCA Noyes et al., 1998
CSB1XR ATTTTTCG/CGA/TTTT/CGCAGAACG Noyes et al., 1998
13Z ACTGGGGGTTGGTGTAAAATAG Noyes et al., 1998
LiR TCGCAGAACGCCCCT Noyes et al., 1998
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Appendix III: Forms for Phase I/II trials
Form A: Information sheet for dog owners (English version)
Form B: Owner / dog details and initial clinical examination
Form C: Recording sheet for baseline clinical examination (before vaccination)
Form D: Daily recording sheet for clinical examination (1-4 days post vaccine)
Form E: Record of veterinary treatments
Form F: Record of Adverse Event
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Form A: Information sheet for dog owners (English Version)
Vaccine trial against Leishmania in dogs
The University of Crete and two UK research establishments (The University of
Warwick and the Cambridge Institute for Medical Research) are testing a potential
canine vaccine to protect dogs and humans against leishmaniasis. There are no
vaccines widely available against leishmaniasis despite it causing serious illness in
both dogs and humans. The novel vaccine that we wish to test has been shown to be
protective in laboratory conditions in mice and dogs. Therefore it is an exciting
development and we hope it to be the first fully proven canine vaccine against
leishmaniasis.
The first phase of the vaccine trial is to test the vaccine in a small number of dogs that
are kept under close observation by us in kennels. This requires enrolling young
healthy dogs from villages where leishmaniasis is endemic Only on completion of
these trials will we be able to proceed to the second phase of the project which is to
test the vaccine in a larger number of dogs in endemic villages to evaluate its efficacy
in reducing the canine disease. Below are answers to your questions. If you have any
doubts please contact:
Maria Antoniou, Laboratory of Clinical Bacteriology, Parasitology, Zoonoses and
Geographical Medicine, Faculty of Medicine, University of Crete, Voutes, Heraklion, Crete 71003,
Greece. Telephone: 00 30 2810 394 746.
Your Questions
What is the aim of the first Phase of the trial?
The trial will be carried out in kennels at the University of Crete to show that the
vaccine induces the immunological responses known to be important in protecting
mice, dogs and humans against leishmaniasis. It will also confirm that the vaccine
causes no side effects. Dogs will not be artificially (or naturally) infected with
Leishmania as this is not necessary nor the intention of the trial.
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How safe is the vaccine?
Different components of the vaccine have been previously tested in mice, dogs and
primates without any adverse side effects. The vehicle component of the vaccine is
widely used in human vaccines and has been rigorously tested for safety. We do not
expect any side effects resulting from the vaccine. However, as for the common
human vaccines, we cannot say that the risk of side effects is absolutely zero. The
most we would expect is a temporary inflammation in the skin at the site of the
inoculation for a few days (as occurs in some human vaccines).
What will be required of my dog?
If you agree for your dog to be recruited into the trial, we will first take a blood sample
to check that it has not been previously infected with Leishmania. If it is negative, then
it can be recruited into the trial. The dog will need to stay with us in our kennels for 4
months during which time it will be monitored by our trained veterinarians. At the end
of the 4 months your dog will be returned to you without harm.
What will happen to my dog?
If your dog is recruited, we will first ask you to bring the dog to stay in the kennels
overnight on a number of occasions for it to become accustomed. The kennels are
brand new and built larger than the EEC ethical recommendations for keeping dogs in
kennels. Dogs will have an outside run (largely shaded) with a dog house in which to
sleep. Food and water adlib will be provided appropriately, and dogs will be checked
by our resident trained animal carer, and also checked daily by our veterinarian. It is in
our interest to keep your dog as happy and as healthy as possible.
Why does my dog have to stay in the kennel?
Your dog will need to remain with us for approximately 4 months to allow it to fully
develop an immunological response to the vaccine. We can only judge the
effectiveness of the vaccine if we can follow-up the dog for the full 4 months in a
controlled environment, where we can monitor its health carefully and prevent any
exposure to infection.
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How will the dog be treated?
If not already vaccinated, dogs will be first vaccinated against Distemper, Parvovirus,
Hepatitis, Leptospirosis and Parainfluenza virus, and wormed against roundworms,
tapeworms and hookworms. It will also receive a full veterinarian clinical
examination. After about two weeks, the dog will be inoculated with either the
Leishmania vaccine or a placebo (for comparison), and a blood sample taken every 2-4
weeks to test for immunological responses. A veterinarian will physically inspect the
dog on a daily basis to ensure all is well. The dog will wear an insecticidal collar with
proven activity against sandflies to protect it against any potential infection, and we
will monitor the area round the kennels using traps to confirm that the area is free of
sandflies.
Can any dog be recruited into the trial?
We are looking to recruit dogs that have not been previously exposed to Leishmania.
This is more likely for dogs >4 months and ≤24 months old. To ensure that the dog has
not been exposed to the parasite, we will collect a small blood sample to test for
Leishmania. Dogs less than 4 months old are excluded from the trial because their
immune systems are not fully developed and therefore would give results that are
difficult to interpret.
If I agree what are my obligations?
If you agree, then we would expect you to permit the dog to stay with us for the entire
4 months so that the study can provide the results necessary to prove that the vaccine
produces the appropriate responses. To avoid excessive disruption and stress which
may affect the results of the trial and upset other dogs in the kennels we would ask
owners not to visit their dog after the initial introduction period, however you are free
to contact us at anytime to enquire regarding the dogs well being. At the end of the 4
months you should accept the return of your dog in good health. You accept that there
will be no form of payment for the temporary loan of your dog.
What will happen next?
Informed written consent will be obtained from you at the time of recruitment, and we
will contact you concerning arrangements to visit the kennels.
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Form B : Owner / dog details and initial clinical examination
Owner details
Name………………………………
Address……………………………
……………………………………
Telephone…..……………….…….
Dog details
Dog ID reference number…………
Dog’s
name………………………………
Breed……………………………
Age (months)
…………………………………..
Sex…………………………………
Neutered YES NO
Previous vaccinations:
Date
Distemper ……..
Hepatitis ……..
Parvovirus ……..
Parainfluenza virus ……..
Leptospirosis ……..
Rabies ……..
Medical history
Condition Date
Clinical examination
Body weight ………………….. kg
Condition score (please circle):
1 2 3 4 5
Thin Fat
Body temperature……………
Are any clinical signs of Leishmania present?
Yes / No
Clinical signs……….………………………….
Are any other signs of illness present?
Yes / No
Clinical signs …………………….
Signature of examiner …………………….
Laboratory Test Results:
ELISA
IFAT
PCR
Declaration:
I agree to lend my dog to the University of
Crete for the purposes described in the
Information Sheet which I have fully read and
understood, and will comply with the
obligations as the owner of the dog as described
in the Information Sheet.
Signed…………………………………………
Date:……………………………………………
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Form C: Recording sheet for clinical examination (Days 0, 28, 42, 70, 98, 126)
Dog ID……………… Examination day: 0 28 42
70 98 126
Body weight: ………………….. kg
Condition score:
1 2 3 4 5
Thin Fat
Body temperature………………………
Pulse: …………………………………..
Resp. rate……………………………….
Capillary refill time……………………..
Mucous membrane colour……………….
Are any clinical signs of Leishmania present Yes / No
Description of clinical
signs……………………………………………………………………….….
……………………………………………………………………………………
Are any other signs of illness present? Yes / No
Description of clinical
signs……………………………………………………………………………
……………………………………………………………………………………
……………………………………………………………………………………
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Form D: Daily recording sheet for clinical exam: Days 1-4 post vaccination
Dog ID:………………………….. Date of vaccine: …………
Signature of Examiner…………
DAY 1 post vaccine:
Temperature:…………………
Pulse: …………………………
Resp. rate………………………
Capillary refill time……………………………
Mucous membrane colour…………………….
Local swelling at injection site Yes / No
Local pain at injection site Yes / No
Alopecia at injection site Yes / No
Generalized urticaria Yes / No
Clinical signs
observed:……………………………………………………………………………
………………………………………………………………………………………………
DAY 2 post vaccine:
Temperature:…………………
Pulse: …………………………
Resp. rate………………………
Capillary refill time……………………………
Mucous membrane colour…………………….
Local swelling at injection site Yes / No
Local pain at injection site Yes / No
Alopecia at injection site Yes / No
Generalized urticaria Yes / No
Clinical signs
observed:……………………………………………………………………………
………………………………………………………………………………………………
DAY 3 post vaccine:
Temperature:…………………
Pulse: …………………………
Resp. rate………………………
Capillary refill time……………………………
Mucous membrane colour…………………….
Local swelling at injection site Yes / No
Local pain at injection site Yes / No
Alopecia at injection site Yes / No
Generalized urticaria Yes / No
Clinical signs
observed:……………………………………………………………………………
………………………………………………………………………………………………DAY 4 post vaccine:
Temperature:…………………
Pulse: …………………………
Resp. rate………………………
Capillary refill time……………………………
Mucous membrane colour…………………….
Local swelling at injection site Yes / No
Local pain at injection site Yes / No
Alopecia at injection site Yes / No
Generalized urticaria Yes / No
Clinical signs
observed:……………………………………………………………………………
………………………………………………………………………………………………
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Form E: Record of veterinary treatments
Dog ID:…………………………
Date:……………………………
Reason for treatment:……………………………………………………………………
…………………………………………………………………………………………..
Name(s) of Veterinary product(s) used:………………………………………………
……………………………..……………………………………………………………
……………………………..……………………………………………………………
How many times was treatment given?………………………………………………..
How many days was treatment given for?......................................................................
Signature of person giving treatment:…………………………………………………..
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Form F: Record of Adverse Event
Definition: An Adverse Event is any observation in the trial dogs that is unfavourable
and unintended, which occurs after the use of the experimental vaccine, whether or
not it is considered to be related to the vaccine.
Dog ID:……………
Letter code of Leishmania vaccine
administered………………………………………………….
Date Leishmania vaccine administered: ………………………………………………
Date and time of Adverse event:……………………………………………………….
Description of Adverse
Event…………………………………………………………………….
…………………………………………………………………………………………
………………………………………………………………………………………
…………………………………………………………………………………………
Duration of Adverse event:………………………..……………………………
Action taken:……………..………………………..………………………….
Signature of person recording Adverse Event………………………………………
Date of report…………………………………
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Appendix IV: Hellenic Republic General Veterinary
Authority approvals for dog trials (translated)
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